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PREFACE 
The present thesis is divided into four parts: I. The histamine 
receptor, II. The muscarinic acetylcholine receptor, III. The 
dopamine receptor, and IV. Simple theoretical models for drug-
receptor interaction. They are preceded by a general introduction 
which has been published as a commentary in Biochemical Pharmacol-
ogy in 1977. For the rest the reader should be aware, that some 
chapters are original manuscripts and others are unchanged 
versions of papers which have been published before. In order 
to meet the lack of coherency, which might be a consequence of 
such a collection of only partly related manuscripts, part I, II 
and III are provided with introductory chapters, which are by no 
means comprehensive reviews. They are meant solely to inform the 
reader shortly on the broader scientific context of the chapters 
in each part. Part IV deals with some simple theoretical receptor 
models, mainly developed to explain some of the experimental find-
ings in part II and III. Part IV is an adaptation of chapter 2 in 
"The Receptors A Comprehensive Treatise" (ed. R.D. O'Brien), 
Plenum Press, New York (1979). This part is self-evident and is 
not provided with an introductory chapter. 
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A proper understanding of drug action requires a molecular 
approach, since a bioactive agent can only induce a pharmacologi-
cal effect in a biological object as the result of an interaction 
between its molecules and certain counterparts in the biological 
object. Consequently the chemical properties of a drug are deter-
minant for its action and activity, and a relationship between 
chemical properties and action must exist (1). Based on experi-
ments with nicotine Langley (2) introduced more than 50 years ago 
already the concept of a receptor substance present in the bio-
logical object with which a drug has to interact in order to exert 
its biological effect. Since then the receptor concept and es-
pecially the views on drug-receptor interaction as a basis for 
drug action have evolved. Starting from a purely conceptual recep-
tor idea its full materialization has been realized now with the 
isolation of the nicotinic acetylcholine receptor in several 
laboratories (3-13). The existence of ß-adrenergic receptors (14-
17), muscarinic acetylcholine receptors (18-26), insulin receptors 
(27-29), estrogen receptors (30-33) and many others not to be 
mentioned separately have been firmly established on basis of 
direct binding studies with radioactively labeled ligands (see 
review articles, 81-83). 
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The molecular sites of action of drugs, i.e. those molecules 
with which the active agent must interact in order to induce the 
effect considered, are called the specific receptors. They are 
located in or on target cells, which are not necessarily the 
cells in which the effect is generated. The parameter, considered 
as effect, is to a certain degree arbitrary. The receptors for 
the convulsant agent strychnine, for instance, are located in the 
central nervous system, but the convulsions are generated in the 
striated muscle. Instead of the convulsions, as a matter of fact 
also the changes in the electroencephalogram may be measured as 
the effect. 
The sequence of processes at the basis of drug action can be 
divided into three mam phases: the pharmaceutical phase compris-
ing the release processes of the active drug from its dosage form, 
thus determining the concentration available for absorption (the 
pharmaceutical availability); the pharmacokinetic phase comprising 
the processes that play a part in the absorption, distribution, 
metabolic conversion and excretion of the drug, determining the 
concentration of the active agent in the plasma and thus at the 
site of action (the biological availability); the pharmacodynamic 
phase comprising the interaction between the active agent and its 
molecular sites of action, initiating a stimulus, leading via a 
sequence of processes covering the transduction, amplification 
and modulation of the stimulus to the change m the parameter 
measured and considered as the effect (34, 35). 
Sometimes the receptors are the active sites on enzymes, 
like for the MAO-inhibitors and acetylcholinesterase-inhibitors. 
In other cases receptors appear to be closely associated with 
enzyme action, possibly by allostenc changes in the enzyme mol-
ecule. Receptors further may be associated with functional macro-
molecules or macromolecular complexes, for instance particular 
lipoproteins, determinant for the properties of membranes. The 
various types of binding sites for bioactive agents that are not 
directly involved in the induction of the effect, such as those 
on plasma albumin, are often indicated as silent receptors or 
sites of loss. They play a role in the pharmacokinetic phase of 
drug action. The same holds true for the active sites on enzymes 
involved in the bio-activation or -inactivation of the drug. 
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Drug-receptor interaction as a rule is reversible and is 
much more dynamic than the classical key-and-lock model suggests. 
It implies a mutual moulding of drug and receptor by intermolecu-
lar forces. In the receptor molecule conformational changes are 
induced constituting the stimulus that triggers the sequence of 
events leading to the effect (36, 37). In the case of enzyme-
substrate interaction the changes induced in the substrate mol-
ecule are most prominent and determinant for the effect. Although 
highly dynamic, the receptors can yet be regarded as pre-existing 
specific structural entities since, for instance, the activities 
of optical isomers often differ to a large extent. However, the 
structural requirements for action are not always highly specific. 
For the various gaseous anaesthetics, for instance, a certain 
lipophilicity appears to be the only requirement. Their anaes-
thetic action is mainly based on a change in the cell membrane 
properties due to a diffuse accumulation in the lipid bilayer of 
the membrane. For plasma extenders and osmotic diuretics the term 
receptor is hardly applicable since they mainly act by binding of 
water (1). 
Analogously to the differentiation between the active site 
on an enzyme and the enzyme, the molecule as a whole, it makes 
sense to distinguish between the receptor site and the receptor 
molecule - the receptor - bearing the receptor site. Enzymes can 
be isolated but not their active sites; similarly receptor mol-
ecules or macromolecular complexes may be isolated but not the 
receptor sites. Since structure-action relationship is based on 
the interaction between the drug molecule and the receptor site 
it may give information on the properties of the site but not on 
the receptor molecule as a whole. 
Bioactive agents can be extremely potent. This implies that 
apparently only a few molecules of the active agent have to in-
teract with the receptors to induce a massive response m which 
tremendous numbers of molecules are involved. This requires am-
plifier mechanisms. The simplest unit for assembling strong am-
plifier systems is the step in which one drug molecule activates 
one enzyme molecule which then converts hundreds of substrate 
molecules to product molecules (34). Such an amplifier unit can 
be coupled to a second one if the product molecules in their turn 
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can activate a second enzyme etc. Examples are the various agents 
which act by activation of adenylate cyclase and generation of 
cyclic AMP (38). 
The activation process may imply an action of the bioactive 
agent as a co-factor. Examples are the vitamins and vitamin ana­
logues that serve as co-enzymes for apoenzymes. The binding of 
steroid hormones such as estrogens to their cytosol receptor 
protein followed by migration of the active complex into the 
nucleus where it finally acts as a derepressor, too can be re­
garded as the combination of a "coderepressor", the steroid hor­
mone, with an "apoderepressor", the cytosol receptor, under for­
mation of the active derepressor. 
In efforts to interpret the characteristics of dose-response 
curves and time-response curves of drugs on basis of the mass 
action law, a variety of partially overlapping theoretical models 
have been worked out part of which can be found in various re­
views (39-55, 90-92). The following model presents a condensate, 
covering essential aspects of various models. 
к к к к 
CD: + с « : Ζ M ~3 С ™ * : - 4 м + ш .· е в : - 5 C R : 
к2 
(case I) 
к к к к 
C D : + CR: Ζ CDR: J C D : + C R * : .· CR*: - 4 ш - 5 CR: 
k 2 
(case II) 
The symbols represent: D drug; R receptive receptors; R activated 
receptors; R non-receptive receptors. 
Case I "occupation" model, case II "Hit and run" model re­
lated to the "rate" model (47). The affinity is mainly determined 
by k./k», the intrinsic activity by k,/k2, high for full, inter­
mediate for partial agonists and very low for competitive antag­
onists. The rate of receptor regeneration, (k-) is mainly deter­
minant for the degree of "fade" in the dose-response curves or 
for the degree of specific desensitization of the receptors and 
thus for tachyphylaxis if k, is low. The stimulus is defined as 
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proportional to the fraction of the receptors in the activated 
state. The receptor reserve phenomenon is interpreted on basis 
of the processes, especially the amplifier systems, relating 
the stimulus to the effect (34-37). 
Receptor activation results in the induction of a stimulus 
which by definition is proportional to the fraction of the recep-
tors present m the activated state. The effect as a rule will 
not be proportional to the stimulus although a certain stimulus 
is postulated to result always in the same effect. The amplifica-
tion processes in the transduction of the stimulus to the effect 
imply that possibly only a fraction of the receptors has to be 
activated to obtain the maximal effect attainable with the ef-
fector system. This is illustrated by the action for, for in-
stance, ACTH and ACTH analogues with regard to the enhancement 
of the Cortisol synthesis m the adrenal cortex. The various 
analogues give clearly different rates of cyclic AMP generation. 
Only those analogues which have a very low capacity in this re-
spect, in other words with a very low intrinsic activity with 
regard to cyclic AMP generation, behave as partial agonists with 
regard to the rate of Cortisol production. Analogues with an in-
termediate intrinsic activity as far as the cyclic AMP generation 
is concerned still act as full agonists for the Cortisol produc-
tion (56). There is a spare capacity as far as the receptor sys-
tem is concerned. It illustrates that in situations where an ef-
fector system is more closely connected with the receptor system 
more direct information on drug-receptor-interaction is provided. 
Direct binding studies of drugs to receptors are advantageous in 
the sense that they give more direct information on receptor oc-
cupation and therewith on affinity, but on the other hand other 
aspects of drug action like receptor activation are largely ob-
scured. 
As shown by binding studies the receptors for various drugs, 
hormones and hormonoids are located in plasma membranes (57). The 
receptors for acetylcholine (the cholinergic receptors) could be 
proven to be located on the outside of the plasma membrane since 
application of cholinergic agents intracellularly appears to be 
ineffective (58). For other receptor types, viz. those for nor-
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adrenaline, histamine and serotonin, a location at the outside of 
the cell membrane is highly probable since these receptors are 
easily accessible for the quaternized form of the respective 
competitive blocking agents, compounds known to penetrate intra-
cellularly only with great difficulty or not at all (1, 59). Also 
for the receptors of various peptide hormones and noradrenaline 
involved m the activation of adenylate cyclase a location on the 
cell membrane has been confirmed by binding studies (60, 61, 82). 
With regard to receptor isolation and identification there 
is an essential difference between soluble receptors, e.g. the 
cytoplasmic steroid receptor proteins and membrane-bound recep-
tors. There is a tight interrelation of the receptor molecule and 
surrounding molecules in the latter case. Separation of the recep-
tor molecule from its surroundings may well disturb its conforma-
tion, and thus its specific characteristics. Undoubtedly the 
isolation techniques, especially those in which detergents (62) 
are used as solubilizing agents, may influence the conformation 
of the isolated protein drastically. The variation in binding 
constants reported for the interaction of drugs with "isolated 
receptors" therefore does not warrant the existence of various 
receptor states or conformations physiologically. A special prob-
lem which holds for the soluble as well as the membrane-bound 
receptors, is that with isolated receptors no measurable "pharma-
cological" effect can be induced anymore, making their identifica-
tion extremely difficult in certain cases. 
Since structure-action relationships (SAR) are based on an 
interaction between the drug molecule and the receptor site, it 
may give information on the properties of this site. Thereby a 
certain degree of chemical complementarity between the drug and 
the specific receptor site with which it interacts is assumed. 
Structure-binding relationships, therefore, can serve as a tool 
for the identification of isolated receptors. However, only the 
receptor molecules, not the sites can be isolated. One may expect 
that structure-binding relationships for isolated receptors, as 
far as these are not to a certain degree denaturated in the iso-
lated form, will parallel the SAR, with this distinction that on 
the isolated receptors as a rule there will be no differentiation 
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between agonists, partial agonists and comretitive antagonists, 
because only affinity and binding capacity are measured and not 
intrinsic activity. Opiate receptors are an exception in this 
sense because agonist binding is dependent on the presence of 
Na or Li ions, while antagonist binding is not, making a clear 
differentiation possible (63). In efforts to isolate and identify 
receptors also use is made of agents which irreversibly bind in a 
selective way to the receptors or better to the specific receptor 
sites. However, such agents are only exceptionally available (64). 
Based on the postulated complementarity for the drug mol-
ecules and the specific receptor site, SAR-studies can be used 
for receptor-site-mapping. Interesting results are thus obtained 
with regard to various membrane-active agents such as acetyl-
choline, histamine and noradrenaline and their respective competi-
tive antagonists. Agonist and antagonist both have an affinity to 
"common" receptors, only the agonists have an intrinsic activity. 
The interaction of the agonist molecule with the receptor results 
in a change to the activated (R ) state or conformation. The com-
petitive antagonist keeps the receptor m the non-activated (R) 
state. With partial agonists only a fraction of the drug-receptor 
interactions result in an activation; the intrinsic activity de-
pends on the size of this fraction (65). 
Taken into account the postulated complementarity of drugs 
and their receptor sites agonists and antagonists should be chemi-
cally related. For the membrane-active agents just mentioned this 
appears hardly or not to be the case (34, 55, 59, 66, 67). The 
various agonists, like acetylcholine, histamine and noradrenaline 
are highly polar molecules with clearcut differences in, for in-
stance, charge distribution. There is little or no chemical rela-
tionship between agonists and corresponding antagonists. There is, 
however, much similarity in the chemical structure of the various 
types of antagonists, anticholinergics, antihistaminics, and a-
adrenergic blockers, predominantly hydrophobic, non-polar m na-
ture. As a rule they have hydrophobic double ring systems located 
at a certain distance (3-5 atoms) of an amino or a quaternary 
ammonium group in common. The hydrophobic groups essentially con-
tribute to the high affinity for the receptors and impossibly can 
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be bound to the receptor site complementary to the highly polar 
agonistic molecules. Introduction of centers of asymmetry into 
various moieties of the drugs, for instance in cholinergic and 
anticholinergic agents, indicates that in the binding of the 
agonists and the corresponding antagonists essentially different 
chemical groups and different receptor sites are involved (34, 55, 
59) . 
The anticholinergics apparently bind through their hydro-
phobic moieties to accessory binding areas topically or func-
tionally related to the receptor site for cholinergic agonists, 
in some way blocking the activation of the receptor by agonists. 
They interfere with the binding of the agonist to its receptor 
site, without occupying this receptor site itself in a strict 
sense. There appears to be a "dualism" in the receptor sites for 
agonists and corresponding antagonists. On basis of this concept 
the lack of structural similarity between agonists and their cor-
responding competitive antagonists, the existence of close struc-
tural relationships between competitive antagonists blocking dif-
ferent types of receptors, the existence of competitive antag-
onists blocking receptors for different agonists, and the depend-
ence of the selectivity in action of the competitive antagonists 
on the stencal configuration of the hydrophobic moieties in the 
molecule (68, 69) are understandable (59). The receptor sites for 
agonists and competitive antagonists are not as common as suggested 
by the original "one receptor site concept". 
The receptor sites for the drugs not necessarily have to be 
located on the surface of receptor proteins. The accessory recep-
tor sites for the hydrophobic moieties in the various competitive 
antagonists of membrane-active agents may well be constituted by 
an interface between a hydrophobic surface of the receptor protein 
and lipid groups m the membrane. The extremely high affinity con-
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stants, 10 and 10 , for competitive antagonists (e.g. anti-
cholinergics and antihistaminics) which are mainly based on the 
contribution of the hydrophobic groups to the affinity can hardly 
be realized on a mere protein surface. Lipoproteins would be more 
suitable in this respect. The lipid molecules in a membrane facing 
the hydrophobic surface of the protein, are fixated to a large ex-
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tent m a quasi crystalline form, making the high degree of 
stereospecificity of the antagonists, especially with regard to 
centers of asymmetry m their hydrophobic moiety, understandable. 
Drug-receptor interaction then results in changes in the inter-
face characteristics. It is even possible that the relatively 
polar sites for agonists are also located at or constituted by 
an interface, e.g. there where the polar groups of a membrane 
protein are close to polar groups of membrane lipids like the 
phosphate and choline groups in phosphatidic acids, phosphatidyl-
cholines and sphingomyelins. The isolation of receptors as mol-
ecular entities would become an impossible task, if this turns 
out to be the case. Studies on purified receptors of such a na-
ture would only be possible after isolation of the constituting 
parts and reassembly into artificial membrane-like structures 
(57) . 
The receptor molecule or macromolecular complex must be 
assumed to occur in different states, an activated and a non-ac-
tivated form dependent on the presence of an agonist or a com-
petitive antagonist. Kasai and Changeux (70) postulated that even 
in the absence of drugs there is a dynamic equilibrium between 
different functional states of the cholinergic receptor. The 
simplest concept in this respect is the "dual receptor concept", 
supposing the occurrence in the cell membrane of an equilibrium 
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between the receptors in the R - and those in the R-form. The 
R -form contributes to the effect, the R-form does not. An 
agonist shifts the equilibrium towards the R -conformation and 
a competitive antagonist to the R-conformation; the agonist has 
a relatively high affinity to the receptors in the R -conforma-
tion, the competitive antagonist to those in the R-conformation, 
thus m a way fixating the receptors in their respective states 
(65, 93, 94). Partial agonists have an affinity for both states, 
the ratio of the affinities being determinant for the intrinsic 
activity of the compound. As long as the rate constants for the 
equilibrium between R and R are large enough, this model will 
predict phenomena similar to those expected for a competition 
between drugs based on the "one receptor site concept". The re-
ceptor sites for agonist and "competitive" antagonist - although 
one receptor protein is involved - are different now (65, 93). 
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This is in accordance with the dualism in receptor sites outlined 
before on basis of structure-action relationships (65). In case 
that the receptor molecules are embedded in the lipid membrane 
structure, one may expect that the behaviour of such protein mol-
ecules, for instance their tendency to aggregate or segregate, 
strongly depends on the hydrophobic and hydrophilic properties of 
the protein surface, especially of that part of the receptor mol-
ecule in contact with the lipids in the membrane. The receptor 
proteins, although hydrophobic, in their overall nature (71), 
have an amphiphilic character. Binding of agonists, usually 
strongly polar agents, could stabilize a relatively polar con-
formation and thus shift the equilibrium towards the more hydro-
philic R -form. Binding of the hydrophobic antagonist would then 
stabilize a hydrophobic R-state. The different character of the 
R - and R-form will imply differences in the quaternary structure 
of the proteins, the degree and type of aggregation among recep-
tor molecules or among receptor molecules and other proteins (e.g. 
effector proteins) present in the membrane. 
This activation-aggregation concept postulates the presence 
of a receptor as well as an effector molecule in the membrane. 
The degree of aggregation between the two,influenced by the pres-
ence of a hormone is supposed to be determinant for the effect. 
The model fits quite well with the fluid mosaic concept for mem-
brane structure (74). 
Various membrane-active drugs clearly change the degree and 
type of receptor protein aggregation in membrane preparations. 
The proteins in the luminal cell membrane of the toad bladder 
aggregate to a mosaic pattern under the influence of the anti-
diuretic hormone (75) . The protem-walled pores thus formed may 
well account for the increased water permeability induced by this 
hormone. Specific receptor proteins for the different hormones 
activating adenyl cyclase are supposed to aggregate with the 
enzyme molecule under influence of the hormones, thus activating 
the enzyme in an allosteric way (72, 73). Also existing modes of 
aggregation of receptor proteins may be changed under influence 
of drugs. 
The amphiphilic character of receptor proteins, shifting to-
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wards a more hydrophilic or hydrophobic state by agonists and 
antagonists respectively, with as a consequence a change in inter-
molecular relationships between receptor and other membrane con-
stituents, may well imply that the extraction of receptor proteins 
from membrane fragments could be either facilitated or impeded by 
the presence of certain drugs. Moreover, such drugs might protect 
the receptor from becoming denaturated once outside the membrane 
by preventing conformational changes to occur. 
Receptor sites for membrane-active drugs also may be located 
on proteins or protein complexes constituting the wall of pores 
(76, 77). The passage by ions of such protein-walled pores in a 
membrane may well change under the influence of drugs as a result 
of an altered charge distribution in the receptor molecules con-
stituting the pores. The proteins may switch from an open to a 
closed conformation. Again an equilibrium between both conforma-
tions, shifted by agonists to an apparently open conformation and 
by competitive antagonists to a closed conformation can be postu-
lated. In the dual receptor site model, although only one type 
receptor protein or protein complex is postulated, the receptor 
sites for agonists and for the corresponding antagonists are func-
tionally distinct interdependent entities. The observation that 
affinity constants of agonists derived from displacement experi-
ments depend on whether agonists or antagonists are displaced 
(78, 79) does not find an explanation in such a model. 
One should not expect that one universal receptor concept or 
theory of drug action will account for all the modes of action of 
the nearly unlimited variability of bioactive agents. Undoubtedly 
the one receptor site concept and the classical theories for drug 
action explain a variety of experimental findings. The dual recep-
tor concept opens intriguing perspectives for the interpretation 
of the action of drugs and hormones, there where the classical 
concepts do not provide a satisfactory explanation. An extensive 
discussion of both theoretical and experimental aspects of the 
dual receptor model is m press (80). 
Although the receptor concept was mainly of theoretical sig-
nificance in the past, it has evolved into concrete reality and 
receptors can now be studied as tangible molecular entities. The 
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design of new drugs can be based on relationship between struc-
ture and receptor affinities measured by direct binding studies 
(84-86); receptor density measurements in malignant tissue can 
tell whether hormonal treatment is indicated or not (87) and al-
terations in receptor properties and density distributions enhance 
insight in certain pathological conditions like myasthenia gravis 
and diabetes (88, 89). 
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PART I THE HISTAMINE RECEPTOR 
CHAPTER 1 
INTRODUCTION 

INTRODUCTION 
An observable effect induced by one or other compound in a 
biological object must be the result of a physico-chemical inter-
action of the molecules of this compound with molecules of one 
or more types forming part of the biological object. This concept 
was expressed by Ehrlich as "Corpora non agunt nisi fixata" as 
early as 1913 (Ehrlich, 1913). To put it more specifically,a com-
pound or pharmacon injected into an experimental animal or added 
to an isolated organ in an organ bath, will reach after passage 
of barriers present (e.g. cell membranes) a primary site of 
action, commonly referred to as receptor. This will result in a 
change in this action site, leading after a chain of events to 
the ultimate effect. 
One of the partners in the pharmacon-receptor interaction, 
the pharmacon, is usually a well defined entity of known composi-
tion and structure. Its concentration in a bath or in body fluids 
often can be estimated relatively easily. Until recently the 
situation with the other partner, the receptor, was entirely dif-
ferent. As to its character and localization, in many cases there 
was a notion that proteins forming an integral part of a membrane 
were a basic element. It was not certain at all, however, whether 
membrane lipids and phospholipids are part of the receptor proper 
or merely create a suitable lipid environment, in which a protein 
can manifest itself as a functional entity with the characteristics 
of a receptor. Detailed information on receptors such as molecular 
weight, amino acid composition and classes of lipids involved is 
still lacking, although in a few cases considerable progress has 
been made (e.g. the cholinergic muscle endplate receptor (Dolly, 
1979), rhodopsin (Van Breugel, 1977) and Ca -ATP-ase (Warren and 
Metcalfe, 1977)) . 
The limitations of our knowledge are illustrated by the 
debate still going on as to the definition of a receptor. 
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Receptors can be visualized as enzymes with an active site. Some 
people argue that the denotation receptor should be reserved for 
the active site proper; others favour a view of a receptor as a 
protein with a specific conformation maintained by a suitable 
environment. Still others deny the existence of a receptor as a 
single molecular entity and regard it as a "hole" in a membrane 
constituted by proteins, lipids of various kinds and metal ions 
as present in the micro-environment in which the receptor mani-
fests itself as a functional entity (Waser, 1966) . Nevertheless 
this lack of knowledge and difference of opinion has not prevented 
the accumulation of an impressive amount of information on drug-
receptor interactions, receptor mechanisms and structure-activity 
relationships. Based on this information receptor models have 
been designed with such details as specific amino acids forming 
part of it and distances between centres of low and high electron 
density specified to one hundredth of a micrometer (Beckett, 1967; 
Korolkovas, 1970). Although such models must be considered with 
scepticism, they have created a general feeling that we have a 
fairly good idea of what receptors really are. 
DIRECT BINDING OF LIGANDS TO RECEPTORS 
Apart from what we know already, it is still felt as a 
serious lack that no direct information on receptors and their 
interaction with pharmaca can be obtained. The main obstacle is 
formed by the practical difficulty to isolate and nurify receotors, 
whereas the biological effect cannot be used as a functional para-
meter anymore once the preparation has been broken down to a sub-
cellular level. With enzymes the product formation following 
addition of a substrate can be taken as a monitor. Regardless of 
how much of the enzyme is present, in principle infinite small 
amounts of enzyme can be detected, since product formation is 
additive. 
Going back to Ehrlich, the only strategy for isolating recep-
tors would seem to be to trace them in broken cell preparations by 
detecting complexes with compounds of which we know they interact 
with the receptor in question, except in cases in which the recep-
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tor simultaneously acts like an enzyme or is structurally related 
to an enzyme. An example is the B-adrenergic receptor/adenylate 
cyclase complex (Lefkowitz et al., 1976). 
In order to be useful as monitoring tools in receptor isola-
tion procedures, the compounds must have besides an adequate 
affinity one or other property by which they can be detected 
chemically or physically m very low concentrations. A compound 
can be made highly fluorescent by denvatization with fluorescent 
groups (Darfler and Mannetti, 1977; Atlas and Levitzki, 1977) 
but frequently this is not compatible with its ability to bind 
to the receptor. Radioactive labelling of a compound with tritium, 
carbon-14 and in those cases where a sulfur atom is present with 
sulfur-35 normally does not affect the pharmacological properties. 
Carbon-14 labelled compounds, if labelled in a proper position 
are stable to exchange reactions in aqueous media. However, they 
have the disadvantage of being expensive and due to the very long 
half-live of carbon-14 such compounds can only be obtained with 
low to moderate specific activities. Tritium labelled compounds 
are cheap and can be obtained with very high specific activities. 
Unfortunately they may undergo tritium/hydrogen exchange in 
aqueous media rather quickly if no thorough care is taken to pre-
vent it. Sulfur-35 combines all the advantages of tritium and 
carbon-14, but has only limited applicability because so many 
compounds suitable for other reasons do not contain a sulfur 
atom. For these reasons drug molecules useful in receptor isola-
tion procedures are almost exclusively labelled with tritium, 
preferably at the highest specific activity possible. 
SPECIFIC RECEPTOR BINDING AND UNSPECIFIC BINDING 
The availability of a labelled drug is not the only pre-
requisite for a successful detection of receptors in tissue or 
tissue homogenates. From pharmacology we know that many drugs 
interact with more than one receptor type. Many antihistaminics 
for example are good anticholinergics at the same time (Ariëns, 
1964; Harms and Nauta, 1960) (see Fig. 1); acidic drugs bind to 
basic components of the tissue, basic drugs to acidic components 
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Fig. 1 Anticholineraic and an tiki stami ni с aativiLy of various 
parasympathiaolytios, antihistaminios and intermediate 
drugs (after Ariens, 1Э6 4) 
and lipophilic drugs to lipoid components. In general, almost 
any drug binds to a protein to a larger or lesser extent. How 
specific the action of a drug towards a certain receptor may be, 
it is hardly reasonable to expect that it would also bind ex­
clusively to that receptor. 
Illustrative in this respect are the experiments of Cook in 
which he used methylene blue to block cholinergic transmission 
in the isolated frog heart (Cook, 1926). He observed that the 
dye is able to exert its anticholinergic effect at low concentra­
tions without visibly staining the preparation. At higher concen­
trations a clear staining, which hardly can be washed out, takes 
place; however, the cholinergic blocking effect can readily be 
overcome by washout, even after application of these high concen­
trations. Obviously the visible staining of tissue components of 
the frog heart by methylene blue is totally unrelated to the 
binding of the dye to the cholinergic receptor. From Cook's ex­
periments one thing is clear: binding of a drug as such, nor its 
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persistence after washing is sufficient to make it a useful tool 
in receptor isolation procedures. 
In 1959 Ehrenpreis reported the isolation of a protein from 
Eleotrophorus eleetrieus electroplax with high affinity for 
curare-like drugs. In his report he claimed to have isolated the 
curare-like nicotinic acetylcholine receptor (Ehrenpreis, 1959, 
1960). Further attempts to characterize the protein gave results 
not consistent with the properties of the nicotinic receptor known 
at that tune (Ehrenpreis, 1963). Chagas had already found binding 
of curare-like drugs to acidic mucopolysaccharides present in 
electroplax. These macromolecules are also found in many other 
tissues without known cholinergic innervation, especially tendon 
and cartilage, which makes it very unlikely that the binding sites 
detected had anything to do with the cholinergic receptor (Chagas, 
1962; Paton and Rang, 1965). These examples illustrate that m the 
past it has been a far from trivial problem to establish that bind­
ing of drugs to tissue fragments represents specific receptor bind­
ing and not binding to other sites totally unrelated to the recep­
tors mediating the biological effect. 
ISOLATION OF THE NICOTINIC CHOLINERGIC RECEPTOR 
A great impetus to the isolation of the nicotinic receptor 
was given by the elucidation by Lee et al. of the mechanisms by 
which certain snake venoms act, notably the venom of Bungarus 
Чиіігсгпоілв (Chang and Lee, 1963; Albuquerque et al., 1979). 
One component of this venom characterized electrophoretically as 
the α-toxin and now commonly denoted as a-bungarotoxm, a poly­
peptide with a molecular weight of about 8000 (Mebs et al., 1971), 
has a strong and long lasting blocking effect on the muscle end-
plate receptor. The effect of the toxin on muscle is an irrevers­
ible paralysis. When the muscle is premcubated with curare, a 
reversible blocker of the nicotinic receptor, the persistent 
paralysing effect of the toxin is prevented for the greater part. 
Experiments measuring the uptake of radioactively labelled toxin 
by electroplax and electroplax membranes revealed a time dependent, 
saturable and practically irreversible binding to tissue components 
25 
(Changeux et al., 1970, 1971; Miledi et al., 1971). The binding 
of α-bungarotoxin to components of electroplax is prevented to 
a major extent by curare. This suggests that the toxin is bound 
specifically and almost exclusively to the cholinergic receptor. 
The availability of α-bungarotoxin, specifically and irreversibly 
bound, combined with a target tissue like electroplax has made a 
fast development possible. The nicotinic cholinergic receptor 
could be detached from its membranous environment by detergents 
without loosing its binding properties and a successful purifica­
tion has been achieved by different research groups simultaneously 
(Eldefrawi and Eldefrawi, 1973; Meunier et al., 1974; Klett et al., 
1973; Karlin and Cowburn, 1973; Schmidt and Raftery, 1973; Heil-
bronn and Mattson, 1974). Today details of the role of the 
cholinergic receptor in the mechanism of translocation of ions 
across membranes are being unraveled. The muscle endplate recep­
tor, although present in striated muscle m much lower concentra­
tions has recently been purified by the same techniques and its 
properties differ only in minor respects from the electric organ 
receptor (Dolly, 1979). 
Unfortunately such powerful tools like a-bungarotoxm are 
not available with respect to other receptors like muscarinic 
cholinergic, histaminergic, dopaminergic, a- and ß-adrenergic 
receptors. In principle, however, a variety of ligands for tag-
ging - agonists and antagonists - is available for each of these 
receptors. Before a particular compound is selected for labelling, 
certain aspects of ligand binding to tissues have to be considered. 
QUANTITATIVE ASPECTS OF DRUG-RECEPTOR BINDING 
As elucidated already no ligand will bind exclusively to the 
receptor which we try to isolate. Apart from such complicating 
factors as positive or negative co-operativity between receptor 
sites, binding of a ligand A to tissue fragments can be looked 
at as occurring to a finite number of binding sites which have 
different affinities and capacities for the ligand, cf. Scatchard, 
19 49. The concentration of the ligand bound as a function of its 
free concentration can be expressed as: 
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E A : bound 
η 
= Ζ 
i=l 
Oil! 
1 + C A D 
in which r. is the concentration of sites of the ith class and 
К its dissociation equilibrium constant for drug A. In general 
Ai 
the distribution of these classes of sites will be such that only 
a few have a high or intermediate affinity while the others have 
a much lower affinity for drug A. For the low affinity binding 
A· 
sites it holds that i >> 1 and consequently the amount of D3 drug bound to such sites is linearly dependent on the free drug 
concentration as long as it is kept in the same range as the 
affinity constants of the high affinity binding sites. In Fig. 2 
a set of theoretical binding curves representing fractional oc­
cupation of binding sites with decreasing affinity is shown. The 
curves for the low affinity binding sites are indistinguishable 
from a straight line. 
f ract ional receptor occupation 
1 0
 Τ Κ=32·10" θ 
Fig. 2 Theoretical binding curves. The curve for the binding 
site with the lowest affinity is indistinguishable 
from a straight line 
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The amount of drug bound to the low affinity sites, however, can 
be substantial if the total capacity of the low affinity sites 
is large compared to the capacities of the high affinity sites. 
Low affinity binding constitutes the unspecific binding en-
countered to a larger or lesser degree in every binding experi-
ment. Characteristic for the unspecific binding is that it is 
linearly dependent on the concentration of labelled drug and that 
it is practically not displaced by competing non-labelled ligands. 
A binding curve as depicted in Fig. 3 (left) is easily analysable 
in its composing parts but a situation can be imagined where the 
capacity of the saturable binding site is so small, that the com-
posite binding curve does not deviate significantly from a 
straight line (Fig. 3, right). Detection of receptor binding 
then becomes practically impossible and a ligand with higher 
affinity and consequently, due to the lower concentrations at 
which receptor saturation occurs, a labelling at higher specific 
activity is needed. In experimental situations binding curves are 
analysed on basis of one or two specific binding sites plus a 
[ A ] bound pmol/g 
20 
16 20 
nM [A] 
Fig. 3 left: composite binding curve (a) resulting from rela-
tively much specific binding (b) and relatively 
little unspecific binding (c) 
right : composite binding curve (a) resulting from rela-
tively little specific binding (b) and relatively 
much unspecific binding (a) 
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linear distribution representing the low affinity binding sites. 
The lack of preciseness of experimental data seldom justifies 
an analysis on basis of theoretical models with more than two 
specific binding sites. 
Comparison of binding affinities of the composing binding 
sites with affinity constants from гп VÙJO experiments, might 
give a clue which of those binding sites, if any, can be iden-
tified as the receptor searched for. 
STEREOCHEMICAL ASPECTS OF DRLG-RECEPTOR BINDING 
Another aspect of drug-receptor interaction is the stereo-
specificity with which it occurs. If in 17-ß-oestradiol the 0H-
group is put in the 17-a position a compound with a much weaker 
oestrogenic activity is obtained (Gorski et al., 1968) . This 
radical change in biological activity can hardly be explained 
by changes in physico-chemical properties like fat solubility 
and electronic distribution in the hormone. Obviously the 0H-
group plays an essential role in receptor binding and activation, 
with strict requirements as to its spatial position in relation 
to the rest of the molecule. 
Compounds with a centre of asymmetry in their molecular 
structure often show a large difference in pharmacological potency 
between their optical antipodes, although the physico-chemical 
properties of such isomers are completely identical (Casy, 1970). 
Potency ratios of two or three orders of magnitude are frequently 
encountered and in many cases it is even questionable, whether 
the least active isomer does have any pharmacological activity 
of its own. A potency one hundredth of the active isomer could 
well be explained by the presence of 1% of the active isomer as 
an optical impurity of the less active isomer. Quantification of 
potency ratios of two orders of magnitude or more must be con-
sidered with great suspicion. In general they are meaningless if 
no adequate proof of the optical purity is given at the same time 
(Barlow et al., 1972). In spite of this uncertainty in many ex-
perimental data, it is apparent that in a group of compounds with 
the same type of action, activity ratios for enantiomeric pairs 
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increase with increasing activity of the more active enantiomer. 
The correlation between potency of the more active enantiomer 
and potency ratios of enantiomers is so general, that it has 
tempted people to denotate tne phenomenon as "Pfeiffer's rule" 
after the investigator first to describe it m a semi-quantitative 
way (Pfeiffer, 1956) . Recently attempts have been made to find a 
fundamental basis for Pfeiffer's rule in thermodynamic theory 
(Lehmann et al., 1976). In fact Pfeiffer's rule is the reflexion 
of the general notion that as the affinity of a compound for a 
receptor is higher, the interaction between the two must be 
tighter and hence differences in stereochemical configuration 
must become increasingly important. Potent antihistaminics like 
diphenhydramine with a large enantiomeric potency ratio as far 
as the antihistaminic activity is concerned, have a smaller but 
definite anticholinergic activity. As has to be expected from 
the foregoing, the enantiomeric potency ratio with regard to the 
anticholinergic activity is much smaller (Fig. 4). 
H 
с -^З—С-0-С-С-І<£ 
" ό 
Isomer 
+ 
ratio 
— 
anticholinergic 
activity 
6,14 
1.9 
see* 
antihistaminic 
activity 
8 76 
77.6 
6 87 
• 
• 
pA2 
Fig. 4 Activity ratio in optbcal isomers of diphenhydramine 
Wbth regard to antihistaminic and anticholinergic 
actvvity (Rekker et al.3 1971) 
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OPTICAL ISOMERS AND RECEPTOR TAGGING 
The question arises whether such enantiomeric pairs can be 
used in the detection of receptor binding and differentiation 
from binding to other tissue components. For instance, the (+)-
iscmer of diphenhydramine, the more potent of the two enantiomers, 
will bind to the histamine receptor in a saturable fashion. In 
the same concentration range the compound will also bind to the 
cholinergic receptor, but according to its much lower affinity 
for this receptor, it will do so in a practically unsaturable 
fashion. The contribution of both binding sites to total binding 
will depend on the relative amounts of both receptors in target 
tissue. The (-)-iscmer, which has a much lower antihistaminic 
activity will hardly bind to the histamine receptor, but binding 
to the cholinergic receptor will take place to about the same ex-
tent as for the (+)-iscmer. It is reasonable to assume that bind-
ing of both isomers to other unspecific binding sites present 
will follow a similar course as binding to the cholinergic recep-
tor. For this reason such a pair of isomers, radioactively label-
led at high specific activity would be useful tools for detection 
of receptor binding in tissue homogenates, because differences in 
binding between the two would probably reflect binding to this 
receptor. Moreover, if stereospecificity of binding is preserved 
after subsequent purification steps it would be good evidence for 
maintained structural integrity of the receptor. 
AGONISTS AND ANTAGONISTS FOR RECEPTOR TAGGING 
Stereospecificity of action occurs both for agonists and 
antagonists. At first sight, an enantiomeric pair of agonists 
would seem to be better choice than a pair of antagonists, 
because by definition agonists bind to the receptor proper, 
whereas antagonists also might bind to a topographically differ-
ent site, mediating their inhibitory action through allosteric 
mechanisms. On the other hand from pharmacodynamic theory several 
arguments against the use of agonists in receptor binding studies 
emerge. In general the effectivity of an agonist is expressed in 
two parameters, affinity and intrinsic activity. In classical 
31 
molecular pharmacological theory intrinsic activity (a ) is an 
operational parameter indicating whether a compound is able to 
induce a maximal or a submaximal effect (Van den Brink, 19 77). 
E E 
Full agonists have an α of one and partial agonists have an a 
between one and zero. It is striking that in almost any series 
of compounds acting on one type of receptor, the majority has 
full intrinsic activity and only a few behave as partial agonists. 
If α would reflect the real efficacy with which an agonist con­
verts a receptor from a non-mediating to a mediating state, it 
is not conceivable that the ability to do so of so many compounds 
would be exactly alike. In other words, one would expect a much 
greater differentiation among agonists as far as intrinsic activ­
ity is concerned. In the concept of receptor reserve full agonists 
only have to occupy a certain proportion of the receptors to in­
duce a maximal biological effect (van den Brink, 1977) . The 
receptors not occupied at just maximal effect is considered the 
receptor reserve. The affinity of an agonist is expressed as pD--
value indicating the negative logarithm of the concentration at 
which half-maximal effect occurs. If an agonist has a large recep­
tor reserve, a maximal effect can be attained already at for in­
stance 20% receptor saturation and half-maximal effect at 10% 
receptor saturation. The real affinity of an agonist defined as 
the concentration of half-maximal occupation of the receptor, might 
be much lower than its apparent affinity expressed by its pD^-
value. In the example in Fig. 5 agonists A and В have equal 
affinities for a given receptor, but due to a receptor reserve 
of 80% for drug A their pD^-values differ by about one order of 
magnitude. The presence of a receptor reserve also may have im­
plications for the stereospecificity of agonistic action. A ratio 
of pD^-values of an enantiomeric pair of agonists might reflect a 
difference in affinity as well as a difference in receptor reserve 
of both compounds. If in the example of Fig. 5 compounds A and В 
represent such an enantiomeric pair, no difference in binding 
between the two would be found although it might be suggested by 
the different pD_-values. The binding of such isomers to tissue 
fractions could be erroneously interpreted as taking place to 
unspecific binding sites and not to the receptor (Cuatrecasas et 
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Fig. 5 Theoretical aoncentration-effeat aurves for agonista 
in presence and absence of a reaep Lor reserve 
curve a: concentration-effect curve of agonist A with 
a reaep tor reserve of 80%. pD2 - 8. 
curve b: concentration-receptor occupation curve for 
agonist Α. К. = 10~7M. 
curve a: concentration-effect curve for agonist В __ 
without receptor reserve. pD? = 7, KR - 10 14. 
al., 1974; Lefkowitz et al., 1973). 
The pD?-values and pA_-values of partial agonists and antag­
onists respectively represent real affinities and no complications 
arising from the presence of a receptor reserve are to be expected. 
Finally antagonists in general have considerable higher affinities 
than agonists and consequently antagonists saturate their specific 
binding sites at much lower concentrations than agonists do. This 
might result in a more favourable ratio of specific to unspecific 
binding. All this together would make a pair of enantiomeric 
agonists as tools in the detection of receptor binding a poor 
choice. A pair of enantiomeric antagonists of which the more ac­
tive enanticmer has the highest affinity for the receptor searched 
for offers the best chance for the detection of receptor binding 
in tissue homogenates. The possibility, that antagonists act via 
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allosteric mechanisms cannot be excluded beforehand, but can be 
tested after each purification step by inhibition of antagonist 
binding by agonists. Changes in this inhibitory pattern as a re-
sult of purification might point to such a mechanism. 
TWO TYPES OF HISTAMINE RECEPTOR 
Histamine or fj-imidazolyl ethylamine was first synthesized 
by Windaus and Vogt in 1907, but its biological significance was 
not recognized until 1910 when Barger and Dale isolated the com-
pound from extracts of ergot. Histamine elicits a host of re-
sponses in animal tissues; it gives contraction of smooth muscles 
like those in the gut and bronchi, it accelerates heart rate, it 
induces gastric secretion and it inhibits contractions of rat 
uterus either induced electrically or by carbachol. Histamine 
plays a complex role in peripheral circulation resulting in a 
lowered blood pressure and in severe cases in collaps and lethal 
shock (Van den Brink and Van Rossum, 1975; Douglas, 1975; Beaven, 
1976). Furthermore, there is growing evidence that histamine 
plays a transmitter role in the central nervous system (Schwartz, 
1979). Histamine in animal tissues is mainly localized in mast 
cells from which it is released upon injurious stimuli or as a 
result of anaphylactic reactions. Like many other biogenic amines 
and neurotransmitters histamine is supposed to mediate its effects 
through specific receptors localized on the plasma membranes of 
smooth muscle and secretory cells. Histamine receptors in the 
various tissues are not of a single class. Contractile responses 
of histamine in bronchial and intestinal smooth muscle are antag-
onized by compounds like mepyramine, tripelennamine or diphen-
hydramine. These compounds, developed in the early nineteenforties 
find application in practical medicine to relieve symptoms of 
histamine liberation in allergic conditions like hay fever and 
urticaria or as a result of insect bites. The classical anti-
histaminics as they are called now, do not antagonize the effects 
of histamine on the gastric secretion, the heart and the rat 
uterus. This has led Ash and Schild (1966) to postulate that 
there are at least two types of histamine receptors. The type 
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present in bronchial and intestinal smooth muscle and blocked by 
the classical antihistaminics was denoted as the histamine H -
receptor. The other ones present in gastric mucosa and smooth 
muscle of rat uterus could neither be fully characterized nor with 
certainty grouped into a single class because no selective stimu-
lants or inhibitors of those receptors were available in 1966. 
In 1972 Black et al. reported after eight years work in which 
more than 700 compounds were investigated the synthesis and test-
ing of burimamide, a selective inhibitor of what was provisionally 
called the histamine H_-receptor. Burimamide was followed by meti-
amide and Cimetidine as selective inhibitors of the histamine H--
receptor ( Black et al., 1973; Durant et al., 1977). In recent 
years also highly selective stimulants of the histamine H_-recep-
tor like dimaprit and impromidine have been developed (Parsons et 
al., 1977; Durant et al-, 1978). It has been our aim to charac-
terize the histamine H.-receptor in intestinal and bronchial 
smooth muscle by means of direct receptor binding studies with 
radioactively labelled antagonists, preferably a pair of enanti-
omers with a high potency ratio with regard to antihistaminic 
activity. The attempts to synthesize the tritium labelled optical 
isomers of chlorpheniramine will be described in the next chapter. 
SELECTION OF LIGANDS FOR LABELLING 
The principal criteria for the selection of a compound to be 
labelled radioactively and used for tagging receptors are the 
following. 
1. The compound should have the highest affinity for the receptor 
under consideration still compatible with other criteria. 
a) Compounds with a high affinity occupy their specific recep-
tors at low concentrations, thus providing favourable cir-
cumstances for the detection of low concentrations of recep-
tor bound ligand. 
b) Receptor concentrations considerably below the affinity of 
the ligand expressed as its dissociation equilibrium con-
stant will remain undetected. 
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с) Ligands with a high affinity might be expected to have a 
more favourable ratio of specific/unspecific binding. 
2. Compounds should be highly selective with regard to the recep­
tor system searched for. 
a) Compounds which bind to other receptors with a high affinity 
as well, are less suited for the detection of a given recep­
tor in tissue homogenates. 
b) Rigid compounds might in general be more selective than 
flexible compounds, although exceptions are known. 
c) Unspecific binding should preferably be as low as possible. 
Compounds with a relatively low fat solubility might be ad­
vantageous in this respect. 
3. Antagonists are better suited for the detection of receptors 
in tissue homogenates than agonists. 
a) The binding pattern of agonists might, as a consequence of 
the transition of the receptor from a non-mediating to a 
mediating state, be more complex than that of antagonists. 
b) Agonists have in general much lower affinities than antag­
onists . 
c) Once receptors have been traced in tissue homogenates with 
labelled antagonists and methods have been developed to 
purify and concentrate them, agonists are indispensable 
tools in clarifying the molecular mechanisms of biological 
action. 
4. The specific activity of the radioactive label should be suf­
ficiently high. The minimal specific activity required should 
give count rates well above background activity at all concen­
trations of ligands to be used. Carbon-14 labelled compounds 
are less suitable than tritium labelled compounds in this 
respect. 
5. Compounds with a centre of asymmetry in their molecular struc­
ture might be advantageous in some respects and disadvantageous 
in others. 
a) When the two enantiomers of a chiral compound with a large 
potency ratio with regard to biological activity are both 
available in a radioactively labelled form, differences in 
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binding between the two might be advantageous in detecting 
receptor binding and further might be good evidence for 
receptor identity and integrity after subsequent purifica­
tion steps. 
b) Stereospecificity of binding can also be tested with a 
labelled ligand - chiral or not - differentially displaced 
by a pair of non-labelled enantiomers with a large potency 
ratio. 
c) Λ radioactively labelled racemic mixture should be avoided 
whenever possible. A racemic mixture can at best be re­
garded as a labelled ligand which is only 50% radiochemi-
cally pure. 
d) When association and dissociation rate constants of ligands 
and receptors are measured, the presence of a less active or 
non-active enantiomer besides the active enantiomer would 
seriously complicate the interpretation of data and be a 
complete nuisance. 
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PART I THE HISTAMINE RECEPTOR 
CHAPTER 2 
SYNTHESIS OF RAD IOACTIVELY LABELLED 
ENANTIOMERS OF CHLORPHENIRAMINE 

SYNTHESIS OF RADIOACTIVELY LABELLED 
ENANTIOMERS OF CHLORPHENIRAMINE 
SELECTION OF COMPOUNDS FOR LABELLING 
In chapter 1 the advantage of antagonists over agonists and 
especially the use of optical isomers m receptor binding studies 
was discussed. For the histamine-Η receptor extensive lists of 
antihistaminic compounds are available in almost any textbook on 
pharmacology (Van den Brink and Van Rossum, 1975; Douglas, 1975). 
Representatives amongst them which fulfil many if not all the 
requirements for the detection of histamme-H receptor binding 
in tissue and tissue homogenates are listed in Table 1. The pA„ 
values were taken from Simonis (1968). Inspection of the table 
reveals a preference for chlorpheniramine, because the potency of 
the d--isomer is the highest of all and also because neobenodine 
and chlorphenoxamme undergo racemization relatively easy, es­
pecially in alkaline media. Chlorpheniramine suffers less from 
racemization as long as strong alkaline media are avoided. 
Chlorpheniramine was found to be the most potent anti­
histaminic among a variety of compounds made in an extensive 
synthetic program on antihistaminic activity by Schering Corpora­
tion in 1950-1951. 
Its synthesis, described by Sperber et al. in 1951, was 
performed as outlined in scheme 1. The racemic mixture was 
shortly thereafter marketed for clinical use by Schering Corp. 
under the trade name Chlortrimeton maléate. 
Resolution of racemic chlorpheniramine into its optical 
antipodes was reported several years later, almost simultaneously 
by Schering Corp. using the enantiomers of phenyl succinic acid 
as the resolving agents (Roth and Govier, 1958), and by Allen 
and Hanburys using di-p-toluoyl-(+)-tartaric acid and di-p-toluoyl-
(-)-tartaric acid (Brittain et al., 1965). 
From studies in different pharmacological tests it appeared 
that the antihistaminic activity resides almost exclusively in 
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TABLE 1 
CH3-
neobenodine 
C l -
chlorphenoxamme 
pheniramine 
C l -
chlorpheniramme 
compound 
C H - O - C H j C H j - N ^ Ú 
C-O-CH-CH j - l ^ ó 
Q 
C H - C H 2 - C H 2 - N 
/ = < CH3 \ f 
^ - N 
сн-сн
г
-сн
г
-м 
anti-histaminic potency 
(pAj-values ) 
(* ) 8 2 
( • ) 8 5 
( - ) 6 4 
( * ) 8 2 ( O 
C- ) 
( t ) 7 8 
( 0 7 5 
( O 6 0 
( O 9 1 
( O 9 3 
( О 7 8 
the d-isomer. Although there were differences of opinion about 
the activity of the 1-isomer, probably due to different degrees 
of optical purity, it may be concluded from these studies that 
the d-isomer is about two orders of magnitude as active as the 
1-isomer (Roth, 1961). 
SYNTHESIS OF RADIOACTIVELY LABELLED COMPOUNDS 
Inspection of the synthetic route to chlorpheniramine and 
the procedures used for optical resolution reveal that it cannot 
easily be adopted for the synthesis of both isomers in a radio-
actively labelled form. The general strategy for the synthesis 
of radioactively labelled compounds is that the radioactive label 
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Scheme 1 
сі-ч / 
CI-Q-CHj-CN • ^ ) - X ^!^2 C H - C N 
X'CI .Br ^ ) 
CH-CN • CI-CHg-CHj-N ¿ C - C H j - C H j - N 
СНз /=( ч снз 
'41 
P N -СИ, To./.u.QO. М ^ .СН3 
C I 4 1 > C N CH C I ~ W С 
^ / - N .CH3 70·/.Η 2 5α ^ / C 
C - C H j - C H j - 1^ -2—2- CH-CH^CHj-f^ 
is preferably introduced in a final stage under conditions which 
do not require extensive handling of radioactive material or 
considerable purification of the product afterwards. The final 
steps must also be easily adoptable to small scale preparation, 
in order to keep the amounts of radioactive material to be 
handled as small as possible. Then, extensive precautions to 
avoid health hazards and radioactive contamination of equipment 
and laboratory environment need not be taken. 
This strategy is of special importance in our case, because 
it was our aim to make compounds with a high specific activity 
still compatible with relatively poor laboratory facilities. 
Presumably receptor concentrations in tissue are low and a ligand 
with a specific activity which is not sufficiently high may not 
be suited to detect receptor binding above background activity. 
Resolution of racemic mixtures often requires several crystalliza­
tions. Therefore from a strategic point of view resolution of 
radioactively labelled racemates will not be the method of choice. 
Hence it was decided to prepare optically active material in which 
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a radioactive label can be introduced m a final reaction step. 
Both enantiomers can then be prepared in parallel. In this con­
text an appropriate reaction sequence seemed the introduction of 
two methyl groups bearing a tritium label into (+)- and (-)-des-
dimethylchlorphemramine by reductive alkylation with tritium 
labelled formaldehyde and formic acid as outlined in scheme 2. 
Tritium labelled formaldehyde could be purchased from The Radio­
chemical Centre, Amersham, England in the form of tritium labelled 
paraformaldehyde (paraformaldehyde is a linear polymer of foriral-
dehyde with on the average 5-10 formaldehyde units per polymer 
molecule). 
Scheme 2 
C l -
/=\ 
CH-CHj-CHg-NH., • CH2(T)=0 
гЛ u 
/ = \ 
н с о ^ М / с н з ( Т ) 
• ^ £ C H - C H j C H ^ N 
/ = < CHjiT) 
w 
Reductive methylation with paraformaldehyde has several 
advantages over methylation with tritium labelled methyliodide. 
Methylation of primary amines with excess methyl iodide usually 
leads to quaternary ammonium salts. With less methyl iodide a 
mixture of the primary, secondary, tertiary and quaternary amine 
is obtained. Moreover with methyl iodide the pyridine nitrogen 
also will be partly methylated. 
Reductive methylation of primary and also secondary amines 
with a slight excess of formaldehyde generally proceeds to the 
tertiary amines in high yield with no danger of alkylation of 
pyridine nitrogen (Weygand-Hilgetag, 1964). Paraformaldehyde is 
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Jess volatile than methyl iodide and contamination problems due 
to evaporation of radioactive iratenal will be less severe. 
SYNTHESIS OF γ-(p-CHLOROPIIENYL)-γ-(α'-PYRIDYL) PROPYLAMINE 
The synthesis of racemic γ-(p-chlorophenyl)-γ-(α'-pyridyl) 
propylamine and its resolution into its optical antipodes, start­
ing materials in the subsequent methylation step were not de­
scribed in the literature at the beginning of this investigation 
(see scheme 2). The literature on the chemistry of related com­
pounds suggests two routes for the preparation of racemic 
γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine. 
Route A 
Alkylation of p-chlorophenyl-(α-pyridyl) acetonitnle with 
ß-chloroethylamine and sodium amide in toluene yielded γ-cyano-
γ-(p-chlorophenyl)-γ-(α'pyridyl) propylamine. Subsequent hydro­
lysis of the cyano group and simultaneous removal of the result­
ing carboxyl group in 70% sulfuric acid leads to the desired 
propylamine (scheme 3). This route is analogous to the synthesis 
of chlorpheniramine from p-chlorophenyl-(a-pyridyl) acetonitnle 
and N,N-dimethyl-8-chloroethylamine by Sperber et al. (1951). 
Scheme 3 
Cl-
ci-
/==\ 
CH-CN* CI-CH-CH5-NH, N aNH£ 
, 2 2 2 
О 
d 
/==\ 
C-CHj-CHgNl·^ 
d 
CH-CHj-CHjNHj 
Q 
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Route В 
Condensation of p-chlorophenyl-(α-pyridyl) acetomtnle with 
methyl or ethyl acrylate in a base catalyzed Michael-type addi­
tion, subsequent hydrolysis and simultaneous decarboxylation in 
70% sulfuric acid leads to T-(p-chlorophenyl)-γ-(α'-pyridyl) 
butyric acid. Then the terminal carboxyl group is converted into 
an amino group by a Schmidt reaction (Wolff, 1946) giving 
γ-(p-chlorophenyl)-γ-(a'-pyridyl) propylamine (scheme 4) 
Scheme 4 
CH-CN» CHyCH-C-O-CJ-L ^ 0 " B» С-СНг-СНг-С-О-СД. ó Ä ö l 
^ - N V - N 
CI 
\ / 70°leHS,O. \ 
С-СН-СНт-С-О-С-Н, Г 4 CH-CHr-CHz-COOH 
'
 2 26 2 5 /=( a 2 
τ— N ^—Ν 
C H - C H 7 C H - C O O H N ^ 3 2 f ^ ¿ ^ ÇH_ C H-CH2NH 2 
^ // \ ¿t 
Although route В contains one more synthetic step compared 
to route A, the reactions in route В are straightforward and 
generally give high yields. Moreover the alkylation step in route 
A might be troublesome and give a low yield due to the increased 
reactivity of S-chloroethylamine and the increased instability of 
the intermediate aziridimum ion formed, compared to N,N-dimethyl 
3-chloroethylamine. Moreover, m route В two possibilities can be 
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envisaged for separation of enantiomers. Resolution of 
γ-(p-chlorophenyl)-γ-(α'-pyridyl) butyric acid is an attractive 
alternative if the resolution of γ- (p-chlorophenyl) -γ- (et ' -pyridyl) 
propylamine might turn out to be troublesome. A serious warning 
in this respect emerges from the reports on the resolution of 
racemic chlorpheniramine. In the beginning it was impossible to 
obtain crystalline salts with any of the available resolving acids 
(Brittain et al., 19 59). For these reasons preference was given to 
route В for the synthesis of racemic γ-(p-chlorophenyl)-γ-
(α1-pyridyl) propylamine. 
RESOLUTION OF RACEMATES 
Resolution of racemic mixtures of compounds is in most cases 
effected through salt formation or complex formation with an op­
tically active compound, making use of the differences in chemical 
properties, especially the solubility in different solvents be­
tween the diastereoisomeric salts or complexes formed (Boyle, 
1971). The success of a resolution strongly depends on the nature 
of the racemic mixture and the resolving agent used, and is dif­
ficult to predict. The choice of a resolving agent for the separ­
ation of a racemic mixture remains to a great extent a matter of 
trial and error. Chromatographic techniques for separation of 
enantiomers using support materials to which optically active 
resolving agents are covalently bound have been reported, but 
such techniques have found limited synthetic application. For the 
resolution of racemic acids a number of optically active bases 
from natural origin are available, such as brucine, cinchonine 
and quinine (Boyle, 1971). Optically active amines like d- and 
1-amphetamine can be used also. The resolution of racemic mixtures 
of bases can be performed by using optically active acids like 
camphorsulf omc acid, phenylsuccinic acid and 0,0-disubstituted 
tartaric acids, for example 0,0-dibenzoyl tartaric acid. In this 
respect a series of substituted tartranilic acids synthesized by 
Montzka et al. (1968) deserves special attention. These acids are 
reported to have a remarkable resolving power towards a variety 
of racemic organic bases. Difficulties often encountered in resol-
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ution of racemic mixtures are the practical impossibility of ob­
taining crystalline salts and the lack of substantial differences 
in solubility between the diastereoisomenc complexes formed. A 
main consequence hereof is a limited resolution in each crystal­
lization step resulting in only partial resolution or low yields 
of the optically pure enantiomers at the end. 
SYNTHETIC ROUTE TO γ-(p-CHLORO?HENYL)-γ-(α'-PYRIDYL) PROPYLATIINE 
Ethyl y-cyano-y-(p-chLorophenjI'-γ-(a'-pyridylÌ butyrate 
Condensation of p-chlorophenyl-( a-pyridyl) acetonitnle with 
methyl acrylate under basic catalysis of Triton-B(benzyltrimethyl-
ammomum hydroxide), a Michael-type addition reaction, in a yield 
of 60% was described by Tagman et al. in 1952. Vie used the ethyl 
acrylate instead of the methylester and 1,4-dioxane as the sol-
vent. The Michael addition is frequently performed in a kmetical-
ly controlled fashion, hence yields may vary considerably with 
reaction time. After one hour at 80-85 С ethyl y-cyano-y-(p-
chlorophenyl)-γ-(α'-pyridyl) butyrate admixed with starting 
material was obtained in 40%-50% yield. No significant change was 
observed when the reaction time was prolonged to 20 hours. How­
ever, shortening of the reaction time to 30 minutes gave an almost 
pure product in 95% yield. The product is sensitive to base. In 
one instance where potassium carbonate was used as a drying agent 
for a solution of the product in ether, the reaction was reversed 
to a large extent and only starting material could be recovered. 
y-(v-Chloropheny L)-y-( a.'-pypbdyl) butyfbe aaid 
The hydrolysis of the ethylester and the cyano group of 
ethyl y-cyano-y-(p-chloropheny])-γ-(a'-pyridyl) butyrate and the 
concomitant decarboxylation was performed by heating the compound 
in 70% sulfuric acid at 135-140 С for approximately 10 hours, 
essentially as described by Sperber and Fncano (1953). Due to 
its amphoteric character, γ-(p-chlorophenyl)-γ-(α'-pyridyl) 
butyric acid can be extracted from aqueous solution with chloro­
form only in the small pH range of 5.5-6.0. A basic byproduct can 
be extracted first with chloroform at a higher pH. The chemical 
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nature of the byproduct was not further investigated. Y-(p-Chloro-
phenyl)-γ-(α'-pyridyl) butyric acid was thus obtained in 89% yield. 
The compound could be made crystalline by trituration with pentane. 
Because of its poor crystallizability no further attempts to pu­
rify the product were made. 
γ-(p-Chlopophenyl)-γ-С a ' -pyridyl) propylamine 
γ-(p-Chlorophenyl)-γ-(α'-pyridyl) butyric acid was converted 
into γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine by a Schmidt 
reaction with sodium azide and concentrated sulfuric acid (Wolff, 
1946). The product was obtained in 86% yield as an oil by distil­
lation under reduced pressure. According to a gaschromatographic 
analysis γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine thus pre­
pared contains a small impurity only. 
RESOLUTION INTO OPTICAL ANTIPODES 
As indicated in the introduction to this chapter two possi­
bilities to obtain ( + )- and (-)-γ-(p-chlorophenyl)-γ-(α *-pyridyl) 
propylamine can be envisaged. 
i. Resolution of (+)-γ-(p-chlorophenyl)-γ-(a'-pyridyl) propyl­
amine with an optically active acid. 
ii. Resolution of(+)-γ-(p-chlorophenyl)-γ-(α'-pyridyl) butyric 
acid with an optically active base and subsequent conversion of 
both enantiomers to the corresponding propylamines by the Schmidt 
reaction. This approach presumes the absence of racemization under 
the strong acidic conditions of the Schmidt reaction. At first, 
attempts were made to obtain crystalline salts from (+)-γ-(ρ-
chlorophenyl)-γ-(α'pyridyl) propylamine and resolving acids. 
Neither (+)-phenyl succinic acid, dibenzoyl-L(+) tartaric acid 
nor (+)-camphor sulfonic acid failed to deposit crystals upon 
salt formation with (+)-γ-(p-chlorophenyl)-γ-(о'-pyridyl) propyl­
amine. 
Special attention was devoted to (2R:3R)-2'-nitrotartranilic 
acid (see formula) and (2S:3S)-2'-nitrotartranilic acid. Both com­
pounds were synthesized according to Montzka et al. (1968) from 
O-nitroaniline and either (2R:3R)- or (2S:3S)-diacetoxysuccinic 
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anhydride followed by mild basic hydrolysis of the acetyl groups. 
Montzka reported in the same article the excellent resolving prop­
erties of phenyl substituted tartranilic acids in general and the 
o-nitro derivative in particular towards different racemic bases 
which could only be resolved with great difficulty otherwise. 
o-Nitrotartranilic acid gave pure enantiomers after one or two 
crystallizations in these cases. However, with (+)-γ-(p-chloro-
phenyD-Y-U'-pyridyl) propylamine, ( 2R: 3R) -2 '-nitrotartranilic 
acid either added in equivalent or half-equivalent amounts failed 
to yield crystalline material. 
As will be described later a small sample of (+)-γ-(p-chloro-
phenyl)-γ-(a'-pyridyl) propylamine synthesized from (+)-γ-
(p-chlorophenyD-Y-ío'-pyridyl) butyric acid by the Schmidt reac-
tion, when combined with an equivalent amount of (2R:3R)-2'-nitro-
tartranilic acid in the presence of a few drops of diethyl ether 
gave a few crystals after standing for several weeks in the re-
frigerator. These crystals could be used to seed solutions of 
racemic γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine and (2R:3R)-
2'-nitrotartranilic acid, with as a result a successful resol­
ution. 
RESOLUTION OF ( + )- γ-(p-CHLOROPHENYL)-γ-(α'-PYRIDYL) BUTYRIC ACID 
With bases of natural origin like brucine and quinine usually 
only one isomer of a racemic mixture can be obtained by crystal­
lization from a chosen solvent. For the isolation of its optical 
antipode sometimes a change in solvent is sufficient but more 
often another resolving agent is needed. Synthetic bases of which 
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both enantiomers are available as is the case with amphetamine 
are advantageous in this respect, because if one enantiomer can 
be isolated with the d-form, the other can be obtained in exactly 
the same manner with the 1-form of the resolving agent. When a 
small sample of (+)->-(p-chlorophenyl)-γ-(α'-pyridyl) butyric 
acid was treated with one equivalent amount of (+)-amphetamine 
in methanol, a crystalline salt was readily obtained after evap­
oration of the solvent. This could be used to seed a solution of 
racemic γ-(p-chlorophenyl)-γ-(a'-pyridyl) butyric acid and ( + )-
amphetamine from which a white woolly crystalline mass separated. 
From the mother liquid the partially resolved optical antipode 
could be recovered and converted to the enantiomeric salt with 
(-)-amphetamine. Upon further crystallization the optical rota­
tions of both salts gradually increased until after 6 crystalli­
zations no further increase was observed. 
A high optical purity particularly for the pharmacologically 
least active isomer is advantageous in analysis and in vivo test­
ing of the radioactively labelled enantiomers. Therefore a few 
more crystallizations to attain that high optical purity were 
performed. It was found that optical rotations were not very 
constant after each crystallization step and to a certain extent 
dependent on the way samples were processed before measuring them. 
Small samples were dried in a drying pistol under vacuum at elev­
ated temperature. Rotations varied with the duration of drying to 
such an extent that it could not be attributed to varying amounts 
of residual solvent. A likely explanation is the following; amphet­
amine is rather volatile at low pressure with the consequence that 
it can escape slowly from the salt during the drying process and 
leaving behind the zwitterionic salt of y-(p-chlorophenyl)-γ-
(α'-pyridyl) butyric acid. A similar phenomenon is encountered 
frequently during drying of hydrogen halide salts of organic 
bases. Here too the hydrogen halide slowly escapes from its amine 
salts upon drying at reduced pressure. 
The partially or completely resolved (+)- and (-)-γ-(p-chloro­
phenyl) -γ-(α'-pyridyl) butyric acidscould be liberated from their 
amphetamine salts and their optical rotations measured after each 
crystallization step. Due to the amphoteric nature of y-fp-chloro-
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phenyl)-γ-(α'-pyridyl) butyric acid and consequently the narrow 
pH range at which it can be extracted from aqueous solutions it 
was not easy to recover the acid on a small scale. Moreover due 
to loss of material during nine crystallizations only a few grams 
of the salts were left at this stage. In view of the low yield in 
the end and the uncertainty with respect to the optical purity it 
is evident that the resolution of racemic γ-(p-chlorophenyl)-γ-
(α'-pyridyl) butyric acid with (+)- and (-)-amphetamine is, al­
though the only method available for the time being, laborious 
and not very satisfactory. 
Part of the (+)-γ-(p-chlorophenyl)-γ-(α'-pyridyl) butyric 
acid was liberated from its (-)-amphetamine salt and converted 
into (+)-γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine by the 
Schmidt reaction. As already mentioned, the salt of this amine 
and (2R:3R)-2'-nitrotartranilic acid could be obtained crystal­
line after several weeks in the refrigerator in the presence of 
a little diethyl ether. The crystals were used to seed a solution 
of racemic γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine and half 
an equivalent amount of (2R:3R)-2'-nitrotartranilic acid. 
RESOLUTION OF γ-(p-CHLOROPHENYL)-γ-(α'-PYRIDYL) PROPYLAMINE 
When a warm solution of racemic γ-(p-chlorophenyl)-γ-
(α'-pyridyl) propylamine and half an equivalent amount of (2R:3R)-
2'-nitrotartranilic acid in 96% ethanol was seeded and slowly 
cooled to room temperature yellow needles separated in approxi­
mately 80% yield and another 15% could be obtained by work-up of 
the mother liquid. The combined crystal crops gave the optically 
pure salt after one recrystallization. A second recrystallization 
gave no further increase in optical rotation. The (+)-γ-(D-chloro-
phenyl)-γ-{a'-pyridyl) propylamine was liberated from this salt 
and converted to its monoformate by adding one equivalent amount 
of formic acid in 1,2-dichloroethane. Upon further recrystalliza­
tion of the monoformate from 1,2-dichloroethane no further in­
crease in optical rotation was found. The (-)-γ-fp-chlorophenyl)-
γ-(α'-pyridyl) propylamine was recovered from the mother liquid 
after the second crop of (+)-γ-(p-chlorophenyl)-γ-(α'-pyridyl) 
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propylamine (2R:3R)-2'-nitrotartranilate had separated by diethyl 
ether extraction and directly converted to its monoforrrate salt 
with formic acid. Crystallization of the monoformate from 1,2-di-
chloroethane gave the laevorotatory compound. The rotations were 
somewhat lower than those found for the dextrorotatory isomer. 
Recrystallization from 1,2-dichloroethane was continued until no 
further change in the optical rotations was found. This was the 
case after 3 crystallizations. 
(+)- and (-)-N,N-DIMETHYL-Y-(p-CHLOROPHENYL·)-γ-(a'-PYRIDYL) 
PROPYLAMINE 
The conversion of (+)- and (-)-γ-(p-chlorophenyl)-γ-
(α'-pyridyl) propylamine to their dimethyl derivatives by the 
Eschweiler-Clarke method was performed under a variety of con­
ditions with unlabelled paraformaldehyde in order to find optimal 
conditions for the labelling procedure itself (Clarke et al., 1933 
Pine, 1971). The reaction appeared to be quite practicable on an 
0.1 mmolar scale, giving yields of 60-70% of the product at 75-30° 
for 2 hours in 50% formic acid. No measurable racemization oc­
curred under these CJrcumstances as judged by the specific rota­
tions of the products, which agreed well with those of authentic 
samples of ( + )- and (-)-chloropheniramme. At lower temperatures 
the reaction slowed down progressively with almost no carbon-
dioxide evolution below 60 C. Temperatures above 80 С were 
avoided to minimize the danger of racemization. In one instance 
where a reaction mixture had been exposed to 100 С for one hour, 
rotations were considerably reduced. The isolation of the product 
in the unlabelled form could easily be achieved by extraction of 
a slightly basic aqueous solution of the compounds with diethyl 
ether, salt formation with oxalic acid and crystallization of the 
monooxalates from ethyl acetate. When following this procedure in 
the actual labelling in the presence of Curie amounts of tritium 
contamination problems can be expected. When the products could 
be isolated by column chromatography, mixing of aqueous solutions 
and organic solvents could be avoided and risks of contamination 
considerably reduced. Thus, after evaporation of volatile compo-
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nents from the reaction mixture, the residue was brought on a 
silicagel column equilibrated with cyclohexane/benzene. After 
preelution of impurities with cyclohexane/benzene, a mixture of 
cyclohexane/benzene/diethylamine (80/15/5) rapidly eluted the 
product. Evaporation of the solvents in a nitrogen stream, treat-
ment of the residue with decolorizing charcoal in diethyl ether 
and subsequent crystallization of the oxalate salts from ethyl 
acetate afforded both optically active isomers m an overall 
yield of 60-70%. 
TRITIUM LABELLED PARAFORMALDEHYDE 
Tritium labelled paraformaldehyde can be prepared by the 
Wilzbach method (Wilzbach, 1957; Evans, 1966); 10-100 mg of the 
compound to be labelled is brought together with a large amount 
of tritium gas, usually 10-100 Ci of carrier free tritium. The 
ß-radiation of the tritium labellizes atom-atom bonds and induces 
free radical chain reactions resulting in exchange of hydrogen 
atoms bound to carbon, oxygen and nitrogen for tritium providing 
a tritium labelled substrate. The success of such an exchange 
reaction depends largely on the chemical properties of the com-
pound and often serious decomposition occurs simultaneously, 
necessitating extensive purification afterwards. To begin with 
excess tritium gas has to be removed by degassing. Tritium atoms 
in labile positions in the molecule, such as those bound to oxygen 
and nitrogen can be removed by repeated addition of water or other 
protic solvents and subsequent evaporation. Finally, non-volatile 
decomposition products which may also be labelled must be removed 
by crystallization or chromatographic purification techniques. 
Paraformaldehyde is a linear polymer of formaldehyde with on the 
average five to ten formaldehyde units per polymer molecule. 
HO - (CH- - O) - Η η = 5-10 
¿ η 
Paraformaldehyde contains two types of hydrogen, carbon bound and 
oxygen bound. Under the conditions of the Wilzbach labelling, 
oxygen bound hydrogen exchanges much faster than carbon bound 
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hydrogen. The oxygen bound tritium in paraformaldehyde after 
Wilzbach labelling would probably constitute the majority of the 
tritium present. The tritium thus bound would not be of much use 
in the subsequent methylation step, because it would rapidly ex­
change for hydrogen with other components of the reaction mixture 
and would not become incorporated into the product. Moreover this 
tritium present as part of volatile components like water and 
formic acid would become a nuisance in further processing the 
reaction mixtures. Therefore we considered the removal of labile 
tritium of paramount importance. Wilzbach labelling is not a nor­
mal laboratory routine. It requires specialized skills and eauip-
ment to handle the large amounts of tritium (up to 100 Ci) in­
volved and is usually performed by manufacturers of radioactive 
materials. At special request The Radiochemical Centre, Amersham, 
England prepared tritium labelled paraformaldehyde by exposing 
the unlabelled compound to 100 Ci carrier free tritium gas for 
10 days. It was agreed that excess tritium gas and labile tritium 
would be removed at The Radiochemical Centre. This appeared to be 
troublesome. Upon adding methanol to the labelled paraformaldehyde 
and evaporation under reduced pressure most of the compound was 
lost. With water nothing was left at all. Most likely paraformal­
dehyde depolymerizes in aqueous or methanolic solution and is 
lost as monomeric formaldehyde during evaporation under reduced 
pressure. 
TRITIUM LABELLED (+)- AND (-)-N,N-DIMETHYL-Y-(p-CHLOROPHENYL)-γ-
(a'-PYRIDYL) PROPYLAMINE 
Upon further consideration it was agreed with The Radio­
chemical Centre that the labelling of paraformaldehyde would be 
repeated. Only gaseous tritium would be removed. The subsequent 
methylation step of (+)- and (-)-γ-(p-chlorophenyl)-γ-(о'-pyridyl) 
propylamine would also be carried out at The Radiochemical Centre 
according to our experimental procedures mentioned above for the 
Eschweiler-Clarke reaction. At this stage labile tritium would 
be removed by repeatedly adding methanol to the crude reaction 
mixture and evaporating at reduced pressure. The residues would 
59 
be dissolved in benzene and supplied to use for further process­
ing and purification (see experimental part). 
EXPERIMENTAL PART 
Ethyl y-ayano-y-fp-oklorophenyI)-γ-(a'-руггауіÌ butyrate 
To a solution of p-chlorophenyl- ( a-pyridyl) acetonitnle 
(22.9 g, 0.100 mol.) in 30 ml of anhydrous and peroxide-free 
1,4-dioxane, a solution of Tnton-B in methanol (0.5 ml, 40%) was 
added with stirring. At a temperature of 80-85oC, 15.0 g (0.150 
mol) ethyl acrylate was gradually added in 20 minutes with 
stirring. After the addition was completed the reaction mixture 
was kept at 80-85 С for 15 m m and then rapidly cooled to room 
temperature. Then water (150 ml) was added, followed by extrac­
tion with ether (300 ml). The ether extract was thoroughly washed 
with 50 ml portions of water, dried shortly over anhydrous sodium 
sulphate and then concentrated at reduced pressure. Distillation 
of the residue gave 31.2 g (0.095 mol) of an almost colorless 
oil, b.p. 167-170oC/0.17 mm. Yield 95%. The oil crystallized 
slowly on standing. A small sample recrystallized from heptane 
had a melting point of 57.5-59.5 C. 
y-(Chlorophenyl)-γ- (Ό '-pyrzdyl) ЪиЬу гв acid 
A mixture of ethyl y-cyano-y-(p-chlorophenyl)-γ-(α'-pyridyl) 
butyrate (50.0 g, 0.152 mol) and 70% sulfuric acid (110 g) was 
heated with continuous stirring at 130 С during 10 h. After cool­
ing to room temperature, the reaction mixture was poured into ice 
water (1 1). The aqueous solution was neutralized with solid 
sodium carbonate, made basic (pH 9-10) with concentrated sodium 
hydroxide solution and extracted with chloroform (extract I). 
The aqueous layer was brought to pH 6.0 with 50% sulfuric acid 
and extracted with chloroform (extract II). Extract I gave after 
drying over anhydrous potassium carbonate and evaporation of the 
solvent 6.9 g of an oily product which could not be identified. 
Extract II was washed with small portions of water, dried over 
anhydrous sodium sulphate and concentrated. The oily residue 
crystallized slowly on standing. Thorough drying of the product 
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under reduced pressure gave 37.2 g (0.135 mol) crystalline 
material melting at 102-105oC. Yield 89%. 
γ- (p-Chlorophenyl) -γ- С α ' -руггауі) propylamne 
γ-(p-Chlorophenyl)-γ-(a'-pyridyl) butyric acid (33.0 g, 
0.138 mol) was added in small portions to cold concentrated 
sulfuric acid. The temperature was raised to 50 С and then sodium 
azide (17.9 g, 0.275 mol) v/as added m portions of about 200 mg 
in 4 h. Each portion of sodium azide was added after the gas 
evolution of the preceding one had subsided. After the addition 
was complete, the mixture was heated at 50 С for 3 h, then left 
at room temperature overnight. After careful dilution with ice 
and water (temp. < 15 C), the aqueous solution was neutralized 
with solid sodium carbonate, made basic with concentrated sodium 
hydroxide solution and extracted with chloroform. The chloroform 
extract was washed with water, filtered and concentrated. Distil­
lation of the residue under reduced pressure gave 29.4 g (0.119 
mol) of a slightly yellowish oil, b.p. 144-144.5 C/0.3 mm. Yield 
86%. The product contains a minor impurity, as was deduced from 
a gaschromatographic analysis on a 3% UCW-98 on Gaschrom-O (60-80 
mesh) column at 175 C. 
Pesolutbon of (+_)-y-(p-ehlorovneayl)-y-( a '-vyrtdyl) Ъиіугга аагд. 
Racemic γ-(p-chlorophenyl)-γ-(α'-pyridyl) butyric acid (32.0 
g, 0.116 mol) and (+)-amphetamine (7.84 g, 0.058 mol) were dis­
solved in ethyl acetate (600 ml). The solution was heated to 
boiling, filtered and cooled slowly to room temperature. The 
crystals were recrystallized from ethyl acetate giving 9.1 g salt 
melting at 127-138 С (rotations: ^ aj] -„Q - 7.6 ; [^ a^  S7a - ^'^ ' 
M 5046 - 9·0θ<· M 42?6 - ΐ8·3θ<· C O 365 - 39·4θ> • 
Upon repeated crystallization the rotations slowly increased. 
After 8 crystallizations 2.5 g of the salt v/as left over (rota-
i- -i 24 , . .ο ι- -i 24 ., _ „o r- -, 24
 η
 _.
 Qo tions: £сГ|
 5 8 9 - 14.4 ; [>] 5 7 3 - 15.0 ; Qa^ 5 4 6 - 17.8 ; 
O D 436 " 3 5 · 8 0 ; [>H 3G5 " 7 3 · 3 0 (c=1.0 in methanol) ) . 
The mother liquid of the first crystallization was concentrated. 
Water was added to the residue and then l M sodium hydroxide 
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solution till basic (pH > 9). The solution was thoroughly ex­
tracted with ether, then brought to pH 6.0 with dilute hydro­
chloric acid and extracted with chloroform. The chloroform was 
evaporated and remaining water removed azeotropically with ab­
solute ethanol. The residue was dissolved together with 7.84 g 
(0.058 mol) (-)-amphetamine in ethyl acetate (300 ml) by heating. 
After filtration of the hot solution and cooling to room tempera­
ture 20.7 g crystalline salt melting at 120-130 С was obtained. 
Two recrystallizations from ethyl acetate gave 13.8 g crystalline 
salt melting at 130-140OC (rotations: [^ α] ^ + 9.3°; 
:
-. 20 , ,_ „ο ι- -ι 20 , _, .
 Ο
ο ,- -, 20 „η .ο. 
aH 546 + 1 2 · 0 ; Μ 436 + 2 4 · 2 ; Μ 365 + 4 9 · 4 ) · 
After six consecutive recrystallizations 6.5 g of the salt was 
left (rotations: [>;] 2 ° 9 + 14.6°; [α]
 2
° 8 + 15.1°; [^ cQ ^ g + 17.7°; 
\lal 436 + 35·00'· [>H 365 + 7 0 · 7 0 (c=1.0 in methanol) ) . 
Resolution of ( + )-y-(p-chlorophenyl)-y-(a'-pyridyl) propylar ine 
(+)-γ-(p-Chlorophenyl)-γ-(α'-pyridyl) propylamine (24.7 g, 
0.100 mol) and (2R:3R)-2'-nitrotartranilic acid (13.5 g, 0.050 
mol) were dissolved in 96% ethanol (300 ml) by heating. After 
a little cooling, the solution was seeded with a crystal of the 
(2R:3R)-2'-nitrotartranilate of (+)-γ-(p-chlorophenyl)-γ-
(α'-pyridyl) propylamine. Upon further cooling to room tempera­
ture 20.2 g yellow crystals melting from 7 6-90 С separated (rota-
j. · ι- -ι 20 ,
 c r
.
 0o ,- -, 20 , t _ -o i- -i 20 , -, ι -1° tions: 0 3
 5 8 9 + 59.8 ; [>] 5 7 8 + 62.6 ; QoQ 5 4 6 + 71.2 ; 
La3 436 + 1 0 7 · 4 0 (c=1-0 i n methanol)). 
Concentration of the mother liquid to 150 ml and cooling to 0 С 
gave another 4.0 g of crystals with somewhat lower rotations. 
Combination of both crystal fractions and crystallization from 
96% ethanol gave 21.2 g (0.041 mol) salt with the following rota-
±. • г- -i 20 . -_ _o ι- -i 20 , ,
c
 ,o r- -i 20 , _, . -o 
tions: Qa]
 5 8 9 + 62.2 ; Qa^] 5 7 8 + 65.3 ; Qa] 546 +
 7 4
·
5
 · 
C a3 436 + 1 1 4 · 2 0 (c=1.0 in methanol)). 
A second recrystallization gave no further increase of optical 
rotations. From 18.0 g of the salt (+)-γ-(p-chlorophenyl)-γ-
(α'-pyridyl) propylamine was liberated by dissolving it in 500 ml 
1 M sodium carbonate solution and subsequent extraction with ether. 
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The ether extract was washed with 0.1 M sodium carbonate solution, 
then with water and concentrated under reduced pressure. Residual 
water was removed by azeotropic distillation with absolute ethanol 
in vacuo. The remaining oil (6.6 g) was converted to the mono-
formate by dissolving it in hot 1,2-dichloroethane and adding 
an equivalent amount of formic acid. Upon cooling 6.9 g of white 
crystals separated (rotations: Q a^ ] rnq + 50.7 ; QaQ J-TQ + 53.6 ; 
Ы sîe + 6 2 · 7 0 ' · C O 436 + ι 2 1 Λ θ · C O 2зб5 + 2 6 5 · 3 0 ( c = 1 · 0 i n 
methanol)). Two consecutive recrystallizations from 1,2-dichloro­
ethane gave no significant increase in optical rotations. Final 
yield: 6.4 g (+)-γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine 
formate. The mother liquid remaining after crystallization of the 
second crop of (+)-γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine 
(2R:3R)-2'-nitrotartranilate was concentrated under reduced press­
ure. The residue was dissolved in 1 M sodium carbonate solution 
(500 ml) and the amine extracted with ether (500 ml). The ether 
extract was washed with 0.1 M sodium carbonate solution and with 
water and then concentrated in vacuo. Residual water was removed 
with absolute ethanol. The remaining yellow oil (13.0 g, 0.053 
mol) was dissolved in hot 1,2-dichloroethane (300 ml), and formic 
acid (2.30 g, 0.050 mol) was added. Upon slow cooling to room 
temperature 10.1 g of white crystals separated (rotations: 
C O 589 - 47.0°; Ца] ^  _
 4 9 . 5 o ; ^ 2 ^ _ 5 7 . 7 o ; 
C O 436 "" 117-70'· C O 365 ~ 2 4 7 · 2 0 (c=1.0 in methanol)). Three 
recrystallizations from 1,2-dichloroethane gave 8.2 g crystals 
/ j. j. • ι- -i 20 .„
 r
o r- -, 20 ,-,, „o r- -, 20
 r
 _
 Oo (rotations: QoQ
 5 8 g - 49.6 ; Qa] 5 7g - 52.0 ; QoQ 5 4 6 - 60.8 ; 
C O 436 ~ 1 2 4 · 1 0 ; C O 365 " 2 6 0 · 6 0 (c=1.0 in methanol)). 
No further increase in the optical rotations was achieved upon 
further crystallization. Final yield: 8.2 g of (-)-γ-(p-chloro­
phenyl) -γ-(а'-pyridyl) propylamine formate. 
( + ) - and (-) -iVj ¡Ί-dime thy Ι-χ- (p-ahlorophenyl) -y- (a '-pyridyl) 
propylamine 
The procedure described is that of the (+)-isomer. The prep­
aration of the (-)-isomer proceeded similarly. 
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(+)-γ-(p-Chlorophenyl)-γ-(α'-pyridyl) propylamine íormate (29.3 
mg, 0.100 mol), paraformaldehyde (7.3 mg, about 10% excess), 
water (50 mg) and forme acid (100 mg) were weighed successively 
into a 5 ml reaction vessel equipped with a small reflux conden-
sor. The mixture was heated in an oil bath at 70-75 С (bath 
temperature) for one hour and for another hour at 75-80 C. The 
initially rapid CO^-evolution then had almost ceased. After 
cooling to room temperature volatile material was removed under 
reduced pressure. The residue, weighing about 40 mg, was purified 
by column chromatography on silicagel. 6.5 g of silicagel (Kiesel-
gel 60 reinst, 70-230 mesh ASTM für die Säulenchromatographie 
Merck 7754) was suspended in cyclohexane and the suspension poured 
into a glass column (200 mm, diam. 8 mm). After equilibration of 
the column the residue was transferred to it with five one ml 
portions of benzene. The column was first eluted with 40 ml 
cyclohexane/benzene (80/20) to remove impurities and then with 
60 ml cyclohexane/benzene/diethylamine (80/15/5). The eluted 
fractions were tested qualitatively for the presence of product 
by thin-layer chromatography (chromatography on DC-Fertigplatten 
Kieselgel 60 Fpc^, 0.25 mm thickness, Merck 57 15 with cyclohexane/ 
benzene/diethylamme (75/15/10) as the eluent. Spots were detected 
by u.v. fluorescence quenching). Most of the product was present 
in fractions eluting from the column between 20 and 27 ml. These 
fractions were combined and freed from solvent by evaporation 
under reduced pressure. The resulting yellowish oil was dissolved 
in diethyl ether (10 ml) and the solution treated with a small 
amount of decolourizing charcoal (5-10 mg). After filtration and 
evaporation of the diethyl ether 25.6 mg of an almost colourless 
oil was left. The product was converted to the oxalate salt by 
dissolving it in methanol with an equivalent amount of oxalic 
acid dihydrate (11.7 mg). The residue after evaporation of the 
methanol was crystallized from ethyl acetate (10 ml). The white 
crystalline product (22.0 mg) melted at 135.5-137.5 С (rotations: 
20 , .
r
 ,o r- -, 20 , .
n л
о г- -, 20 ,
 c c
 .о r- -ι 20 C -i Ο ι -, .Ο , 1) _,- .Ο ι- -, U 1 Ί Ί -Ο α 1 589 + 4 5 · 1 '" Μ 578 + 4 7 · 4 ? CO 546 + 5 5 '4 '" Μ 436 + ^ ' 5 ; 
С
Л
И 365 + 2 2 9 · 2 0 (c=1.0 in methanol)). Yield 22.0 mg, 0.060 mmol 
(60%). The same procedure for the (-)-isomer gave 21.6 mg white 
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crystals melting at 136-138 С (rotations: Га~\ -„„ - 44.2 ; 
M 5708 - 46·70'· M He - 54·5θ<· M 436 - 109·20'· 
CaII 36" " 2 2 6 · 2 0 (c=1-0 l n methanol)). Yield 21.6 mg, 0.059 mmol 
(59%) . 
Purification of trzігип Labelled (+)- and (-)-N, Ч-лътеthyl-y-
(p-chloropneryl) -y- ( a ' -vyridjl) pvopylamne 
Batches of crude tritium labelled (+)- and (-)-N,N-dimethyl-
γ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine in 25 ml benzene 
solution containing approximately 1.5 Ci of tritium each were 
obtained from The Radiochemical Centre, England. The purification 
was performed at the "Instituut voor Toepassing van Atoomenergie 
in de Landbouw (ITAL)", Wageningen, The Netherlands. 
All manipulation of radioactive material was done in a well 
ventilated hood under continuous surveillance of a Nuclear 
Enterprise type 1762 A radioactive gas monitor (air velocity 
10 1/min). The air outlet of the hood was equipped with dispos­
able activated charcoal filters. 
The ampoule containing the (+)-isomer released considerable 
amounts of gaseous radioactive material (> 500 pCi/cm ) upon 
opening, constituting a serious contamination and health physics 
problem. It was decided to go through the whole sequence of ex­
perimental steps with a small part of the ampoule contents before 
considering any further processing of the whole batches containing 
(+)- and (-)-isomer. 
Purifica l ί,οη of ЪУИЪЛТ* labelled ( + ) -!!, 7-агпе thy l-y- (p-onloro-
vhenyl)-y-' a '-руггі .І) рго уіатьпе on a small scale 
36.4 mg (0.100 mmol) (+)-Ν,N-dimethyl-Y-(p-chlorophenyl)-γ-
(α'-pyridyl) propylamine was dissolved in 2.0 ml methanol; 1.0 
ml (4% of the ampoules contents) of batch TRO 194 containing the 
tritium labelled (+)-isomer was added and the total volume made 
up to 25.0 ml with benzene. The total activity of the solution 
appeared to be approximately 75 mCi upon sampling and measurement. 
The solution was transferred to a 50 ml round bottom flask and 
evaporated until dry with a stream of nitrogen. The nitrogen 
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supply was protected from radioactive contamination by washing 
bottles with activated charcoal, silicagel and paraffin oil. The 
expelled nitrogen was led through a dry ice/acetone condenser, a 
trap immersed in dry ice/acetone, a washing bottle with activated 
charcoal and finally into the outlet system of the hood. The 
crystalline residue after evaporation of the solvent was dis-
solved in approximately 2 ml of methanol and the solution brought 
onto a column (1 = 200 mm, diam. 8 mm) of 6.5 g of silicagel 
(Kieselgel 60 reinst, Korngrösse 0.063-0.200 mm, 70-230 mesh 
ASTM, Merck) suspended in cyclohexane/benzene (80/20). The column 
was pre-eluted with 40 ml cyclohexane/benzene (80/20) to remove 
minor impurities and then with 60 ml cyclohexane/benzene/diethyl-
amine (80/15/5). The cyclohexane/benzene/diethylamine eluate was 
collected in 12 fractions, ranging in volume from 2-25 ml and the 
radioactivity of each fraction measured by Liquid Scintillation 
Counting after appropriate dilution. Samples were counted in a 
Nuclear Chicago Mark I Liquid Scintillation Counter in 15 ml 
scintillation cocktail (5.0 g Terphenyl , 0.5 g Dimethyl POPOP, 
Toluene ad 1 1) with an efficiency of 45%. The volume activity 
profile of the columns eluate is shown in Figure 1. Of the total 
activity eluted from the column 89% was found in a single fraction 
eluting between 14.5 and 19.5 ml. The activity eluted from the 
column amounted to only 18% of the total activity applied to it 
mCi/ml-ICr3 
3000-
2000 -
1000-
8 16 24 32 40 48 56 64 
elution volume ( ml ) 
F i g . 1 Elution profile of ( + ) -N, N-diiie thy £ - i - (p-chlovopheny I) -y-
(a '-piridyI) propylamine- H 
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LLüSS^^^BBI^B 
and present in 1.0 ml of batch TRQ 194. This implies that over 80% 
of the radioactivity in batch TRQ 194 is present as impurities, 
largely resinous products strongly adhering to the silicagel at 
the top of the column. The radiochemical purity of fraction 4 was 
checked by thin-layer chromatography on a silicagel plate (DC-
Fertigplatten, Kieselgel 60, 0.25 mm thickness, Merck) with cyclo-
hexane/benzene/diethylamine (75/15/10) as eluent. After develop­
ment of the chromatogram 1 cm strokes of the plate were scraped 
off and mixed with 15 ml scintillation cocktail (Toluene/0.5% 
Terphenyl/0.05% Dimethyl POPOP). The samples were counted for 1 
minute in a Nuclear Chicago Mark I Liquid Scintillation Counter 
set for tritium counting. The radioactivity distribution is shown 
in Fig. 2. Over 96% of the radioactivity is contained in the 
product peak. A minor contamination remains on the start. The 
small scale purification was considered satisfactory and no in­
surmountable difficulties with higher amounts of tritium were 
anticipated. It was decided to proceed with the purification of 
batches TRQ 194 and TRQ 195, containing the (-)- and the (-)-
isomer in an analogous manner. 
cpm 
400.000 η 
200.000-
-••V ' 
Φ 
ш 
= ™ — , гн 
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start 
15 
I cm 
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F i g . 2 Thin-layer ahvomatogram - radiochemical purity of fraction 
4 eluting between 14.5 and 19.5 τι I from a silicagel column 
with cyclohexane/benzene/diethylarnine (80/15/5 ) . Elution 
time 24 min; elution distance 12.5 cm; total activity on 
start 3,000,000 dpm.; eluent: cyclohexane/benzene/diethyl-
amine (7 5/15/10). 
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Purrfboatbon of Сигге атолпів of (+)- and '-)-Л,N-dbieihyl-y-
(p-chlorophenyl)-y-(a '-pyrtdyJ) propylamine 
The contents of batch TRQ 194 and batch TRQ 195 were trans­
ferred to 50 ml round bottom flasks and taken to dryness with a 
stream of nitrogen with adequate protection of the nitrogen 
supply and similar contamination precautions as described earlier 
for the purification of a 1.00 ml sample of TRQ 194. The nitrogen 
flow was continued 3-5 hours after the solvent had evaporated m 
order to expelí most of the volatile radioactive material which 
mignt still be present. The dark-brown oily residues were shortly 
thereafter redissolved in 3 ml of benzene to minimize autoradio-
lysis on standing. 
At this stage radioactive contamination of equipment and 
waste material was measured and had not exceeded acceptable 
levels. The column chromatographic purification of both isomers 
was performed parallel. 6.5 g of silicagel for each column was 
suspended in cyclohexane and the suspensions poured into glass 
columns partly filled with cyclohexane. Special care was taken, 
that the columns did not contain any air bubbles. The columns 
were placed in half open plastic cylinders to protect them from 
disturbing influences of the air draft in the hood, maintained 
to keep radioactive contamination of the laboratory environment 
below acceptable levels. The columns were equilibrated with 40 ml 
cyclohexane/benzene (80/20) after which the 3 ml benzene solutions 
of (+)- and (-)-isomer were placed on the top of the columns. The 
brown-coloured impurities strongly absorbed at the top of the 
column except for a 1 cm broad yellow band, which moved slowly 
downwards with benzene. This was surprising, because in the small 
scale purification only some brown resinous material, strongly 
absorbing at the top of the column, was observed. The yellow band 
was first removed from the column with benzene prior to the addi-
tion of diethylamine, a basic component, that would also have 
eluted the product. After 60 ml of benzene had been eluted the 
yellow band had left the column. The columns were again equi-
librated with cyclohexane/benzene (80/20) and then the products 
were eluted with cyclohexane/benzene/diethylamine (80/15/5) . The 
products moved down the columns as easy visible transparent bands 
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and were collected in one fraction of 5 ml. Collection was 
started just before the transparent bands left the columns; for 
the (+)-isomer between 13.5 and 18.5 ml of eluate and for the 
(-)-isomer between 15 and 20 ml. Other fractions were collected 
thereafter, but these were not processed further to recover 
products. 
The m a m fractions, hereafter referred to as fractions 4(+) 
and 4(-) were transferred to 25 ml measuring flasks and the sol­
utions made up to 25 ml with benzene. The radiochemical purity of 
both fractions 4(+) and 4(-) was checked by thin-layer chromato­
graphy. 100 \xl of the 25 ml solutions of each isomer was mixed 
with 9.9 ml carrier solution. The carrier solution contained 
1.0 mg/ml (+)-N,N-dimethyl-Y-(p-chlorophenyl)-γ-(α'-pyridyl) 
propylamine in benzene. The solution thus obtained was further 
diluted by mixing 1.00 ml of it with 9.0 ml carrier solution. 
From this secondary solution 25 μΐ for the (+)-isomer and 50 yl 
for the (-)-isomer were spotted on thin-layer plates (DC-Fertig-
platten Kieselgel 60, layer thickness 0.25 mm, Merck). The 
chromatograms were developed with cyclohexane/benzene/diethyl-
amme (75/15/10) and after drying 1.00 cm strokes were scraped 
off and mixed with 14 ml scintillation cocktail (Toluene/Terphenyl 
0.5%/Dimethyl POPOP 0.05%) and 1.0 ml carrier solution containing 
5.0 mg (+)-carrier per ml benzene. The samples were left for 24 
hours and then counted in a Nuclear Chicago Mark I Liquid Scintil­
lation Counter for 10 minutes. The radioactivity distribution on 
the chromatograms is shown in Fig. 3a, b. Of the total radio­
activity on the plates 96.8% and 96.7% for (+)- and (-)-isomer 
respectively is present in the product peak. Assuming a counting 
efficiency of 35% the total activities in fractions 4(+) and 4(-) 
were calculated to be approximately 206 mCi and 229 mCi, respect­
ively . 
The 25 ml solutions of (+)- and (-)-isomer were further 
processed as follows. The solvents were evaporated with a stream 
of nitrogen and the light-brown residues, which darkened appreci­
ably in colour already on standing for a few hours, were redis-
solved m 10 ml diethyl ether. The ethereal solutions were treated 
with a small amount of decoloun/mg charcoal (10 mg) by swirling, 
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and ( -) -"'ff-.Vj N-dime thyl-y- (p-ahlorophenyl) -γ- (a '-pyridyl) 
piOvy lamine after aol.i'nn Chromatographie purification 
(Fraction 4(+) and 4(-)). 
then filtered through two layers of filterpaper and taken to dry­
ness again with a stream of nitrogen leaving almost colourless 
oily residues. For the (+)-isomer 28.4 mg of oily residue was 
found. The residues were not completely freed from solvents, 
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because this would have implied prolonged treatment of the product 
in a concentrated form with as a consequence the risk of appreci­
able autoradiolysis. For this reason no accurate dry weight was 
determined and it was assumed that the crude yield in this stage 
of purification was around 90%, the same as was found more than 
once in preparing the unlabelled isomers. Based on this assumption 
10.9 mg (0.086 mmol) and 11.3 ng (0.090 mmol) of oxalic acid di-
hydrate was added to the residues of (+)- and (-)-isomer, resp., 
a minimal amount of methanol added to effect dissolution and the 
methanol evaporated with a stream of nitrogen. The residues v/ere 
dissolved in 10 ml ethyl acetate by heating at a temperature 
slightly below boiling. The warm solutions were filtered through 
filterpaper, the receivers wrapped in cotton wool and set aside 
for crystallization overnight. Crystallization was much slower 
compared with the unlabelled material. 
The crystals consisted of small cubes instead of the white 
needles obtained in the unlabelled case. In fact the crystals re­
sembled much more those obtained upon crystallization of the mono-
oxalate of the racemic mixture than those of the pure isomers. 
Although other explanations are feasible, the possibility that 
racemization might have taken place cannot be excluded. Especially 
radiation-induced racemization of the optically active compounds 
deserves serious consideration. Because at the time racemization 
could neither be proved nor disproved, both crystals crops were 
further treated as if no racemization had taken place. The crys­
tals were collected on small glass filters, washed with little 
ethyl acetate and air dried. Yields: 20.6 mg (59%) for the (+)-
iscmer and 22.9 mg (63%) for the (-)-isomer. 
Both isomers were transferred quantitatively to 50 ml measur­
ing flasks with 10 ml of methanol in small portions and the flasks 
made up with benzene. Primary dilutions were made m duplicate by 
mixing 50 yl of the solutions with 10 ml of a carrier solution in 
benzene/methanol (25/1) containing 0.20 mg (+)-ΝjN-dimethyl-y-
(p-chlorophenyl)-γ-(α '-pyndyl) propylamine per ml. 200 μΐ of the 
primary dilutions were mixed with 10 ml carrier solution and of 
tins secondary dilution 200 μΐ samples were counted in 15 ml scin­
tillation cocktail (Toluene/Terphenyl 0.5%/Dimethyl POPOP 0.05%). 
Counting efficiencies were assessed by internal standardization 
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with a toluene-Η3 standard. The results, total activities and 
specific activities calculated are summarized in Table 2. 
TABLE 2 
Speatfia аоЬг гЬу of tritium-labelled ( + ) - and (-)-ΙΙ,Ν-
durethyl-y-(p-ohloroDhenyl)-y-'a'-pyrbdyl) propylamine 
sample a c t i v i t y b a t c h a c t . 
b a t c h 
weight 
specific 
act. 
(+)-isomer 
(-)-isomer 
3+R 
3+P 
3-R 
3-P 
dpm 
104580 
106380 
114650 
116830 
mCl 
120.7 
122.8 
132.3 
134.9 
mg 
20.6 
22 .9 
Ci/mmol 
2.15 
2.13 
Reverse zsotope dilutbon analysis 
For further assessment of the radiochemical purity of both 
isomers a reverse isotope dilution analysis was performed. In 
reverse isotope dilution analysis the radiochemical purity of a 
compound is usually expressed as the radioactivity found in the 
crystals as a percentage of the activity expected if the compound 
had been 100% radiochemically pure. 
Small samples (10-20 mg) of either (+)- or (-)-N,N-dimethyl-
Ύ-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine monooxalate were 
mixed with known amounts (100,000-200,000 dpm) of tritium labelled 
(+)- or (-)-isomer as indicated in the table and the whole crystal­
lized from ethyl acetate (5-10 ml). The crystals were collected on 
glass filters, washed with a few ml of ethyl acetate and air dried. 
Then samples were weighed into scintillation vials, dissolved in 
15 ml scintillation cocktail according to Bruno-Christian (dioxane 
800 ml, naphtalene 48 g, PPO 9.6 g, POPOP 2.48 g, cellosolve 160 
ml) and counted in a Nuclear Chicago Mark I Liquid Scintillation 
Counter. Counting efficiencies were determined by internal stan-
dardizai-ion with toluene-Η standard. The results are summarized 
in Table 3. For the (+)-isomer a radiochemical purity of 99.6% 
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TABLE 3 
Reverse isotope dilution analysis of tvitium-labelled (+)- and 
(-) -'!, 'J j dine thy l-y- (p-ohlorophenyl) - γ - ("α '-pyridy I) propy lamine 
Sanple 
4+R 
4+P 
4-R 
4-P 
Before c r y s t a l l i z a t i o n 
a c t i v i t y weight of 
of sample c r y s t a l s 
adîed 
dpn rog 
209160 11.0 
212760 9.5 
229300 10.3 
233660 21.4 
After c r y s t a l l i z a t i o n 
weight of a c t i v i t y of 
crys ta l s crys ta l s 
recovered recovered 
mg dpm 
6.2 117450 
5.7 127190 
6.5 132590 
13.9 142430 
Spec i f ic a c t i v i t y 
found calculated 
dpm/ing dpn/mg 
18943 19014 
22314 22396 
20398 22262 
10250 10918 
Radiochanical 
purity 
99.6% 
99.6% 
91.6% 
93.9% 
Samples 4+R and 4+P refer to the (+Ì-isoner and samples 4-R and 4-P to the (-)-ioomer 
Λ spécifia activity expected for the radioohemiaally pure eonpound 
was found in duplicate samples but for the (-)-isomer the results 
were less satisfactory. A radiochemical purity between 90 and 95% 
was found. 
Although the reverse isotope dilution analysis as carried 
out in the present case may be subject to criticism, especially 
with regard to accuracy (weighing 5 mg of a compound with an 
accuracy of 0.1 mg already introduces an experimental error of 
2%), this does not explain the difference in results for (+)- and 
(-)-isomer unless the (-)-isomer is impure indeed. On the other 
hand analysis by thm-layer chromatography gave a radiochemical 
purity of 96.8% and 96.7% for (+)- and (-)-isomer respectively, 
but this can also not be taken as reliable evidence for radio­
chemical purity, because impurities might well have moved with 
the same Rf-value as the compound to be analysed. 
In conclusion, it can be stated that no single criterion can 
be taken as sufficient evidence for radiochemical purity. Only a 
combination of criteria all giving a positive result is a reason­
able guarantee that a compound is radiochemically pure. 
In principle reverse isotope dilution analysis offers the 
possibility of optical purity determination of labelled enantio­
meric compounds provided a well crystallizing diastereoisomenc 
salt with one or another chiral acid is available. (2R:3R)- or 
(2S:3S)-2 *-nitrotartranilic acid might well serve such a purpose 
in view of the successful resolution of racemic γ-(p-chlorophenyl)-
γ-(α'-pyridyl) propylamine described earlier, but attempts to 
prepare crystalline salts of either acid with (+)-N,N-dimethyl-Y-
(p-chlorophenyl)-γ-(α'-pyridyl) propylamine were not successful. 
No further attempts to obtain crystalline salts of (+)- or (-)-
N,N-dimethyl-Y-(p-chlorophenyl)-γ-(α'-pyridyl) propylamine with 
other chiral acids were made, because they would have been very 
time consuming and offer no guarantee for success. 
Another possibility for the assessment of optical purity in 
this case, at least in a semi-quantitative sense, is offered by 
measuring the biological activities of both isomers, either as 
antihistammic potencies in isolated gut experiments or as bind­
ing affinities derived from concentration-dependent binding ex­
periments to histamine receptors. It should be possible to detect 
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specific receptor binding with the radiolabelled (+)-chlor-
pheniramine whether it be optically pure, partly or completely 
racemized, provided receptor concentrations in target tissue 
are not too low. Once receptor binding has been demonstrated 
differences in the shapes of the binding curves for H-(+)- and 
H-(-)-chlorpheniramine should be indicative of only partial or 
complete racemization of H-(-)-chlorpheniramine. 
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PART I THE HISTAMINE RECEPTOR 
CHAPTER 3 
PRELIMINARY BINDING STUDIES WITH ( +)- H-CHLORPHENIRAMI NE 

PRELIMINARY BINDING STUDIES WITH (+)- H-CHLORPHENIRAMINE 
INTRODUCTION 
Until recently it was not possible to demonstrate the pres­
ence of histamine H -receptors in target tissue by direct binding 
of radiolabelled histamine or antihistamines beyond reasonable 
3 
doubt. Earlier reports on "specific" binding of H-dibenamine, 
an irreversible blocker of histaminergic as well as α-adrenergic 
and muscarinic cholinergic receptors in vivo, to cat intestinal 
smooth muscle strips (Takagi and Uchida, 1970) have later on been 
seriously doubted (Hill et al., 1977). "Specific" binding of H-
dibenamine probably takes place for a major part to sites un­
related to the histamine H -receptor (Hill et al., 1977). 
As soon as radiolabelled (+)-chlorpheniramine became avail­
able to us, we performed orienting binding experiments with a 
crude plasma membrane fraction of bovine tracheal smooth muscle 
using equilibrium dialysis as the binding technique. Bovine 
tracheal smooth muscle gives contractile responses at low con­
centrations of histamine. They are readily antagonized by the 
classical antihistaminics. 
The binding of (+)- Η-chlorpheniramine increased linearly 
with increasing concentration in the medium. There was no indi­
cation whatsoever of saturation of binding at least not up to 
concentrations at which (+)-chlorpheniramine occupies more than 
90% of histamine H.. -receptor sites, calculated on basis of its 
1
 3 
pA_-value. Moreover bound (+)- Η-chlorpheniramine was not dis­
placed within experimental error by a large excess of unlabelled 
(+)-chlorpheniramine. It means that specific binding was either 
absent or, more likely, so small that it is lost in an overwhelm­
ing amount of unspecific binding. 
In equilibrium dialysis bound concentrations are calculated 
as the difference between total concentration of the bag-contents 
and free concentration in the medium. When bound concentrations 
are less than 2% of the total concentration in the dialysis bag 
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it will go undetected, because the accuracy with which concentra­
tions of labelled compounds can be measured conveniently is of 
the same magnitude. 
With the introduction of new binding techniques like fil­
tration and rapid centrifugation of membrane fragments bound 
ligand can be measured directly, thus considerably improving 
detection limits. 
In 1977 Hill et al. reported specific binding of H-mepyr-
amine, a well-known antagonist of histamine H -receptors with 
high affinity, to membrane fragments of guinea pig intestinal 
smooth muscle using a centrifugation assay. Histamine H -recep­
tors have since then been demonstrated in a number of other 
tissues, especially brain of various species (Chang et al., 1978; 
Hill et al., 1978; Palacios et al., 1979; Chang et al., 1979a, b). 
In view of these developments and the availability of (+)- H-
chlorpheniramme it seemed worthwhile to demonstrate specific 
histamine H -receptor binding m guinea pig ileum as well and 
3 
compare the results with those obtained with H-mepyramine in 
the same preparation. 
MATERIALS AND METHODS 
Labelled compounds 
3 3 
H-Mepyramine (pyrilamine- H, spec. act. 28.5 Ci/mmol) was 
purchased from NEN-Chemicals, GmbH, Germany. The synthesis of 
(+)- Η-chlorpheniramine is described in part I, chapter 2. The 
conpound had accumulated impurities up to 20% on storage in 
benzene/methanol as judged by thin-layer chromatography. The 
compound was repunfied by preparative thin-layer chromatography 
on silicagel (DC-Fertigplatten, Kieselgel 60, Schichtdicke 0.25 
mm, Merck) with cyclohexane/benzene/diethylamine (75/15/10) as 
the solvent. Unlabelled (+)-chlorpheniramine maléate was kindly 
donated by Schering Corp., Bloomfield, New Jersey. 
Target tissue 
Guinea pigs were of either sex. The longitudinal muscle of 
the small intestine was prepared as described by Paton and Rang 
(1965) . 
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Чотодепгааьгоп 
The longitudinal muscle strips were divided into small 
pieces with scissors and homogenized with carborundum (350 mesh) 
in a mortar. The membrane pellets were prepared essentially as 
described by Beld and Ariëns (1974) for bovine tracheal smooth 
muscle. 
Вгпаьпд experfnents 
Prior to use the membrane pellets were washed with Krebs-
Henseleit solution by Potter homogenization and centrifugation 
of the suspension at 100,000 g for 45 minutes. The resulting 
pellet was resuspended in Krebs-Henseleit solution to give a 
tissue concentration of 0.10 g/ml and the suspension used for 
binding experiments. The method used for the assay of particle 
bound radioactivity was the rapid centrifugation of membrane 
fragments using a microfuge (for details, see methods of part 
II, chapter 3). Assay temperature 20 C. 
RESULTS AND DISCUSSION 
The concentration-dependent binding of (+)- H-chlorphenir-
3 
amine and H-mepyramine to a crude membrane preparation of longi­
tudinal muscle of guinea pig ileum is depicted in Fig. la and 
Fig. lb respectively. For reasons of comparison both experiments 
were performed simultaneously with the same membrane preparation. 
Both compounds show approximately the same amount of specific 
binding (3.0 and 3.4 pmol/g for mepyramine and (+)-chlorphenir­
amine respectively). The unspecific binding is substantially 
higher in case of (+)-chlorpheniramine, 0.9 ml/g as compared to 
0.5 ml/g for mepyramine. 
The specific part of the binding was analysed with a com­
puterized curve fitting procedure with a one binding site model 
(for details of the method, see part II, chapter 3). The binding 
affinities, binding capacities and coefficients for unspecific 
binding are summarized in Table 1. The affinity constants for 
H-mepyramine and (+)- H-chlorphemramine agree well with values 
obtained by Hill et al. (1977). Our results and those of Hill et 
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TABLE 1 
Analysz-s of the spécifia part of the Ъгпагпд 
of ( + ) -3¡¡-chlorpheniramine and ^И-'черугатгпе 
according to a one binding site model 
К r. χ
2
 С 
t л exp 
( 1 0 ~ 9 . M ) ( 1 0 " 1 2 . т о 1 / д ) ( n ) + (ml/g) 
( + ) - ^ - C h l o r ­
p h e n i r a m i n e 
3 
2.2 (11) 3.4 (7.6) 5.6 (10) 0.88 
H-Mepyramine 1.2 ( 6.6) 3.0 (4.1) 4.3 (10) 0.54 
К = dissociation equilibrium constant, r = concentration of 
binding sites per gram tissue jet weight, С = coefficient for 
unspecific binding ^ i 
Values in parenthesis indicate relative standard errors 
+
n - decrees of freedom 
χ - weighted residual swn of squares 
al. (1977) indicate that H-mepyramine and (+)- H-chlorphenir-
amine probably label the same specific receptors m guinea pig 
small intestine. The lower unspecific binding of H-mepyramme 
makes this compound a better ligand for studying histamine H -
3 i 
receptors in guinea pig ileum than ( + )- H-chlorpheniramme. 
Recently a paper has been published, suggesting a hetero­
geneity in histamine H -receptors in guinea pig brain (Chang et 
al., 1979b). The study of histamine H -receptors in guinea pig 
1
 3 
brain as well as other tissues with two labelled ligands, H-
mepyramine and (+)- H-chlorpheniramme may lend further support 
for this heterogeneity. 
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bound cone in pMole/ g 
15 
10-
bound cone in pMole/g 
15 
3 3 
Fig. 1 Binding of ( + ) - H-ahlorphenirarnine (a) and H-mepyramine 
(b) to plasma membranes of guinea pig intestinal smooth 
muscle, о total binding, в unspeoifia binding. 
Vnspeaifia binding was measured as residual binding in 
the presence of 10~ M (+)-chlorpheniramine. The specific 
part of the binding is obtained by subtracting unspecific 
binding from total binding (dashed curves). 
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PART II THE MUSCARINIC ACETYLCHOLINE RECEPTOR 
CHAPTER 1 
INTRODUCTION 

THE MUSCARINIC ACETYLCHOLINE RECEPTOR 
INTRODUCTION 
Muscarinic cholinergic receptors are present in many peri-
pheral organs and tissues and in the central nervous system. The 
neurohumoral transmitter at muscarinic receptors is acetylcholine. 
Muscarinic receptors are selectively stimulated by a host of drugs 
of natural and synthetic origin; among them muscarine, a compound 
first isolated from the fly fungus, Amanita muscaria, which has 
lent its name to this particular type of receptor. Muscarinic 
receptors are selectively blocked by atropine, the principal 
alkaloid of Atropa belladonna. Muscarinic receptors are not stimu-
lated by nicotine, the alkaloid from tobacco leaves, a compound 
which stimulates cholinergic receptors in the autonomic ganglia 
and in the myoneural junction. Nicotinic cholinergic receptors 
are blocked by decamethonium (depolarizing) and curare (non-de-
polarizing) , while those in the autonomic ganglia are selectively 
blocked by hexamethonium and less so by decamethonium and curare. 
Decamethonium, curare and hexamethonium are not active on 
muscarinic receptors and muscarine and atropine do not act at 
nicotinic cholinergic receptors. Muscarinic receptors are present 
in the cells of tissues with a parasympathetic innervation. Para-
sympathomimetic drugs have a negative chronotropic, a negative 
inotropic and a negative dromotropic effect on the heart. Para-
sympathomimetics stimulate exocrine glands e.g. salivary glands, 
sweat glands, mucous glands and the glands of the digestive tract. 
The direct sympathomimetic effect of acetylcholine on the vascular 
system is a dilatation. Parasympathomimetics give contractions in 
a host of smooth muscles like those in the gut, stomach, bladder, 
bronchi etc. An easily observable muscarinic effect of acetyl-
choline is the contraction of the circular muscles regulating 
pupil diameter (Koelie, 1975; Innés and Nickerson, 1975). The 
most widely used antagonists of acetylcholine at muscarinic 
receptors are atropine and scopolamine, the main alkaloids of 
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Atropa belladonna species. The pupil-dilating effects of Atropa 
belladonna extracts were known already in ancient history. 
Atropine is still frequently used in practical medicine, although 
numerous other compounds equally active and selective are avail­
able now. 
A prominent feature of muscarinic and antimuscannic activity 
is the stereospecificity with which it occurs. The enantiomers of 
0-methacholine show a large potency ratio at muscarinic receptors. 
Antimuscannic compounds with a centre of asymmetry like several 
esters of cyclohexylphenylglycollic acid also have one active 
isomer, the antipode almost being devoid of antimuscannic activ­
ity (Ellenbroek et al., 1965). Atropine, which is a racemic mix­
ture of (+)- and (-)-hyoscyamine is also highly stereospecific in 
its action. (-)-Hyoscyamine is at least 30 times as active as the 
optical antipode at muscarinic receptors. The optical isomers of 
atropine, however, are not easy to work with because they racemize 
rather quickly. 
In 1970 Van Wijngaarden reported stereospecific retention of 
the tritium labelled (+)-isomer of benzetimide as compared to the 
tritium labelled (-)-isomer in the caudate nucleus of the rat. 
Dexetimide, as (+)-benzetimide is called now, is a highly potent 
and selective antimuscannic compound, clinically used to suppress 
Parkmson-like symptoms in neuroleptic therapy. (-)-Benzetimide 
has a very weak antimuscannic activity, which might as well be 
attributable to a minor contamination with (+)-benzetimide. The 
availability of the tritium labelled enantiomers of benzetimide 
would make an approach for tagging receptors as outlined for the 
histamine H.-receptor in the introductory chapter of part I also 
possible for the muscarinic cholinergic receptor. 
In 1965 Paton and Rang had already demonstrated specific 
3 3 
binding of Η-atropine and H-methylatropine to guinea pig in­
testinal smooth muscle strips. Also H-benzilylcholine mustard, 
at least part of it was bound irreversibly to muscarinic receptors 
in guinea pig intestinal smooth muscle (Rang, 1967). These authors 
were not able, probably as a consequence of methodological prob­
lems, to demonstrate specific muscarinic receptor binding in 
homogenates of intestinal smooth muscle under comparable circum-
88 
stances at which specific uptake of ligands to intact smooth 
muscle strips was taking place. 
Tritium labelled optical isomers of benzetimide were obtained 
from Janssen Pharmaceutica, Beerse, Belgium through the courtesy 
of Dr. W. Soudyn and Dr. I. van Wijngaarden. With these compounds 
we were able to demonstrate muscarinic receptor binding to homo-
genates of bovine tracheal smooth muscle. This work is the subject 
of chapter 2, part II of this thesis. 
Almost simultaneously several other papers were published on 
muscarinic receptor binding using labelled ligands like H-
3 3 
quinuclidylbenzilate, H-propylbenzilylcholme and H-atropine. 
A compilation of ligand binding studies at muscarinic receptors 
can be found in a number of excellent reviews (Snyder et al., 
1975; Birdsall and Hulme, 1976; Heilbronn and Bartfai, 1978). 
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A J ΒΓΙ D jnd E J ARILNS Stereospectfic binding as a tool in attempts to localize and isolate muscarinic 
receptors II Binding oj (+/ benzetnnide ( t-henzetimide and atropine to a fraction from boi me tracheal smooth 
muscle and to bonne caudate nucleus Furopcjn J Phdrmacol 25(1974)203-209 
The concentration-dependent binding of (+) benzcumide П3 and ( )-benzctimide H3 the active and inactive 
enantiomers, respectively of the anticholinergic agent, (•) benzcumide and of atropine H3 to a Iraction Irom 
bovine tracheal smooth muscle was studied by equilibrium dialysis Anal}sis of the bindine curves revealed (ht 
presence of a saturable high affinity binding site for (+) bcnzetimidc and atropine but not for ( ) bcn^ctimidc The 
stereospecificity of the binding and the results of competition experiments with cholinergic and non-chohnergic 
compounds provided evidence, that the high affinity binding sites for (+) benzetimidc and atropine are identical 
with the muscarinic receptor Attempts to solubllize the binding sites with detergents commonly used in this type 
of work, resulted in complete loss of stereospecificity Dlgitonin, a plant glycoside with mild detergent properties, 
released components to which {+) benzelimide H3 and ( ) benzetimide H3 were still bound differently strongly 
suggesting the presence of solubllizcd muscarinic receptors The stereoselective binding sues for anticholinergic 
agents as observed in the caudate nucleus could also be solubihzed with dlgitonin but only after hexane extraction 
of lyophilized homogenstes 
Muscarinic receptor Bovine tracheal smooth muscle Stereospecific binding Benzetimide-H3 
Bovine caudate nuclei Solubilization, dlgitonin Equilibrium dialysis 
1 Introduction 
In a critical and extensive review Ehrenpreis et al 
(1969) concluded, that after a decade of attempts to 
isolate pharmacological receptors, although much in 
formatton about receptors had been obtained, no de 
fmitive answers had appeared Since then, much pro 
gress, discussed in recent reviews (O'Brien et al , 
1972, Potter and Molinoff, 1972 Hall, 1972) has 
been made with the isolation of the nicotinic acetyl 
choline receptors from a variety of animal tissues 
The isolation of the muscarinic acetylcholine receptor 
has lagged behind mainly oecause the search for re 
ceptor binding with muscarinic and antiniuscanmc 
ligands in tissue homogenatcs is complicated by the 
lack of specificity which makes it difficult to dilfer 
entiate between binding to the receptor and to other 
binding sties (O'Brien et al 1971) Recently Farrow 
and O'Brien (1973) reported the presence of a high 
affinity binding site for atropine most probably the 
muscarinic receptor in rat brain fractions 
In the first part of (his series (Soudijn et al , 1973) 
it was indicated how this problem of lack of binding 
specificity might be circumvented bnantiomcrs of 
chiral compounds often possess large differences in 
pharmacological polcncy With competitive antago 
9 3 
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nists (compounds with no intrinsic activity) such dif­
ferences can only be due to different receptor alfim-
ties Comparison of the binding of the biologn.ally 
highly active isomer with that of the poorly active 
isomer to various tissue fractions can serve as a means 
of delecting the presence ot stereoselective binding 
sites For the binding sites - receptors - involved in 
the anticholinergic or muscarinic action of the drugs 
studied, stereoselectivity for, and saturation of the 
binding sites, and affinity constants for the highly ac­
tive isomers of the order of those found biologically 
may be expected For indifferent binding sites ab­
sence of stereoselectivity, a low affinity and a proba­
bly high, hardly saturable binding capacity are feasa-
ble Additionally, preservation of stereoselectivity is 
good evidence of the structural integrity of the iso­
lated receptors The enantiomers of the anticholiner­
gic agent (±)-benzetimide [(±)-l-ben¿yl-4 (2,6-
dioxo-3-phenyl-3-piperidyl)-pipendineJ represent a 
pair of isomers suitable for this kind of approach in 
relation to the muscarinic acetylcholine receptor 
The antimuscannic properties of (±)-benzelimide 
reside almost exclusively in the (+) isomer, while the 
activity ol the ( )-isonier, estimated to be lower by 
at least three orders of magnitude, is slightly more 
than an indication of its optical purity 
Details of the pharmacology, synthesis, tritium la-
beling and enantiomeric resolution of (±)-benzetimide 
are given in Part I of this series (Soudijn et al , 1973) 
In our approach we used the equilibrium dialysis tech 
nique for concentration-dependent binding studies 
Bovine tracheal muscle was used as a target organ 
since this tissue could be obtained in large amounts 
relatively easily and responses of muscarinics to it are 
well documented 
The detachment of particle bound receptors is 
usually performed with ionic and non-ionic detergents 
such as sodium laurylsulfate, sodium desoxycholate, 
Triton-X-100, Lubrol-WX, etc in 0 1-1% solutions 
(Eldefrawi et al 1972, Meunier et al , 1972) Altera-
tions of the properties of particle-bound receptors 
and enzymes upon exposure to these agents, depend 
ing on the type of agent and the concentrations ap-
plied, are frequently encountered (Razin, 1972, 
Coleman, 1973) 
The plant glycoside digitonin frequently applied 
in the extraction of visual pigments from rod cells, 
has to our knowledge never been used before for the 
solubilization of pharmacological receptors 
2 Materials and methods 
2 I Target tissue 
Bovine tracheae were obtained from ihe local 
slaughterhouse and stored in Krebs Henseleit solu-
tion at 0-4 С The smooth muscle layer was removed 
within 24 hr and separated from the mucous layer 
and connective tissues as well as possible The smooth 
muscle was stored overnight at -20oC In all the ex­
periments pooled material of 5 10 tracheae was 
used 
Bovine brains were transported in an ice bath from 
the slaughterhouse to the laboratory and the caudate 
nuclei were removed as quick as possible 
2 2 Homogemzatton 
25 g of smooth muscle were divided into small 
pieces with scissors and ground thoroughly with 50 g 
of carborundum (120 Mesh) in a mortar 50 ml of 
buffer (5 mVI Tris HCl 1 mM hDTA, 0 25 M Manni-
tol pH = 7 1) or 50 ml of Krebs-Henseleit were 
added After mixing, the resulting pulp was pressed as 
dry as possible through gauze cloth The residue in 
the cloth was ground a second time and extracted in 
the same way The extract was filtered through a 100 
Mesh gauze filter, made up to a final tissue concentra­
tion of 20% and centnfuged at 8000 RPM (5000 g) 
for 20 minutes The microsomal pellet was made by 
centrifuging the supernatant at 35 000 RPM 
(100,000g) for 1 hr in rotor 42 ma Beekman L2-65B 
ultracentrifuge Other homogenization techniques 
were less successful due to the tougluiess of the tis­
sue The microsomal pellets were stored at -20°С 
and used up to two weeks after homogenization The 
whole procedure was carried out at 0 4<>C 
Bovine caudate nuclei were homogenized ( 1 /10) m 
Krebs Henseleit with or without digitonin by Potter 
homogenization at ice bath temperature 
2 3 Binding experiments 
The microsomal pellets were resuspended by 
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Potter homogenizalion in Krebs Henseleit to an ong 
mal tissue coni-entration ol 0 50 g'ml In those cases 
where detergents were used the pellets were resus 
pended to a tissue concentration of 0 50 g'ml in 
Krebs Henseleit solution conummg the detergents in 
the jppropnale concentration The resulting suspen­
sions were centnluged at 40 000 RPM (190 000 £) 
for 45 mm (rotor SW 40 in a Beekman L2-65B ultra 
centnluge) 
A 27r digitonin solution in water was made with 
healing After cooling to 1 ^40C part of the digitonin 
crystallized The solution was cleared by nitration 
and contained about l9rdigitonin The digitonin solu 
Hon was then made up according to Krebs Henseleit 
Dialysis bags of 1 0 ml contents prepared from 
8/32 inch Visking cellulose dialysis tubing were sus­
pended in 25 0 ml Krebs Henseleit solution with the 
appropriate concentrations of hgands contained in 
stoppered 40 ml tubes The 25 0 ml solutions were 
prepared by mixing varying amounts of freshly pre 
pared standard solutions of labeled and non labeled 
hgands with Krebs-Henseleit lo a final volume of 
25 0 ml Free concentrations of labeled hgands in the 
medium as depicted in figures and tables were always 
measured at the end of the dialvsis run The tubes 
were rotated at 1 RPM during 15 hr to ensure equilib­
rium 
0 50 ml samples of the bag contents were solubil-
ized with Soluene (Packard) and mixed with 15 ml of 
Instagel-1 N HCl (9/1) (Packard) 5 00 ml or 3 00 ml 
of the medium were mixed with 10 ml of Instagel The 
samples were counted in a Packard Tricarb LSC 
model 3380 with standard deviations of 1% or less 
The free concentrations in the medium, which did 
not differ appreciably before and after equilibrium 
had been established, were calculated from the radio 
activity in the medium at the end of the dialysis pe­
riod Bound concentrations were obtained by sub 
stracting the free concentration from the total con 
cenlration of the bag contents for each sample 
All the binding experiments were carried out at 
room temperature 
2 4 Materials 
Atropme-H3 (spec act 400 mCi/mmol) was from 
the Radiochemical Centre England (+) Benzeti 
mide H 3 d-camphor sulfonate (spec act 642 mCi/ 
mmol), (-) benzetimide-H3 d-dibenzoltartrate (spec 
act 614 mCi/mmol) and unlabeled (+)- and 
( ) benzetimide were gifts Irom Dr I van Wijngaar 
den and Or W Soudijn (Janssen Pharmaceutica 
Beerse, Belgium) R(-) methacholme iodide and 
S(+) methachohne iodide were gitts Irom Dr BW J 
Fllenbroek (Org chem Lab Kalhoheke Universiteit 
Nijmegen), Digitonin was from h Merck Darmstadt 
3 Results and discussion 
The concentration dependent binding of (+) and 
(-) benzetimide from 0 25-8 0 nmol/1 is depicted in 
fig la The binding curve for (+) benzetimide H 3 has 
the characteristics of a combination of binding sites, 
one of high affinity and saturable and one or more of 
low affinity The low affinity binding sites manliest 
themselves as a distribution because only a small per 
centage are occupied in the measured concentration 
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Fig 1 (a) Binding of (+) jnd ( - ) benzetimide H 3 to the 
100 000 g pelici oí bovine tracheal muscle (b) Bindmp of 
(+) benzetimide H 3 and inhibition by large jmounK of un 
labeled (+) and ( )-bcn/ctimlde ( I 0 2 x с) (c) Binding of 
(+) benzetimide H 3 and inhibition by atropine (ΙΟ 2 X с) and 
(+)-chlorphcnirjminc (IO 2 X с) (d) Binding ol atropine I I 3 
and inhibidon b> (+) and ( ) benzelimidc ( 10 X c) 
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range ( ) Ben/etmudc is e4clusi\elv hound to llic 
low jl Unity binding sites js exemplified by the hneir 
dependency ol the binding on lile иоікепіг mon 
The validity of this expljn.ition is lurllier illus 
trjtcd in fig lb (+) Ben/ctimide H ' is displ Kcd 
troni its high jtlimty binding site bv л lumdicd told 
(.ontentration ol unlabeled (Obtn/el imidi . while the 
binding to the low alfmity binding sites is not j l 
lected ( ) Bcn/etmiide in J hundred lold coni-entrj 
tion is not able to displace (+) ben/etiimdc H* trom 
the high allmity binding site or Irom the other sites 
The speutic binding ol (+) bcn/etimide H 3 is also 
abolished by atropine in ι hundred told lünient r i 
don (on a molar bisis) (lig U ) It is inltresting to 
observe that (+) Llilorpheniramme a potent antihis 
taminie with only weak antimuscannic properties 
does not interfere with the binding ol (+)ben/et i 
mide(lig U ) 
The concentration dependent binding of atropine 
H3 trom 0 2S io 8 0 nmol 1 and its inhibition by both 
enantiomers of ben/eumide were also studied Atro 
pine being a raceniic mixture o( which the ( t) isomer 
is at least 40 times less active than the ( ) isomer can 
be regarded as a single substance with an jl Unity con 
slant twice the altinity constant ot the more active 
isomer as elucidated by Paton et al (1%5) The 
shape ol the binding curve points to a high altmitv 
binding site and almost no unspccific binding (+) 
Ben¿etimide present in a ten told concentration in 
hibits the binding ot atropine completely while 
( )-benzetimide has only a minor effect at the high 
est concentration tested (fig Id) 
The binding curves of (+) bcn/etimide H 3 and 
atropine H 1 lollowed up to 20 nmol 1 and the corre 
sponding Scatchard plots arc shown in Ug 2 A com 
pulenzed curve lilting procedure based on a least 
squares method lor a model with one saturable bind 
mg site and a distribution revealed for (+)ben7eti 
mide a binding site K = 4 : ± 1 2 X 1 0 1 0 mol 1 with 
a capacity of I I 5 ± 1 0 X 10 ' 2 mol'g tissue (wet 
weight) and a distribution 0 82 ^ 0 07 X 10 3 l o r 
atropine the same procedure revealed one binding 
site, K = 2 6 ± 0 1 X IO"9 mol/1 with a capacity of 
21 2 + 0 3 X 10 ' 2 mol/g tissue 
Comparison of the affinities derived from our 
binding studies with those from pharmacological ex 
penments is made in table 1 The close proximity of 
the affinity constants to the pharmacological data 
lie 2 (l) ind (h) Binding tune ol (+) bLnzctimuU. H3 ind 
Si.iti.hjrd pint (c) ind (d) Binding turvc ο ι r pint U 1 ind 
Scdtch ird plot 
and the stereospecilicitv ol the binding suggests that 
the demonstrated binding sites ire m is^annic гесер 
tors 
With respect to the other binding parameter the 
с ipautv one point remains to be ciani led The ca 
pacit> ol the specific binding site is approximately 
twice is miKh lor atropine H 3 as lor (+)ben/eti 
m i d e H 3 A similar phenomenon has been observed 
by Paton and Rang studying the uptake ol atropine 
and methylatropine by the longitudinal muscle of 
guinea pig small intestine Here too atropine was 
bound twice as much as methylatropine to a binding 
Tabic 1 
Comparison of Ihe allinuy consljnts Irom binding expen 
irii-nts and from inhllntion ol niuhadwlinc in auincipip 
ileum Til», in vivo dati were cakulüted trom pAjo values 
(pAio Іо^ К log 9) jLiordmg to Ariens and Van 
Rossum (1957) The pAj о values were taken Irom Soudijn cl 
at 1973 
\ffinity constants 
Compound — — 
Dose response Binding 
Atropine 4 7 X 1 0 ' 2 6 X I 0 9 
(+) Benzeiimide 8 9 Х І О - 1 0 4 2 x 1 0 ' 0 
9 6 
Λ f Hi Id b.J. \ги*п\ ütiidinc of cholinergic ligando to iotiipontnti Jrom mwolh illuseli and caudau nutlctn 
i-l · tv, l f 1 « , 
^l 
~ 10 e - IJ l " Il 4 M 
Fig 3 Binding ol atropmc-H3 and inhibition by S(+)-mcthu-
cholmc and R( -)-mctha(.holinc I гее сопсспіглюпь ot atro­
pine ÏI3 Irom II 12 nMol, corresponding "o approximately 
80% receptor saturation 
sue supposed to be the muscanmc receptor (Paton 
et a l , 1965) 
The binding speufiuty is also present with respect 
to muscarinic agonists The enantiomers of the agent 
methachohne known to ditter about two orders of 
magnitude in their muscarinic potency are lound to 
differ in a similar way in their potency to displace the 
anticholinergic atropine from its stereoselective bind-
ing sites The binding of atropine at a fixed concen-
tration corresponding to approximately 80% receptor 
saturation is inhibited by increasing concentrations of 
S(+)-methacholine and R(-)-methacholine (fig 3) 
S(+)-methachohne, the more active isomer, is also the 
stronger inhibitor of atropine binding. R(-)-metha-
chohne is less active by two orders of magnitude 
The next step in the isolation and purification of 
the muscarinic receptors is to obtain them in a molec-
ularly dispersed lorm, to which purpose detergents 
are the reagents of choice, as is also the case with 
nicotinic receptors Thus the binding capacities ol the 
microsomal pellet for (+)- and ( )-ben/etimide at 
5 X 10"* M were measured in the presence of Triton-
X 100, sodium desoxycholatc and Lubrol-WX in con-
centrations ranging from 0 1 to 1 0'f 
With Tnton-X 100 present at a concentration of 
0 \'/c the binding for ( )-ben/etimide was unatfected, 
while the binding of (+)-benzctimide leveled olt and 
became identical with that for ( )-ben¿etimide So-
dium desoxycholate was less destructive at a concen 
tration ofO 1% however, the remaining specific bind-
ing appeared to be particle bound alter cenlrifugatton 
at 190.000g for 45 min Lubrol-WX al a concentra-
tion of 0 l'/í strongly reduced the binding ol (+)-
ben/elimide At higher concentrations (0 5 and 1 0'/r) 
the binding ol (+)-ben¿eümide was slightly different 
from controls while at the same time the binding of 
( ) beiuctimidc was raised to almost the same level 
The remaining dilterence also appeared to be particle-
bound These procedures resulted in solubilization ol 
only non stereoselective binding sites with binding 
characteristics as observed for the poorly active iso-
mer and which therelore can be considered as indif-
ferent binding sites The procedures also resulted in a 
loss of the stereoselective binding capacity in the re-
sidual pellet indicating a denaturalion of the stereo-
selective binding sites In those studies in which the 
above procedures were found to be effective in the 
solubilization ol nicotinic (Meunier et al , 1972, fclde-
frawi et al 1972) and β adrenergic (Lcfkowil/ et al . 
1973) receptors, stereoselectivity was either not in­
volved or not taken into account 
Alter the unsuccessful application ol the common 
detergents to solubilize the muscarinic receptors, our 
attention was drawn to digilonin, a heart glycoside 
with mild detergent properties and first used by 
Tansley (1931) to extract visual pigments from sus 
pensions ol rod cells Digitonm is still used Irequcnlly 
in this type of work (Adams, 1969, Borggreven, 
1971) 
When the microsomal pellets of tracheal muscle 
were treated with digitonm dissolved to approximate­
ly 1% in Krebs-Henseleit solution about k07( of the 
stereospecific binding sites for (+)-benzetimide were 
present in the supernatant after centnfugation at 
190,000£ for 45 mm The remaining 20% were re­
tained in the pellet (table 2) 
Analogous procedures were followed in the effort 
to solubilize the stereoselective binding sites for anti­
cholinergic agents as observed in the caudate nucleus 
(Soudijn et a l , 1973) Bovine caudate nucleus was 
used to obtain sulfiuent material In the total ho-
mogenale of this tissue in Krebs Henseleit solution 
stereoselective binding ol benzetimide takes place 
Homogenization in Krebs Henseleit solution contain­
ing \% digitonm resulted in a partial (about 20%) 
solubilization of the stereoselective binding sues The 
pellet retained 80% ol this capacity Since the lipids, 
abundantly present in the nerve tissue may interfere 
with the solubilization lipid extraction was per 
formed A homogenate ol the caudate nuclei in dis­
tilled water was lyophih/ed by freeze drying and then 
9 7 
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Tjblc 2 
Amounts al (+)-h(;nze(im]íle-Il3 and ( )-bcn/ctmildc II4 bnund to .1 suspension ol the miLrosomal pellet ot bovine trjLhcjl 
тичсіс m krebs Mcnselcit solutions without (I ) .ind unit (2) 1" d^ltontn The digitomn-tomaimny suspension WJS tentnluced 
at 190 000 A' 'or 45 mm and the bindmy was measured in supcnatait (3) and pellet liter resuspension in Krebs llcnseleil (4) 
Values are means ol duphtates Original tissue юікепігапоп OSOPíinl I ree eoneenuations ol (+)-and { ) ben/etimide II3 
between 5 6 and 6 9 nmol/1 
Sample 
(1 ) Suspension in Krebs Hcnseler (Lontrol) 
(2) Suspension m Krebs Mcnselcit loniaining 1 < digilonin 
(3) Supernatant ol (2) (190 000 д, 45 min) 
(4) Pellet ol (2) (190 00П g 45 min) 
Hound benzetimidc II esprcssed as pmoLg tissue 
l+)-isomer ( )-isonier 
187 
20 1 
15 0 
5 8 
2 1 
6 0 
3 6 
2 2 
Table 3 
Amounts ol f+)-benzetimide H 3 and ( )-ben7elimide-H3 bound to a suspension in Krebs llcnseleit ol lyophtlizcd bovine caudate 
nucleus bclore (1) and after (2) he\ane extraction at 0 oC The hcxanc-extraLted residue was also suspended in Krebs Henscleit 
containing 1 r digilonin (3) The diintnnin-containmg suspension was centnluged ai 190,0()0¿í lor 45 nun and the binding was 
measured 111 supernatant (4) ami pellet alter resuspension in Krebs Mcnselcit (5) Values arc means ol duplicates Original tissue 
concentration 0 10 g/ml I ree concentrations ol Í+) and ( )-benzcuiiiide-H3 between 6 9 and 7 9 nniol/l 
Sample 
(1 ) Suspension in krebs Mcnselcit betöre licxane extraction 
(2) Suspension in krebs llcnseleit after hexane extraction 
(3) Suspension in krebs-Menseleit containing IT dlgltonin 
alter hexane extraction 
(4) Supernatant ol (3) (190 000 jç 45 min) 
(5) Pellet of (3)( 190 .000£ ,45 mm) 
Itound ben7ctiniide-H expressed as pmol'g tissue 
(+) isomer ( J-isomer 
167 
105 
77 
17 
32 
20 
36 
extracted with hexane at 0oC The residue obtained 
after centrifugalion of the suspension in hexane at 
2700 g for 10 mm was dried under vacuum and then 
resuspended in Krebs-Henseleit solution conlainmg 
\7c digitomn This resulted in practically complete 
solubilization of the stereoselective binding sites for 
the anticholinergic as present in the pellet obtained 
after the lipid extraction (table 3) 
We are currently involved in further attempts to 
purify, concentrate and characterize the solubili/ed 
stereospecific binding sites trom bovine tracheal 
smooth muscle and caudate nucleus 
Acknowledgements 
We wish to thank Dr J MPM Borpgreven lur valuable 
suggestions The skilled technical assistance of Mr D Loze-
koot Miss M A P Zegers and Miss S san den Moven is grate-
lull) acknowledged 
References 
Adams, R G , 1969, Isolation and identification ol phospho-
lipids ol bovine rhodopsin J Lipid Res 10 473 
Ariens, FJ and J M van Rossum, 1957 p D x , p A x and pD^ 
salues in the analysis of pharindCod>namics, Arch Intern 
Pharmacodyn 111) 275 
Borggrcven J Μ Ρ M , 1971, Phospholipids of photoreceptor 
membranes in relation to the binding site of relinaldchyde 
in rhodopsin,Thesis, University ot Nijmegen 
Coleman R , 1973, Membrane bound enzymes and mem­
brane ultraslructure, Biochim. Blophys. Acta 300, 1. 
Ehrenpreis, S , J Η I leisch and TW Mittag, 1969, Ар 
proaches to the molecular nature of pharmacological re­
ceptors, Pharmacol Rev 21 131 
9 8 
A J Beid t.J Anens, Binding of cholinergic Iigands to components from smooth muscle and caudate nucleus 
Hdefravu, M 1 ,ΑΤ Licletrawi S Seifert and R D O'Brien, 
1972 Properties of 1 ubrol-solubilized atetylcholinc re­
ceptor Irom Torpedü bleuropldx, Arch Biochem Bio-
phys 150,210 
Tarrow, J Τ ma RD O'Brien 1973, Binding of atropine 
and must-jrone to rat brain fractions and its relation to 
the acetylcholine receptor, Mol Pharmacol 9,33 
Hall, Zach W , 1972, Release of neurotransmittors and their 
interaction with receptors in Annual Review of Bio­
chemistry, Vol 41,eds L F Snell, D D Boyer. A Meis­
ter and R L Sinsheimer (Annual Reviews ine , Palo Alto, 
California) ρ 925 
Lefkowit/, R J ,GW G Sharp and I- Haber, 1973, Speutic 
binding of β adrenergic catecholamines (o a subcellular 
fraction from cardiac muscle, J Biol Chem 248,342 
Meunier, J С. RW Olsen, A Menez, R íromageot, Ρ 
Boquet and J Ρ С lungeux, 1972, Some physical proper 
ties of the cholinergic receptor protein from tlectropho 
rus electneus revealed by a 4ilia led a-io\in from \a/a 
mgncoUis venom, Biochemistry 11 1200 
O'Brien, R D , M h tldclrawi, Α ι Hdefrawi and J Τ far­
row. 1971, Binding of cholinergic ligando to electroplaxes 
and brain tissue, m Cholinergic Ligand Interactions, eds 
DJ Tnggle, J Ь Moran and h A Barnard (Academic 
press, New York, London) ρ 49 
O'Brien, RD , M L Fldefrawi and A Τ Hdefrawi, I 972, Iso­
lation of acetylcholine receptors, Ann Rev Pharmacol 
12.19 
Paton, W D M , Γ R S Rang and Η Ρ Rang, 1965. The up­
take of atropine and related drugs by intestinal smooth 
muscle of the guinea-pig in relation to acetylcholine re­
ceptors,Proc Roy Soc В 163,1 
Potter, LT and PB Molinoff, 1972 Isolation of cholinergic 
receptor proteins, in Perspectives in Neuropharmacology, 
a Tribute to Julius Axelrod ed Solomon H Snijder 
(Oxford University Press Ne* York) ρ 9 
Razin, S , 1972. Recumlitution of biological membranes, 
Biochim. Biophys. Acta 265,241. 
Soudijn W , 1 van Wijngaarden and 1 J Anens, 1973, Dexe-
iimide,a useful tool in acetylcholine receptor localisation, 
t-uropcanJ Pharmacol 24,43 
Tansley, К , 1931, The regeneration of visual purple; its rela 
tion to dark adaptation and night blindness, J. Physiol 
71,442. 
99 

PART II THE MUSCARINIC ACETYLCHOLINE RECEPTOR 
CHAPTER 3 
ARE MUSCARINIC RECEPTORS IN THE CENTRAL 
AND PERIPHERAL NERVOUS SYSTEM DIFFERENT? 

ARE MUSCARINIC RECEPTORS IN THE CENTRAL AND PERIPHERAL NERVOUS 
SYSTEM DIFFERENT? 
Arie J BELD, Sylv1a VAN DEN HOVEN, Alfonsus С WOUTERSE and Maria A Ρ ZEGERS 
Department of Pharmacology, University of Nijmegen, The Netherlands 
Received 29 November 1974, accepted 20 December 1974 
A J BELD, S VAN DEN HOVEN, А С WOUTERSE and M A P ZEGERS, Are muscarinic receptors in the 
central and peripheral nervous system differenf, European J Pharmacol 30 (1975) 360—363 
The concentration dependent binding of atropine ^H to membrane fractions from bovine tracheal muscle, 
parotid gland and caudate nucleus, measured b> equilibrium dialysis, revealed the presence of virtually identical 
high affinity binding sites in all three tissues Sch 1000 and Sch 1178, geometrical isomers of N-isopropylatropine 
bromide with a large potency ratio as antimuscannics, inhibited atropine binding identically in all three tissues 
Differences in properties of muscarinic receptors in these tissues are either non existent or too smaJI to be 
detected by the applied techniques 
European Journal of Pharmacology, 30 (1975) 360—363 
© North Holland Publishing Company 
Short communication 
Bovine tracheal muscle, parotid gland, caudate nucleus 
Muscarinic receptor 
Sch 1000 
1. Introduction 
Muscarinic agonists and antagonists affect 
smooth muscle, the central nervous system, 
the heart, the eye and exocrine glands 
through muscannic receptors. The question 
arises whether these receptors are all the same 
or can be divided into different types, analo­
gous to 0ι and 02 type adrenergic receptors 
and H, and Нз type histaminergic receptors 
With the objective of differentiating between 
muscarinic receptors of various origin, the 
parameters of the action of antagonists have 
been determined by means of several biologi­
cal methods. Barlow et al. (1972) measured 
affinity constants of muscarinic antagonists in 
the ileum, bronchial muscle and ins of the 
guinea pig. Inch et al. (1973) determined cen­
tral and peripheral activities of antiacetyl-
choline drugs in the central and peripheral 
nervous system. Both studies led to the same 
Affinity constants 
Atropine binding 
Sch 1178 
conclusion, that antimuscannic drugs do not 
differ in their intrinsic potency to inhibit cen­
tral or peripheral muscarinic receptors. 
We have looked at the problem from a 
different perspective by calculating the affini­
ty constants of atropine for muscannic recep­
tors in bovine tracheal muscle, parotid gland 
and caudate nucleus. The data were obtained 
from determinations of direct binding of triti­
um-labeled atropine to crude membrane frac­
tions prepared from these tissues. The results, 
which show only minor differences between 
the affinity constants in the different tissues, 
lead to the conclusion that muscarinic recep­
tors throughout the organism are identical as 
far as the experimental method can discern. 
We also measured the inhibition of atropine 
binding to these tissue fractions by Sch 1000 
and Sch 1178, geometrical isomers of N-
isopropyl-atropine bromide. Given by inhala­
tion, Sch 1000 is a potent bronchodilator of 
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the anticholinergic type and has almost no 
side effects on heart rate, salivary secretion 
and central activity (Engelhardt and Wick, 
1957; Ulmer et al., 1973, Pappius and Salonn-
ne, 1973; Minette et al., 1973). However, 
when injected intravenously in humans Sch 
1000 is a strong inhibitor of acetyl-ß-methyl-
choline-induced parotid secretion (Diamant et 
al., 1974). In our experiments Sch 1000 in-
hibited atropine binding in tracheal muscle, 
parotid gland and caudate nucleus in the same 
way, confirming the conclusion of Diamant, 
that Sch 1000 is a general and potent anti-
cholinergic of the muscarinic type. The lack 
of side effects when the, drug is given by 
inhalation must be ascçibeu to distribution 
phenomena and not to different affinities for 
muscarinic receptors in various tissues. Sch 
1178, a compound with much weaker anti-
muscanmc properties (Wick, 1974, personal 
communication) also inhibited atropine bind-
ing in all three tissues identically, but at a 
much higher dose level. 
2. Materials and methods 
2.1. Materials 
Atropine-3 H (spec. act. 400 mCi/mmol) 
was purchased from The Radiochemical Cen-
tre, England. Sch 1000 and Sch 1178 were 
obtained from C.H. Boehnnger Sohn, Ingel-
heim, Germany through the courtesy of Mr. J. 
Siebelmk. Sch 1000 is the quaternary N-
isopropyl derivative of atropine with the 
isopropyl group endo to the three atom 
bridge of the tricyclic tropinol skeleton. In 
Sch 1178 the isopropyl group is in the oppo-
site position. 
2 2 Target tissues 
Bovine tracheae, brains and parotid glands 
were obtained from the abattoir. The brains 
and parotid glands were transported to the 
laboratory in an ice bath; the tracheae in cold 
(0—4°C) Krebs—Henseleit solution. The tra-
cheal muscle and parotid glands were sepa-
rated from adhering non-target tissue as much 
as possible. 
2 3 Homogenization 
The homogenization of the tracheal muscle 
and parotid glands and the preparation of the 
microsomal pellets were the same as described 
previously for tracheal muscle (Beld and 
Ariens, 1974). Caudate nuclei were removed 
from the brains and homogenized in Krebs— 
Henseleit solution to a final tissue concentra-
tion of 10% in a Potter teflon-glass homoge-
nizer. 
2 4 Binding experiments 
The microsomal pellets of tracheal muscle 
and parotid glands were resuspended in 
Krebs—Henseleit by Potter homogenization to 
an original tissue concentration of either 0 50 
or 1.00 g/ml. For the caudate nuclei the 10% 
homogenate was used as such m the binding 
experiments. The equilibrium dialysis binding 
and calculation of free and bound concentra-
tions were essentially as described earlier 
(Beld and Anens, 1974). All the binding ex-
periments were carried out at room tempera-
ture. 
3. Results and discussion 
The concentration-dependent binding of 
atropine- 'H (10—28 0 nmol/1) to prepara-
tions of bovine tracheal muscle, parotid gland 
and caudate nucleus is depicted in fig. 1. 
Atropine was used in preference to other cho-
linergic hgands, because it shows almost no 
unspecific binding in the concentration range 
measured, as judged by the shape of the bind-
ing curves and the Scatchard plots (not 
shown) where there are only slight deviations 
from linearity at the highest concentrations. 
Other anticholinergics show (Beld and Ariens, 
1974) or could show considerable unspecific 
binding. 
1 0 4 
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Tro i rh f i í i smoo th tnn*,\. le 
/ 
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At ι opine H3(tiee} 
Table 1 
Binding parameters for atropine- 3H m bovine tracheal 
muscle, parotid gland and caudate nucleus Affinity 
constants mol/l * S E. Binding capacities mol/g tissue 
(wet weight) = S E. 
Tissue Affinity constant Binding capacity 
Tracheal 2.96 ± 0 23 X ICf9 19 9 ± 0 6 X 10 1 2 
muscle 
Caudate 1 89 t 0 07 X IO"9 167 8 ± 2 4 X IO" 1 2 
nucleus 
Parotid 2 09 ± 0 07 X 1Ö"9 17.5 ± 0.2 X 10"'2 
gland 
A t i v i n e ^ 
Li ï i ic i i Î te nuc leus 
Ю 15 20 25 0 " ' M 
At rop i i ì e ИЗ ^ггее·) 
A t r o p i n e H ^ 
p M o l e s bouivd/ζ t i s s u 
JÚ 
15 
10 
5 
^-— 
/ ^ 
1 
1 
Pat u t . d ^ l a n d 
* 
0 5 10 15 Z0 25 1 0 " ' M 
A t r o p i n e M3 (free) 
Fig 1 Binding curves of atropine-3 H to bovine tra-
cheal muscle, parotid gland and caudate nucleus 
(1 .0-28.0 nmol/1) 
The binding curves can be fitted to a model 
of one single saturable binding site. Binding 
parameters (affinity constants and binding 
capacities) were calculated from the binding 
data by a computerized curve fitting proce-
dure, which is a least squares fitting method, 
based on a gradient method for the non-linear 
paiameters and a linear regression method for 
the linear parameters, originally developed by 
G. Fast (University Computer Centre, Nijme-
gen). The corresponding standard errors of 
the parameters were calculated in the last 
iteration with the usual equations applied to 
the quasi-lmearization (table 1). Attempts to 
fit the binding curves to a model consisting of 
a saturable high affinity binding site and a 
linear distribution of low affinity binding sites 
revealed only minimal contribution from 
those sites. No improvement of the goodness 
of fit was obtained with this model. 
The affinity constants for parotid gland 
and caudate nucleus are equal within the ex-
perimental error, while the value for tracheal 
muscle deviates significantly by the same cri-
teria. This difference, however is so small, 
that it cannot be taken as conclusive evidence 
for differences in receptor properties in pa-
rotid gland and caudate nucleus on one hand 
and in smooth muscle on the other. For the 
time being, we cannot exclude the possibility 
that with other radioactively labeled choli-
nergic ligands the differences in affinity con-
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.000/Ъ I 
Fig 2 Inhibition of atropine H binding in bovine 
tracheal muscle, parotid gland and caudate nucleus 
by Sch 1000 and Sch 1178 Bound atropine is express 
ed as a percentage of binding in the controls Free con 
co η trat ions of atropine 3 H ranged from 10 to 12 nmol/ 
1, corresponding to approximately 80% receptor satu 
ration in the controls Points are the mean of dupli 
cates 
stante are larger and hence differences in re­
ceptor properties can be substantiated. Fur­
ther experiments will be performed m our 
laboratory to investigate this possibility. 
The affinity constants of Sch 1000 and Sch 
1178 could not be measured directly, because 
the compounds were not at our disposal in a 
labeled form of sufficiently high specific ac­
tivity. Therefore we measured the inhibition 
of atropine binding by increasing concentra­
tions of both compounds. As can be seen in 
fig. 2. Sch 1000 inhibits atropine binding in 
all three organs to the same extent within the 
experimental error. From this observation, 
the conclusion can be drawn that Sch 1000 is 
a potent antimuscarmic compound with no 
selectivity of action as far as its binding to 
receptors in different tissues is concerned. Re­
ported selectivity of pharmacological action 
must therefore be ascribed its manner of ap­
plication form and/or distribution. Sch 1178 
also inhibits atropine binding identically in 
the three different tissues, but at much higher 
doses, as could be expected from its lower 
potency as an antimuscarmic. 
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PART II THE MUSCARINIC ACETYLCHOLINE RECEPTOR 
CHAPTER 4 
ON THE NATURE OF AGONISM IN MUSCARINIC 
RECEPTOR-LIGAND INTERACTION. A STUDY 
OF THE BINDING OF A HOMOLOGOUS SERIES 
OF METHYLFURTHRETHONIUM ANALOGUES AT 
THE PERIPHERAL MUSCARINIC RECEPTOR 
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Nijmegen. The Netherlands. 
INTRODUCTION 
As a result of inconsistencies in structure-activity rela-
tionships of cholinergic and anticholinergic drugs, Ariëns postu-
lated that antagonists do not bind to the receptor in a similar 
way as agonists do, but find their binding affinity for the 
greater part by binding to lipophilic areas in the direct vicin-
ity of the receptor (Ariëns and Simonis, 1967). The question 
whether agonists and antagonists act on common receptors or not 
has regained interest with the recently performed receptor bind-
ing studies with radioactively labelled ligands in broken cell 
preparations. Concentration dependent inhibition of labelled 
antagonist binding by non-labelled antagonists displays normal 
sigmoid behaviour and can be explained on basis of competition 
between labelled and non-labelled compounds for a single class 
of binding sites (Hulme et al., 1978). A prominent feature of 
inhibition curves of labelled antagonists by non-labelled 
agonists is a deviation from sigmoid behaviour. The curves are 
less steep than might be expected on basis of a simple competi-
tion. The Hill-plots are non-linear and the inclinations in the 
middle part of the curve strongly deviate from one (Birdsall et 
al., 1978, 1979). A non-linear Hill-plot with a slope smaller 
than one is frequently taken as evidence for negative co-oper-
ative behaviour amongst receptor molecules, but this is not the 
only possible explanation for the observed phenomena. If it is 
assumed that there are two independent non-interconverting bind-
ing sites for which antagonists have identical or almost ident-
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ical affinities and for which agonists have different affinities 
a simple explanation for a number of experimental findings is 
offered (Hulme et al., 1975). With such a "two site" receptor 
model and properly chosen parameters theoretical inhibition 
curves and Hill-plots can be constructed which are indistinguish-
able from experimental curves (Beld et al., 1978; Ariens et al., 
1979) . 
Although the two site receptor model accounts for many if 
not all experimental observations, it leaves a few important 
questions unanswered. Are both binding sites or is only one of 
them related to the receptor mediating the physiological response 
and if it is only one is it the low or the high affinity binding 
site? The two site receptor model lacks internal consistency. 
Antagonists with a high affinity for the two binding sites must 
be in intimate contact with both of them. When we assume, as is 
common practice, that intimacy of contact is correlated with af-
finity, the interaction of agonists with the two binding sites 
must be less close judging from their relatively low affinities. 
Yet agonists do differentiate between the two binding sites and 
antagonists do not. This is contradictory to the general feeling 
that specificity and discriminative power of ligands must increase 
with increasing affinity. Furthermore it is rather fortuitous to 
assume that antagonists like Dexetimide and atropine would bind 
to both sites with the same high affinity and that all other 
antagonists studied would equally do so. 
Often there are large structural differences between agonists 
on one hand and antagonists on the other and it is not clear from 
what we know whether discriminative behaviour towards the two 
binding sites is confined to one structural class of compounds or 
whether it is inherent to the nature of agonisir. itself or for that 
matter to intrinsic activity. The study of a homologous series of 
compounds in which there is a gradual transition from agonist to 
antagonist such that the compounds can still be seen as belonging 
to one structural class might provide some of the answers towards 
these questions. 
3 
We wish to report on the inhibition of H-Dexetimide binding 
by a homologous series of methylfurthrethomum analogues, m which 
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there is a gradual change from full agonists via partial agonists 
to antagonists with increasing chain length of one of the alkyl 
groups on the quaternary nitrogen. 
MATERIALS AND METHODS 
Target tissue 
Bovine trachea were obtained from the local slaughterhouse 
and transported to the laboratory on crushed ice. The smooth 
muscle layer was removed within a few hours and freed from mucous 
layer and connective tissue as well as possible. In all experi­
ments pooled smooth muscle of 5-10 animals was used. 
Homogemzatbon 
25 g of smooth muscle was divided into small pieces with 
scissors and ground thoroughly with 50 g of carborundum (80-120 
mesh) in a mechanically driven mortar. After mixing with 50 ml 
of Krebs-Henseleit buffer the pulp was centrifuged at low speed 
(2000 rpm) for 5 minutes. The supernatant was decanted; the pel­
let was ground a second time and extracted with Krebs-Henseleit 
in the same way. The combined extract was made up to a final 
tissue concentration of 20% and centrifuged at 8000 rpm (5000 g) 
for 20 minutes. The plasma membrane pellet was made by centrifug-
ing the supernatant at 100,000 g for 1 hr in rotor 40 in a Christ 
Omega II ultracentrifuge. The crude plasma membrane pellets were 
stored at -20 С and used up to two weeks after homogemzation. 
The whole procedure was carried out at 0 -4 С. 
Вгпагпд expennents 
Prior to use, the membrane pellets were washed with Krebs-
Henseleit by Potter-homogenization and the suspension obtained 
was centrifugad at 100,000 g for 45 minutes. The resulting pellet 
was resuspended in Krebs-Henseleit to give a tissue concentration 
of 0.50 g/ml. The method used for the assay of particle bound 
radioactivity was the rapid centrifugation of membrane fragments 
using a microfuge (Terenius, 1974). Assay tubes received 1.00 ml 
membrane suspension, 0.100 ml of an H-Dexetimide solution to 
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give a free concentration of approximately 10 M corresponding 
to 95% receptor saturation and 0.100 ml of either Krebs-Henseleit 
or a solution of unlabelled drug in Krebs-Henseleit to give the 
concentrations depicted in tables and figures. Incubation volume 
1.20 ml. Assays were done in 1.5 ml stoppered polypropylene tubes. 
The tubes were rotated at 1 rpm for 20 minutes to ensure equi-
librium. The membrane fragments were pelleted by centnfugation 
at 25,000 g for 15 minutes in a Christ Heraeus Hämofuge-912. The 
free concentration of radioactively labelled ligand was measured 
by mixing 0.50 ml of supernatant with 10 ml of Instagel (Packard) 
and counting. Radioactivity in the pellet was measured by cutting 
the tips of the centrifuge tubes, dissolving in 1 ml Soluene 
(Packard) and mixing with 15 ml of Instagel/1 N HCl (9/1) . The 
samples were counted in a Packard Liquid Scintillation Counter 
Model 3 380 with standard deviations of 1% or less. Free and bound 
concentrations of labelled ligand were calculated from the radio-
activities measured. Free concentrations of unlabelled ligands 
were calculated from the standard solutions added and were as-
sumed not to differ appreciably before and after equilibrium had 
been established. 
Curve fi.tbi.ng 
The parameters of the theoretical binding models applied 
were fitted to the experimental data with a computerized curve 
fitting procedure, which is a least squares fitting method based 
on a gradient method for the non-linear parameters and a linear 
regression method for the linear parameters, originally developed 
by G. Fast (Breimer, 197 4) . The corresponding standard errors of 
the parameters were calculated in the last iteration with the 
usual equations applied to the quasi-lmearization. The weighted 
2 
residual sum of squares (χ ) after the last iteration, is taken 
as a measure for the goodness of fit. In the weighting process it 
is assumed that experimental error in the data amounts 5%. 
Materzals 
H-Dexetimide (spec.act. 420 mCi/mmol), unlabelled Dexetimide 
and (-)-benzetimide were gifts from Janssen Pharmaceutica, Beerse, 
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Belgium. Alkylated methylfurthrethonium analogues were syn­
thesized according to known procedures. Other reagents were 
obtained from commercial sources and were of the highest quality 
available. 
Binding models applied 
Binding of a ligand A to tissue fragments can be looked at 
as occurring to a finite number of binding sites with different 
capacities and different affinities for the drug bound (Scatchard, 
19 49). When inhibition of binding by a competing ligand В is also 
considered the concentration of drug A bound "Ц^Ц^оипа" a s a ^ и п с -
tion of the free ligand concentrations A and В can be expressed 
as : 
η L*L1 
Ц А Ц . , = Σ τ, (Eq. 1) 
•- -
1
 bound . . K_. . r_n 1=1 , . Αϊ
 +
 LBJJ 1 + 5==^  (1 + ψ^) 
Bi Π Α : - • к. 
J_1_ 
in which r. is the concentration of sites of the i class of 
ι 
binding sites and K,. and K„. are the dissociation equilibrium 
th 
constants of drugs A and В for the i class. The distribution 
of these classes of sites will be in general such that some of 
these sites are of high or intermediate affinity and the remain­
ing sites are of much lower affinity for drugs A and B. For the 
low affinity sites it holds true that 
ω , „
 KAi 
41 " 1 and m 
Binding to the low affinity sites, however, can be substantial 
if the capacities are large enough. It constitutes the unspecific 
binding encountered to a larger or lesser degree in every binding 
experiment. Characteristic for the unspecific binding is that it 
is linearly dependent on the concentration of drug A and that it 
is practically not displaced by the competing ligand B. In experi­
mental situations binding curves and inhibition curves are ana­
lysed on basis of one or two specific binding sites plus a linear 
distribution comprising the low affinity binding sites. The lack 
of preciseness of experimental data seldomly justifies an analysis 
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on basis of models with more than two specific binding sites. We 
have analysed our inhibition curves on basis of the following two 
models. 
Model 0101 one specific binding site (n = 1, equation 1) 
Model 0202 two specific binding sites (n = 2, equation 1) 
The unspecific binding is determined as the residual binding in 
the presence of a 1000-fold excess of unlabelled drug A. Bound 
concentrations are calculated by subtracting unspecific binding 
from total binding. In model 0202 it is assumed that drug Λ has 
identical affinities for the two specific binding sites, hence 
identical values for К
д
 for the first and the second binding site 
are taken. The free concentration of the ligand to be displaced 
— R 
is kept as constant as possible at approximately 10 M. In com­
paring the models preference is given to the complicated model 
over the simple model when a significant diminution in the re­
sidual sum of squares is obtained. A statistical comparison of 
the goodness of fit is made by means of the F-test (Boxenbaum et 
al., 1974) . 
RESULTS 
The inhibition of H-Dexetimide binding by methylfurthre-
thonium is depicted in Fig. la, b. The curve in Fig. la is cal­
culated on basis of a one site receptor model and represents the 
best fit to the experimental data when simple mass action dynamics 
are assumed. It is obvious that a curve through the points follows 
a much flatter course. The Hill-plot, m which log (.
 η η 0 r-^tr) 
10U-% inhib. 
is plotted against log В (Fig. 2) strongly deviates from a straight 
line. Its slope is everywhere less than one and reaches a minimum 
of 0.37 at approximately 50% inhibition. The Hill coefficients of 
all compounds tested are included in Table 3 and can be seen as a 
semiquantitative measure for deviation from simple mass action 
behaviour. In Fig. lb a two site receptor model is fitted to the 
same data. The curve fits the experimental data much better than 
in case of a one site receptor model. This is further supported 
2 by the highly significant diminution in χ in going from a one 
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Fig. 1 Inhibition of H-Dexetimide binding by methylfurthre-
thonivn. The curve in fig. la is the best fit to the 
experimental points according to the one site receptor 
model. The curve in fig. lb is the best fit to the ex­
perimental points according to the two site receptor 
mode I. 
l/oce: the two site receptor model fits the experimental 
points mue h better than the one site receptor model 
site receptor to a two site receptor model (Table la, b) . VJhen 
3H-Dexetimide binding is inhibited by the N-ethyl analogue of 
methylfurthrethoniura a two site receptor model also fits the 
experimental data significantly better than a one site receptor 
model (Fig. 3). In case of the N-propyl (Fig. 4) and the N-allyl 
2 
analogue (Fig. 5) of methylfurthrethonium the diminution in χ 
in going from a one to a two site receptor model is still sig­
nificant although to a lesser degree (for F-values see Table lb). 
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(100-°/o inhibition) 
МеГигМеэ 
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log cone inhibi tor ( ηΜ ) 
Fig. 2 Hill-plot of the inhibition of H-Dexetimide binding by 
methyIfurthrethonium. The curve is calculated from a two 
binding site model with a fixed capacity ratio of 1.0 
(for parameter values see Table 2, experiment I) 
The inhibition of H-Dexetimide binding by the N-isopropyl (Fig. 
6) and N-butyl (Fig. 7) analogue can be described adequately by 
2 
a one site receptor model and no significant diminution in χ is 
obtained when the curves are fitted on basis of a two site recep­
tor model. It is tempting to believe that methylfurthrethonium 
and all the analogues bind to two binding sites and that the 
butyl and isopropyl analogue do so with identical or almost 
identical affinities while for the other analogues and methyl-
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3 Fig. 3 Inhibition of Ч-Dexetimide binding by the N-ethyl 
analogue of me thyLfurthrethoniwn (for details see Fig. 1) 
furthrethomum itself the two affinities lie clearly apart 
(Table la, b). 
The results of Table 1 are still unsatisfactory as far as 
model 0202 is concerned, because the ratio of the capacities for 
the first and second binding site is subject to large variability. 
Within the definitions of model 0 202 assuming two independent 
non-interconverting binding sites, it is not conceivable that the 
capacity of the high affinity binding site can be relatively large 
in case of the ethyl analogue, intermediate m case of methylfur-
threthonium and small in case of the propyl analogue. Furthermore 
the ratio of the capacities of the binding sites shows a similar 
degree of variability in separate experiments with the same corn­
il? 
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TABLE la 
3 Analysts of the іпЫЪгЬгоп of H-Dexe timide 
binding by Tiethylfurthrethonium derivatives 
according to the one site receptor model ΟΊΟΙ 
К r,. χ
2
 С 
t л exp 
(10~ 1 2 mol/g) (n+) (ml/g) 
MeFurMe, I 4.1 (18) 14.1 (3.1) 43 (20) 0.53 
11.1 (3.8) 80 (28) 0.45 
 
I I 
I 
I I 
( 1 0 " 
. 1 
5 . 5 
2 . 9 
1 . 9 
•
б
. м ) 
 
( 1 5 ) 
( 1 6 ) 
( 1 5 ) 
MeFurMe.Et  9  12.0 (4.2) 75 (20) 0.42 
7.8 (4.3) 48 (30) 0.56 
MeFurMe-Pr I 9.0 ( 9.5) 13.0 (2.2) 11 (21) 0.79 
II 10.0 (10) 16.9 (2.5) 33 (32) 0.55 
MeFurMe2Allyl I 9.2 (16) 16.8 (2.8) 36 (21) 0.53 
II 7.4 ( 8.5) 15.2 (2.2) 24 (22) 0.52 
MeFurMe2iPr 8.4 ( 8.9) 16.8 (3.0) 31 (22) 0.47 
MeFurMe2Bu 14.0 ( 8.0) 14.1 (1.8) 17 (22) 0.45 
К - dissociation constant 
r. - total concentration of binding sites per gram tissue 
С - coefficient for unspecbfic binding (Г/.~] ... , , = 
exp
 r
 Γ/ι-!) t- j J U -¡unspecbfbc bound 
C
exp-^AJJ 
Values in parenthesis indicate геіаіъ е standard errors 
+ = degrees of freedom 
I and II refer to separate experiments 
Fig. 4 Inhibition of H-Dexetimide binding by the N-propyl 
analogue of methylfurthrethonium (for details see Fig. 1) 
3 Inhibition of H-Dexetimide binding by the N-allyl 
analogue of mevhylfurthrethonium (for details see Fig. 1) 
119 
TABLE lb 
Analysis of the inhibition of li-Dexetimide binding by methyl·fur-
threthonium derivatives according to the two site receptor model 0202 
2 
К r K 9 r X F-value 
1 2 
(10"6.M) (10~12 mol/g) (10"б.М) (10 - 1 2 mol/g) (n+) 
MeFurMe^ I 0.27 ( 46) 7.2 (14) 17 ( 13) 7.6 ( 13) 8.7 (18) 36** 
II 0.12 ( 51) 5.6 (14) 11 ( 19) 8.2 ( 8.2) 22 (26) 34 
MeFurMe9Et I 1.2 ( 20) 11.1 ( 4.7) 216 ( 63) 1.7 ( 23) 15 (18) 36** 
II 0.86 ( 45) 6.7 (15) 30 (150) 1.5 ( 69) 35 (28) 5.2* 
MeFurMe Pr I 0.49 Ü80) 2.7 (68) 13 ( 28) 10.8 ( 18) 7.0 (19) 5.4* 
II 0.90 (150) 3.9 (71) 15 ( 30) 13.8 ( 21) 24 (30) 5.6** 
It 
4.8* MeFurMe Allyl I 0.91 (120) 5.9 (50) 19 ( 37) 11.3 ( 26) 24 (19) 
II 2.0 ( 58) 8.1 (36) 18 ( 41) 7.6 ( 40) 11 (20) 5.4 
MeFurMe-iPr 8.4++ - 8.3++ - 31 (20) 0 
MeFurMc2Bu 9.8 ( 49) 12.0 (41) 64 (200) 2.2 (220) 15 (20) 1.0 
К = dissociation constant, r, = total concentration of binding sites per gram tissue 
K¿ - dissociation constant for the i^h class of sites. 
r, = concentration of binding sites of the i^^ class per gram tissue. zi 
For values of С , see Table la. 
Values in parentnesis indicate relative standard errors, + = degrees of freedom 
+ + = no meaningful standard error, t ρ < 0.05, xst ρ < 0.01 
I and II refer to separate experiments 
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Fig. 6 Inhibition of H-ùexet%mide binding by the N-isoprcpyl 
analogue of methyl furthreIhonium (for details see Fig. 1) 
pound. The variability is more or less inherent to the analytical 
procedure, because the weighted residual sum of squares is rela-
tively insensitive to variations in the ratio of the capacities 
of the two binding sites. This is also apparent from the large 
standard errors of the binding capacities in model 0202 as com-
pared to model 0101. In cases where the two binding affinities 
are very close and in which the data might as well be analysed 
with a one binding site model, the uncertainties in the binding 
capacities become extremely large as exemplified by the isopropyl 
and butyl analogues of methylfurthrethonium. 
In view of the definitions of the two site receptor model a 
variation in the ratio of the binding capacities is contradictory 
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Fig. 7 Inhibition of H-Dexetimide binding by the N-butyl 
analogue of ne thy Ifurthrethonium (for details see Fig. 1) 
and a much better approach would be to analyse the data by a two 
binding site model with a fixed ratio of the binding capacities. 
Such a model can be fitted to the experimental data with one 
parameter less and the capacities calculated for the two binding 
sites add up to the total specific binding capacity. One problem 
remains; what numerical value should be given to the fixed ratio 
of the binding capacities. The best value for this ratio can be 
derived from the inhibition of H-Dexetimide binding by methyl-
furthrethonium, because the affinities for the binding sites lie 
farthest apart in this case. A slight indication of a plateau in 
the middle part of the inhibition curve is discernable and the 
Hill-plot has its smallest inclination at approximately 50% inhi-
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bition. Therefore, the best value to fix the ratio of the binding 
capacities seems to be 1. Subsequent calculations with fixed ca-
2 
pacity ratios of 2/3 and 3/2 demonstrated that χ is relatively 
insensitive to variations in the capacity ratios in the range 
0.66-1.50 anyway. Table 2 gives the affinities and binding capac­
ities of the two binding sites when the ratio of the capacities 
is fixed at 1.0 (model 0204) . Comparison of the data with those 
calculated with model 0202 reveals a considerable improvement of 
the standard errors of the affinity constants especially for the 
compounds where the К values for the high and low affinity bind-
2 ing site are close. Concomitantly χ shows a slight tendency to 
increase although within acceptable limits. The affinity for the 
high affinity binding site (hereafter called first binding site) 
-7 decreases with increasing chain length going from 2.2.10 M for 
methylfurthrethonium to 8.4.10 M for the isopropyl analogue. 
The affinity for the low affinity binding site (hereafter called 
second binding site) varies to a much lesser extent ranging from 
1.0.10~5 M - 2.5.10 M only. The affinity for the first binding 
site approaches the affinity for the second binding site with in­
creasing chain length, both values becoming essentially the same 
for the isopropyl and butyl analogue. The results are graphically 
represented in Fig. 8 in which the ratios of the affinity con­
stants for the second and the first binding site are depicted as 
a function of chain length. 
DISCUSSION 
The inhibition of H-Dexetimide binding by a homologous 
series of methylfurthrethonium analogues reveals normal competi­
tive behaviour for the antagonists amongst them (e.g. the iso­
propyl and butyl analogue), exemplified by sigmoid inhibition 
curves and linear Hill-plots with a slope close to unity. The 
agonists (the methyl and ethyl analogue) and partial agonists 
(the propyl and allyl analogue) are anomalous in the sense that 
inhibition curves are less steep than may be expected on basis 
of competition for a single class of binding sites and that Hill-
plots are non-linear. The deviant inhibitory behaviour of agonists 
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TABLE 2 
3 Analysis of the inhibition of H-Dexetimide binding by methylfuv-
threthonium derivatives according to a two site receptor model in 
which the ratio of the capacities is fixed at 1.0 (model 0204) 
(10 .M) (10~6.M) 
r = r t, t 
(10 
1 
-12 
2 
mol/g) (n+) 
MeFurMe. 
MeFurMe2Et 
MeFurMe^Pr 
MeFurMe2Allyl 
I 
II 
I 
II 
I 
II 
I 
II 
0 
0, 
0, 
0 
2. 
3 , 
2. 
1. 
.32 
.22 
.32 
.37 
.9 
.6 
.0 
.9 
( 2 3 ) 
( 2 7 ) 
( 4 2 ) 
( 4 7 ) 
( 2 6 ) 
( 2 3 ) 
( 3 5 ) 
( 2 0 ) 
18.1 (11) 
15.8 (12) 
10.1 (18) 
5.5 (22) 
20.4 (15) 
23.6 (14) 
25.3 (18) 
17.9 ( 9.6) 
7.4 (1.4) 
6.9 (3.2) 
6.6 (4.5) 
4.2 (5.3) 
6.7 (1.9) 
8.7 (1.9) 
8.6 (2.1) 
7.9 (1.7) 
8.7 (19) 
26 (27) 
35 
39 
8.3 
26 
24 
11 
(19) 
(29) 
(20) 
(31) 
(20) 
(21) 
MeFurMe-iPr K1 = K 2 = 8.4 (8.9) 8.4 (3.0) 31 (22) 
MeFurMe_Bu K1 = K 2 = 13.8 (8.0) 7.1 (1.8) 17 (22) 
The values for the isopropyl and butyl analogues are according to the one site 
receptor model. For symbols, see Table 1. 
Values in parenthesis indicate relative standard errors, + = degrees of freedom 
I and II refer to separate experiments 
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methyl ethyl allyl propyl iso- butyl propyl 
Fig. 8 Ratio of affinity constants for the second and first 
binding site in a homologous series of methyl furthrethonium 
analogues. K-values are calculated from a two binding site 
model with a fixed capacity ratio of 1.0 (model 0204; see 
Table 2). 
Data points are weighted means of duplicates ; vertical 
bars indicate SEM-values. The inhibition by the isopropyl 
and butyl analogue was adequately described by a one bind­
ing site model, implicating that the ratio of the affinity 
constants for the two binding sites is close to unity for 
these compounds. 
as compared to antagonists cannot be explained by interaction 
models in which agonists and antagonists are considered as belong­
ing to structurally different classes of compounds. Vie feel that 
anomalous binding behaviour is not confined to a particular 
structural class of compounds but is in one way or another con-
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nected with the very nature of agonism itself. 
The binding phenomena as such can easily be explained by 
postulating two muscarinic binding sites, although the unlikely 
assumption that all antagonists bind with equal affinity to both 
binding sites has to be made. But suppose, the presence of two 
binding sites is the correct explanation; then the question can 
be raised which of the two is mediating the biological response 
and what is the physiological role of the other one? Comparison 
of the pharmacological parameters and the binding parameters 
obtained with model 0204 shows a correlation of the pD-ZpA. 
values and -log К (r = .82; ρ < .1) (Table 3). The ratio K2/K 
parallels the decline in intrinsic activity along the series of 
compounds; agonists have a high K2/K ratio, partial agonists 
have an intermedíate K^/K. ratio and antagonists have a value 
for K^/K. of unity. All this points to the high affinity binding 
site as the one directly involved in mediating the biological 
response. 
Birdsall et al. (1977) argue that such a relationship must 
be spurious because pD.-values do not reflect true affinities as 
a result of the existence of spare receptors and that affinity 
constants derived from contractile responses in smooth muscle 
after spare receptors have been removed with an irreversibly 
reacting antagonist are better correlated with the affinity con-
stants of the low affinity binding site. Concepts like intrinsic 
activity and spare receptors, however, find their basis in the 
assumption of a simple bimolecular interaction between drug and 
receptor and it is questionable whether these concepts can be 
used unmodified in the more complex situation of the muscarinic 
receptor as it is apparent from binding experiments. We really 
have doubts whether the concept of spare receptors can provide 
arguments in favour of or against one of the two binding sites 
being involved in mediating the biological response. Protection 
experiments with agonists and irreversibly reacting antagonists 
in intact smooth muscle might be critical in this respect. It 
should be possible to find a concentration of a particular 
agonist such that the high affinity binding site is largely pro-
tected from becoming alkylated and the low affinity binding site 
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TABLE 3 
Ccnparison of binding parameters with in vivo drug para­
meters in a series of methylfurthrethonium analogues 
\ 5 ^СНз 
снз^оЛгн^ 
Model 0204 
R 
-CH3 
-сн2-сн3 
-сн2-сн=сн2 
-сн2-сн2-сн3 
.
с н
з 
-CH X 
α 
1.0 
1.0 
-
0.9 
0 
pD2/pA2 
7.2 
6.3 
-
5.3 
5.8 
-log K1 
6.6 
6.5 
5.7 
5.5 
5.1 
-log K 2 
4.8 
5.1 
4.7 
4.7 
5.1 
nH 
0.41 
0.58 
0.72 
0.80 
1.0 
-CH2-CH2-CH2-CH3 0 4.4 5.2 5.2 1.0 
Κ
η
 and К_ are the affinity constants for the high and low affinity 
binding sites respectively 
n„ = Hill coefficient 
tl 
рор/рЛр values and intrinsic activity (a) values are taken from 
van Rossum and Hurkmins (1962) and were obtained from contractile 
responses in isolated rat intestine. 
is not. Dependent on whether the contractile response is blocked 
or not under these circumstances, it can be argued that one of 
the two binding sites and not the other is related to the phar­
macological receptor. 
An attractive interpretation of the binding results is 
offered by receptor models like the two step receptor model 
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(Boeynaems and Dumont, 1977) or the mobile receptor model (Jacobs 
and Cuatrecasas, 1976) in which the receptor or pharmacon-receptor 
complex is supposed to interact with an effector unit also present 
m the fluid membrane. In such models a receptor R is supposed to 
be in equilibrium with a cofactor E which might be an effector 
molecule as in the case of the mobile receptor model. 
R + E 
+ 
D 
к1 И 
RD + E 
-
— 
RE 
+ 
D 
Нк 2 
RED 
An agonist will have a preference for RE, causing the equilibrium 
between R and E to shift to the right. An antagonist will have 
preference for R thus stabilizing the R-form. If the pharmaco­
logical effect is supposed to be a function of (RE+RED), phenomena 
like intrinsic activity, spare receptors and resting tone are all 
implicit m this model. When the concentration of effector mol­
ecules E_ is lower than the concentration of receptor molecules 
RT, an agonist will preferentially bind to RE and as soon as E is 
depleted will bind to R with a much lower affinity thus apparently 
showing binding to two independent sites with different affinity. 
RE corresponds to the high affinity site and R corresponds to the 
low affinity site. An antagonist will bind almost exclusively to 
R thus showing only one population of binding sites. Inhibition 
of H-Dexetimide binding by methylfurthrethonium or its butyl 
analogue can be described equally well by the mobile receptor 
model as by the two site receptor model (Fig. 9). 
Experiments with irreversibly reacting antagonists by Bird-
sail et al. (1978) in which 90% of the binding sites have been 
eliminated show an unaltered inhibitory pattern for agonists for 
the remaining sites and do not seem to fit into a mobile receptor 
model or other antico-operative receptor assemblies. Such experi­
ments, however, do not exclude floating receptors m rapid equi­
librium with effectors in the гп Vbjo situation. It could well be 
that as a consequence of cell breakdown the equilibrium between 
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RECEPTOR-EFFECTOR MODEL 
Iractional occupation 
4 6 8 
log cone i n h i b i t o r in nM 
F i g . 9 Inhibition of " 4-Dexeti>ride binding by me thy Ζ furthre thonium 
and by i t s butyl analogue. Curves through the points were 
aalavlated according to nobile receptor theory with the 
following assumptions for the parameter values nade. 
R„ = 20 пЧ; ¿ \ - 10 nil; L = 100 nM 
0.37 nu, K0 = 1000 пЧ 
  К 
Dèxetimide : К. 
HeFurì'e • Klj - ISOOO пУ, К 
:ieFur-íe0Bu: К, = 15000 nM3 К, 
0 . l i nM 
1000 пУ 
R and E is not rapidly reversible anymore. Such a frozen state of 
floating receptors and effectors is essentially the same mechanism 
behind the multiplicity in muscarinic binding sites as the propo­
sal of Birdsall that part of the receptors is coupled to effectors 
in a tight manner. If it could be demonstrated that receptors and 
effectors are mobile in the in vivo situation we would not be left 
having no functional role for one or more muscarinic receptor sub­
types. Blockade of receptors with alkylating compounds in intact 
smooth muscle and assessment of the binding characteristics of 
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residual receptors will possibly provide evidence for such a 
mechanism. 
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PART III THE DOPAMINE RECEPTOR 
CHAPTER 1 
INTRODUCTION 

THE DOPAMINE RECEPTOR 
INTRODUCTION 
Electrophysiological investigations of neurones of the sub-
oesophageal ganglionic mass of the snail helix aspersa revealed 
that dopamine inhibits the spontaneous electrical activity of 
most neurones. Some cells, however, react to dopamine with an 
increase in action potential frequency. The effects of dopamine 
on both types of cells are differentially mimicked and blocked 
by compounds known to be active at dopamine receptors. The re-
sults have been interpreted by postulating two types of dopamine 
receptors (Struyker Boudier et al., 1974). Almost simultaneously 
evidence for the existence of two types of dopamine receptors in 
the feline brain was obtained from the study of ipsilateral and 
contralateral head turning behaviour after direct application of 
dopamine, dopaminomimetics and dopammolytics in different parts 
of the caudate nucleus (Cools et al., 1976) . The functionally 
different effects of dopamine at topographically different sites 
do not necessarily mean that both effects are mediated through 
different receptors. The feasibility of such a supposition, how-
ever, is supported by the finding that the functionally different 
dopamine sensitive brain areas and the two types of cells in the 
snail can also be differentiated by a different sensitivity to 
dopaminergic ligands - agonists and antagonists. Apomorphme and 
halopendol are agonist and antagonist respectively of the 
dopamine receptors m the rostromedial part of the caudate 
nucleus of the cat and of the cells excited by dopamine in the 
snail. (3,4-Dihydroxyphenylamino)-2-imidazoline (DPI) and ergo-
metnne are agonist and antagonist of the dopamine receptors in 
the anterodorsal part of the caudate nucleus and of the cells 
inhibited by dopamine in the snail. The dopamine receptors, 
selectively activated by apomorphme and blocked by halopendol 
and other neuroleptics are denoted as excitation-mediating (DA -
receptors) and the receptors selectively activated by DPI and 
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blocked by ergometrine as inhibition-mediating (DA -receptors) 
dopamine receptors (Struyker Boudier, 1975; Cools and Van Rossum, 
1976; Cools et al., 1976). 
Other evidence for the existence of at least two types of 
dopamine receptors, classified by Kebabian as D-l and D-2 recep­
tors, stems from biochemical studies. D-l receptors are linked to 
a dopamine sensitive adenylyl cyclase m the rat striatum. D-2 
receptors are involved in inhibition of prolactin release and are 
not related to adenylyl cyclase (Kebabian and Calne, 1979). In 
what way DA - and DA -receptors are related to D-l and D-2 recep­
tors is not clear. 
It is generally agreed that receptor binding studies with 
radiolabelled ligands are indispensable in elucidating the struc­
tural and topographical differences of the supposedly different 
dopamine receptors. Receptor binding studies with tritium labelled 
dopamine and neuroleptics by Burt et al. (1975) have led to the 
postulation of two states of the dopamine receptor, an agonist 
state binding preferentially agonists and an antagonist state 
binding preferentially antagonists. The biphasic inhibition of 
H-dihydroergocryptine binding by dopamine is also taken as evi­
dence for the existence of two types of dopamine receptors 
(Titeler et al., 1978). The question which of those binding sites 
is related to the functionally demonstrated DA - and DA -receptors 
1
 e ι
 c 
is still open. It has been our aim to make a contribution to 
answering this question by studying the inhibition of H-spiperone 
binding by selective DA - and DA -agonists and antagonists. Such 
studies are the subject of the next chapter. 
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SUMMARY 
Dopamine receptor interaction was studied by concentration 
3 
dependent inhibition of Η-Spiperone binding to calf caudate 
nucleus homogenates with (+)-butaclamol, haloperidol, ergometrine, 
apomorphine and dopamine. The results were analyzed in terms of a 
one and a two site receptor model using computerized curve fitting 
procedures. Evidence is given in favour of a two site receptor 
model on basis of statistical criteria. The presence of two in­
dependent non-interconverting receptor sites for dopamine in calf 
caudate nucleus is consistent with binding data from others and 
with in vivo experiments. 
The existence of functionally and pharmacologically distinct 
excitation-mediating (DA -receptors) and inhibition-mediating 
(DA.-receptors) dopamine receptors has now been firmly established 
(1). Receptor binding studies with radiolabeled ligands might 
further aid in answering the question whether this differentiation 
is based on structural differences between DA -receptors and DA,-
e
 c
 χ 
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receptors or simply on a different accessibility for drugs гп 
3 
situ. Experimental binding inhibition curves with H-Spiropendol 
as the labeled ligand and other drugs, dopamine agonists and an­
tagonists as inhibitors were fitted to simple models and the 
quality of the fits evaluated on basis of statistical criteria. 
MODEL CALCULATIONS 
The models applied are elaborations of well known concepts 
for drug receptor interaction with a main emphasis on ligand 
binding and inhibition of binding. The equations describing the 
models have been published elsewhere (2). In this paper the char­
acteristics of the models are summarized. 
In the one site receptor model a simple bimolecular reaction 
between drug and receptor is assumed. The model predicts sigmoid 
inhibition curves, a parallel shift of the inhibition curves with 
increasing concentrations of A (Fig. la, b) and a slope of the 
Hill-plots of one. 
In the dual receptor model it is assumed that the receptor 
exists in two forms R and R in rapid equilibrium with each other. 
The R form contributes to the effect, the R form does not. 
Agonists bind preferentially to the R x form thereby shifting the 
equilibrium between R and R towards the R x form. Antagonists 
bind to the R form and thereby prevent the equilibrium from shift-
ing to the R form. Inhibition curves calculated with properly 
chosen numerical values for the parameters are indistinguishable 
from those calculated on basis of the one site receptor model. 
The same holds for the Hill-plots, which all have a slope of one. 
In the allosteric receptor model it is assumed that the 
receptor molecule contains two receptor sites one for agonists 
and one for antagonists. The two binding sites are related in an 
allosteric way. Binding of an agonist to the agonist site reduces 
the affinity of antagonists for the antagonist site and viae 
versa. The allosteric receptor model predicts normal agonist-
agonist and antagonist-antagonist interaction. The interaction 
between agonists and antagonists and уъае versa steadily de­
creases with increasing concentrations. At high concentrations no 
further inhibition takes place. The Hill-plots have a slope of one 
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(Fig. 2a, b). 
In the two site receptor model it is assumed that there are 
two independent, non-interconvertible binding sites R. and R-
which may be not or may be located on a single macromolecule. 
Agonists and antagonists may bind to both sites with similar or 
different affinities. Each of the two binding sites behaves in 
the same manner as the binding site in the one site receptor 
model. In experimental situations in which inhibition is plotted 
as a percentage of control values the curve may deviate signifi­
cantly from sigmoid behavior. Such a behavior can be explained 
easily by the two site receptor model. It can not be excluded, 
however, that a more complex situation is at hand in which ident­
ical receptor sites are related in a cooperative manner. The two 
site receptor model as well as cooperative models of drug recep­
tor interaction predict a deviation from one for the slope of the 
Hill-plots (Fig. 3a, b). Furthermore, the two site receptor model 
predicts that agonists displace radiolabeled agonists more effec­
tively than antagonists do and vice versa. 
MATERIALS AND METHODS 
3 3 
H-spiperone ((phenyl-4(n)- H) spiroperidol, specific activ­
ity 21 Ci/mmol) was obtained from the Radiochemical Centre, 
Amersham, England. Unlabeled spiperone was obtained from Janssen 
Farmaceutica, dextro and levo butaclamol were generous gifts of 
Ayerst Laboratories. Other compounds were purchased from commer­
cial sources. Caudate nuclei were dissected from freshly obtained 
calf brains and stored at -20 С before use (2-3 days). Homogeniza-
tion was performed essentially as described by Burt et al. (3). 
The method used for the study of the binding of radioactive 
ligands was the rapid centrifugation of the membrane fragments 
using a microfuge (4). 
RESULTS AND DISCUSSION 
Binding of Η-spiperone to calf caudate nucleus homogenates 
was inhibited by the DA -antagonists (+)-butaclamol and haloperi-
dol, the DA.-antagonist apomorphine, the antagonist on both types 
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of dopamine receptor ergometrme and dopamine itself. Tor reasons 
of limited space only the inhibition curves of ergometrme and 
(+)-butaclamol and the corresponding Ilill-plots are displayed 
(Figs. 4, 5). Curves through the points were drawn with inhibi­
tion constants, K. and K_ and binding capacities, Q and Q_ cal­
culated from the experimental values with a computerized curve 
fitting procedure (5) either for the one or the two site receptor 
model. Numerical values of the parameters for all drugs tested 
are summarized in Table 1 together with the residual sum of 
2 
squares, χ , as a measure for the quality of the fit for the 
one site and the two site receptor model. 
Included in Table 1 are the parameters for the binding of 
3 
Η-spiperone fitted to a one and a two site receptor model. Al­
though there is a diminution in the residual sum of squares in 
case of the two site receptor model the difference is not sig­
nificant and judging from Η-spiperone binding alone it must be 
concluded that spiperone binds to a single homogeneous class of 
binding sites. Such a conclusion, however, is not consistent with 
other experimental findings. Ergometrme displaces spiperone from 
its binding sites in a biphasic manner and although the binding 
sites may seem homogeneous with regard to spiperone, they cer­
tainly are not homogeneous with regard to ergometrme. Therefore 
we assume as a first approximation that spiperone binds to two 
classes of binding sites with identical affinities. The concentra­
tion dependent inhibition of Η-spiperone binding by ergometrme, 
apomorphme and dopamine can then be much better described with 
a two site than with a one site receptor model. The diminution 
in the residual sum of squares in going from a one site to a two 
site receptor model is highly significant for all three compounds. 
Inhibition of Η-spiperone binding with (+)-butaclamol can be 
best described with a one site receptor model; with a two site 
receptor model no improvement of the quality of the fit is ob­
tained. Obviously (+)-butaclamol just as spiperone itself does not 
differentiate between binding sites. With haloperidol a hardly sig­
nificant diminution of the residual sum of squares is obtained m 
going from a one site to a two site receptor model. Inhibition of 
H-spiperone binding by dopamine reveals a high affinity binding 
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Fig. 4 Inhibition of H-spiperone binding by ( + )-butaalamo I. The 
curves were fitted to the experimental points according to 
the one site receptor model 
Ζ Fig. 5 Inhibition of H-spiperone binding by ergane trine. The 
curves were fitted to the experimental points according to 
the two site receptor model 
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TABLE 1 
Analysis of binding and inhibition experiments 
compounds 
inhibition of 
3H-spiperone 
binding by: 
butaclamol 
butaclamol 
halopendol 
Haloperidol 
apomorphme 
dopamine 
ergometrinc 
erg ome tri ne 
binding of 
^H-spiperone 
n' 
14 
18 
16 
20 
16 
14 
18 
24 
28 
one 
Kl 
nM 
7.4 
3.4 
32.8 
23.4 
494 
50250 
424 
363 
0.37 
!-site 
(19) 1 
( 9) 
(25) 
(24) 
(14) 
(40) 
(20) 
(21) 
' (8) 
receptor modi 
«1 
pMolos/g 
54 
51 
48.8 
49.5 
47.1 
49.1 
41.5 
37.3 
46 
(5) 
(3) 
(6) 
(6) 
(3) 
(7) 
(4) 
(5) 
(5) 
el 
^ 
11.3 
8.8 
10.8 
16.2 
13.2 
37.2 
31.0 
30.4 
11.3 
1. 
3. 
13 
4. 
43 
35 
26 
20 
0. 
Kl 
nM 
,0 
,3 
,4 
.27 
( - ) 
( - ) 
(160) 
(440) 
(114) 
( 82) 
( 45) 
( 81) 
(49) 
two-•site receptor 
Ql 
pMoles/g 
1.8 
0.02 
34.2 
15 
20 
22 
24 
19 
33.5 
( - ) 
( - ) 
(113) 
(300) 
( 45) 
( 18) 
( 12) 
( 25) 
( 57) 
model 
K2 
nM 
2. 
9. 
158 
38 
1134 
11910 
2000 
987 
10 
,5 
.4 
( - ) 
( - ) 
(341) 
(137) 
( 54) 
( 31) 
( 37) 
( 47) 
( - ) 
pMc 
54 
52 
16. 
36 
31 
3b. 
23 
25 
77 
Q2 
iles/g 
( - ) 
( - ) 
4 (240) 
(127) 
( 30) 
6 ( 10) 
( 13) 
( 19) 
( - ) 
V 7 
11.3 
8.8 
4.6X 
13.6 
4.1 х 
2.9 х 
4.4 х 
2.4" 
8.3 
[nhibit^on (ix^erirvents are performed at a free H-Spiperone concentration of 1-1. b η'·ί. The акаіузіз in ter^s of 
J·*- or tJo-site receptor rnodel concerns the specific part of the bbndiny. Saturable or specific bindinj of 
ii-.~pip<j r'>ne was meas tred as the excess over blanks taken in the presence of 1 и Л Spiperone. 
' - n^Kber of datapoints; 1 = relatzoe standard error; χ = significantly irproved on a 0J% lejcl ('-test). 
-J 
site (K-value 35 nM; cap 22 pMol/g tissue) and a low affinity 
binding site (K-value 12 лМ.; cap 36 pMol/g tissue). The K-value 
of the high affinity site is quite close to the K-value (17.5 nM) 
for dopamine from direct binding studies with H-dopamine (3). 
The K-value of the low affinity site is in the same range as the 
ED,-- value (2 </M) for dopamine stimulated adenylate cyclase ac­
tivity (8) . 
The experimental findings of Snyder and collaborators in 
dopamine receptor binding studies, that agonists displace agonists 
more effectively than antagonists and viae versa can easily be ex­
plained by the two site receptor model. Theoretical calculations 
based on this model are entirely consistent with the experimental 
findings (2). On the contrary so called two state models (6, 7) 
as elaborated by us in the dual receptor model can not explain 
the inhibitory behavior of agonists and antagonists. Also the 
allosteric receptor model appears to be less suited to explain 
the apparently abnormal binding phenomena, as it predicts no 
large differences between agonists displacing agonists and ag­
onists displacing antagonists. 
There also might be a relation between the two dopamine 
binding sites and the functionally distinct DA and DA receptors. 
The experimental results thus far although not inconsistent with 
such a relationship do not allow definitive conclusions in this 
respect to be drawn. 
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PART IV 
SIMPLE THEORETICAL MODELS FOR DRUG-RECEPTOR INTERACTI ON* 
Taken from: Ariens, E.J., A.J. Beid, J.F. Rodrigues de Miranda 
and A.M. Simonis, The pharmacon-receptor-effector concept. A 
basis for understanding the transmission of information in 
biological systems, in: The Receptors (R.D. O'Brien, ed.), Vol. 
I, Plenum Press, New York and London (1979) . 

1. Introduction 
The interaction between the bioactive agent (the pharmacon) and its re-
ceptors is much more dynamic than the classical lock-and-key model suggests 
It is actually the result of intermolecular forces mutually molding drug and receptor 
(Anens, 1964) Conformational changes in the receptor molecule are induced 
simultaneously, triggering the sequence of biochemical and biophysical events 
leading to an effect Although dynamic in nature, the receptors can be regarded 
as preexisting structural entities For instance, the optical isomers of an agent 
often differ largely in their biological activity It is generally assumed that a certain 
degree of structural complementarity between the drug and the site of action on 
the specific receptor molecule is required Consequently, the chemical properties 
of an agent determine the type of action as well as its magnitude. Structure-
activity relationships find their justification in this basic assumption However, 
the structural requirements for action are not always highly specific For local 
anesthetic agents, a certain degree of lipophihcity and polarity are the main re-
quirements These agents probably act by accumulation m the lipid phase of the 
cell membrane in which proteins functionally involved in ion transport processes 
are embedded The local anesthetics probably shift the physicochemical properties 
of the lipid annulus from the gel to the liquid-crystalline state (Lee, 1977) For 
the various gaseous anesthetics a certain lipophihcity appears to be the only 
requirement for actioa The action of these general anesthetics is mainly based 
on a change in the membrane properties due to a diffuse accumulation of these 
agents in the lipid fraction of the membrane (Haydon et al, 1977) For plasma 
extenders and osmotic diuretics the term receptor is not applicable anymore since 
they act mainly by binding water The receptors for a drug do not necessarily 
have to be located in the organ in which its response is observed Strychnine, for 
instance, causes convulsions in striated muscle, but the receptors on which the 
effect is induced are located in the central nervous system In the case of 
pharmacon-receptor interaction, the conformational changes in the receptor are 
particularly important in relation to the effects (In the case of an enzyme-substrate 
interaction, the conformational changes in the substrate result in an activation with 
subsequent chemical conversion ) This is analogous to the differentiation between 
the active site on an enzyme and the enzyme molecule as a whole Thus it makes 
sense to distinguish between the receptor site and the receptor molecule Under 
certain circumstances the receptor site may be constituted from an interface 
between different molecules Sometimes the receptor sites for the bioactive agent 
are the active sites on enzymes involved in the conversion of endogenous sub-
strates In other cases receptors may be located on sites of the enzyme molecule 
topographically different from the active site, thus changing enzyme action via 
allostenc mechanisms. The concept of a pharmacon-receptor interaction as the 
basis of action is not always applicable in its simplest form In many cases, the 
active agent is not the pharmacon applied but its derivative(s) or metabolite(s) 
This holds true for the various pro-drugs, precursors of the ultimate active agent, 
which are designed to fulfill particular requirements, as, for example, in maximizing 
absorption or distribution In this context, the biotoxification of various agents 
brought about by reactive alkylating agents with carcinogenic or mutagenic 
action should be mentioned In these cases, the pharmacon-receptor concept can 
be applied to the ultimate pharmacon or ultimate toxic (Heidelberger, 1973; 
Ariëns and Simonis, 1977). The generation of the ultimate pharmacon can be 
considered part of the pharmacokinetic phase of action. The pharmacodynamic 
phase then comprises the interaction of the ultimate pharmacon with its molecular 
sites of action, its specific receptors in the biological object, and the results it 
causes. In this regard, indirectly acting agents should be mentioned. They act 
by virtue of other endogenous agents or mediators. Examples are releasers of 
neurotransmitters (e.g., norepinephrine), liberators of histamine, and compounds 
which inhibit the re-uptake of neurotransmitters in the storage sites at presyn-
aptic nerve endings, thus potentiating the action of the neurotransmitter. In 
cases where the drugs act as inhibitors of enzymes involved in the inactivation of 
endogenous mediators, such as acetylcholinesterase inhibitors, it is the accumu-
lation of the mediators which lead to the effect. The pharmacon-receptor inter-
action concept is still applicable here since the active agents have their specific 
sites of action on the membrane of the storage granules of nerve endings or on 
the enzymes involved A borderline case is the situation where the activity of a 
pharmacon is based on a change in the pharmacokinetics of another foreign-body 
agent, as, for example, the delay or enhancement of bioactivation or bioinacti-
vation or change in distribution due to displacement from binding sites on 
plasma albumin. Usually such effects are considered under the heading pharmaco-
kinetics; however, the change in the pharmacokinetics of the first agent in this 
case is due to the effect induced by the second agent on its sites of action, be it an 
enzyme or plasma albumin. The various types of binding sites for bioactive agents 
that are not directly involved in the induction of the effect, such as those on plasma 
albumin, are called silent receptors or sites of loss. They are important in phar-
macokinetics. The same holds true for active sites on enzymes involved in the 
biochemical conversion of pharmaca. 
Although the receptor concept was mainly of theoretical significance in 
the past, it has evolved into concrete reality, and receptors can now be studied 
as tangible molecular entities. The design of new drugs can be based on relation-
ships between structure and receptor affinities measured by direct binding studies 
(Creese et al., 1976; Raynaud, 1977a,b), receptor density measurements in malig-
nant tissue can tell whether hormonal treatment is indicated or not (McGuire 
et ai, 1975), and alterations in receptor properties and density distributions 
enhance insight into certain pathological conditions such as myasthenia gravis and 
diabetes (Grob, 1976; Maugh, 1976). 
2. Pharmacon-Receptor Interaction 
The efforts to interpret the characteristics of dose-response curves and time-
response curves of drugs boil down to some form of application of the mass-action 
law. A variety of partially overlapping theoretical models has been worked out 
and can be found in various reviews (Ariëns, 1966 , 1974; Colquhoun, 1973; 
Monod et ai, 1965; Rang and Ritter, 1970a,b; Waud, 1968, 1974, 1976; Belleau, 
1964; Paton, 1961; Triggle, 1965; Lüllmann and Ziegler, 1973; Lüllmann 
et α/, 1974; Gosselin and Gosselin, 1973; Burgen, 1970; Rocha e Silva, 1970; 
Schueler, 1960; Van den Brink, 1973; Thron, 1973; Karlin, 1967; Podleski and 
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Changeux, 1970; Clark, 1937), and an extensive treatise of distinct drug-receptor 
interaction models can be found in the monograph by Van Rossum (1977). The 
following sequence of reversible reactions is a. condensed form covering essential 
aspects of these models: 
Kl «2 *3 ^* *5 
D + R ^ ^ DR ?==* DR* ^ = ^ D + R* ^ = è R ^ ^ R 
where D = drug, R = receptive receptor, R* = activated receptor, and _R = 
nonreceptive, nonactivated receptor (Ariens and Simonis, 1976). Χ,, K2, K3, 
К*, and K5 are the equilibrium constants governing the relative amounts of the 
different receptor species and are defined in such a way that X, = k-Jk,. Re­
ceptor species DR* and R* contribute to the stimulus formation, and species R, 
DR, andJRL do not. Total concentration of receptors is represented by r. In the 
occupation-activation model it is assumed that the activated state of the receptor 
exists predominantly as a complex with the pharmacon, i.e., as DR*. For this 
model it holds true that at equilibrium 
[R*] 3 L J 
In the hit-activation model it is assumed that the activated state of the receptor 
exists predominantly in the noncomplexed form i.e., as R*. Thus for this model 
it holds true that at equilibrium 
[R*] 3 L J 
For both these models the stimulus is, by definition, proportional to the fraction 
of receptors present in the activated state; i.e., 
c / ÍDR* + R*) (DR*) S(:) « 
r r 
for the occupation model, and 
(DR* + R*) R* 
S(:)- * — 
r r 
for the hit model. The effect as a whole will in general not be proportional to the 
stimulus, although under comparable circumstances a certain stimulus is 
postulated to bring about the same effect. In the rate theory of drug action ori-
ginally postulated by Paton (1961), stimulus formation is proportional to the rate 
of receptor activation. The rate concept can be applied both to the occupation 
model, i.e, S(:)fe2(DR), and to the hit and run model, i.e., S(:)fc3(DR*). The 
presence of the nonreceptive, nonactivated species R is not essential in both 
occupation and hit models; however, it accounts for the degree of fade in the 
dose-response curves or for the degree of specific desensitization of receptors 
155 
and thus for tachyphylaxis The extent of the phenomenon is dependent on 
whether К5 is small or large In rate theory, the regeneration step in which R 
is converted to R is not needed to explain fade or desensitization since here the 
initial rate of activation is always higher than the rate of activation at equilibrium 
There is growing experimental evidence favoring the occupation model A 
classical example is the action of vitamins and vitamin analogues that serve as 
coenzymes for apoenzymes The binding of the steroid hormones to their receptor 
proteins in the cytosol followed by the action of the complex as a derepressor in 
the cell nucleus can also be regarded as a combination of a coderepressor, the 
steroid hormone, with an apoderepressor, the receptor protein, to form an active 
derepressor (Ariens and Simonis, 1976) In fact, the interaction of the pharmacon 
with the receptor changes the functional state of the receptor molecule 
In pharmacon-receptor interactions one can distinguish between (1) the 
constants primarily determining the fraction of the receptors involved in the 
interaction and thus giving the affinity of the pharmacon for the receptor, re­
presented by Kl and (2) the constants for the fraction of the receptors present in 
the activated state as a result of the drug-receptor interaction and giving the 
intrinsic activity of the pharmacon, represented by K2 In those cases where the 
drug-receptor interaction does not result in a receptor activation (X2 <sc 1), 
the pharmacon acts as a blocker of the receptors, and the intrinsic activity is zero. 
Compounds with an intermediate intrinsic activity will act as partial agonists; 
the intrinsic activity is a measure of the fraction of the receptor occupations 
which give receptor activation (Anens, 1974; Anens and Simonis, 1964) 
3. Receptor Binding and Receptor Isolation 
Binding studies of drugs to receptors are advantageous in the sense that they 
give direct information on receptor occupation and therefore on affinity, but, 
on the other hand, other aspects of drug action such as receptor activation are 
largely obscured 
As shown by binding studies, the receptors for various drugs, hormones, 
and hormonoids are located in plasma membranes (de Robertis, 1976) The 
receptors for acetylcholine (the cholinergic receptors) appear to be located on 
the outside of the plasma membrane since application of cholinergic agents 
intracellularly appears to be ineffective (Del Castillo and Katz, 1955) For other 
receptor types, viz those for norepinephrine, histamine, and serotonin, a location 
at the outside of the cell membrane is highly probable since these receptors are 
easily accessible to the quatemanzed form of the respective competitive blocking 
agents, compounds known to penetrate intracellularly only with great difficulty 
or not at all (Anens, 1967, 1971 ) In addition, for the receptors of various 
peptide hormones and norepinephrine involved in the activation of adenylate 
cyclase, a location on the cell membrane has been confirmed by binding studies 
(Greengard, 1976, Cuatrecasas, 1974, 1975) 
The receptor sites for the drugs do not necessarily have to be located on the 
surface of receptor proteins The accessory receptor sites for the hydrophobic 
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moieties in the various competitive antagonists of membrane-active agents may 
well be made up of an interface between a hydrophobic area on the receptor 
protein and lipid groups in the membrane The extremely high affinity constants, 
109 and 1010, for competitive antagonists (eg, anticholinergics and antihista-
minics) which are based mainly on the contribution of the hydrophobic groups 
to the affinity can hardly be realized on a mere protein surface Lipoproteins would 
be more suitable in this respect The lipid molecules in a membrane facing the 
hydrophobic surface of the protein are fixed to a large extent in a quasi-crystalline 
form, making the high degree of stereospecificity of the antagonists understandable, 
especially with regard to centers of asymmetry in their hydrophobic moiety 
Drug-receptor interaction then results in changes in the interface characteristics. 
It is even possible that the relatively polar sites for agonists are also located at 
or made up of an interface, e g, where the polar groups of certain membrane 
proteins interact with polar groups of membrane lipids like the phosphate and 
choline groups in the phosphatidic acids, phosphatidylcholines, and sphingo-
myelins The isolation of receptors as molecular entities would become an im-
possible task if this turns out to be the case Studies on purified receptors of this 
nature would be possible only after isolation of the constituent parts and re-
assembly of these parts into artificial membrane-like structures (deRobertis, 1976) 
With regard to receptor isolation and identification there is an essential 
difference between soluble receptors, e g, the cytoplasmic steroid receptor 
proteins and membrane-bound receptors In the latter case there is a tight inter-
relation of the receptor molecule and surrounding molecules Separation of the 
receptor molecule from its surroundings may well disturb its conformation and 
thus its specific characteristics Undoubtedly the isolation techniques, especially 
those in which detergents (Maddy and Dunn, 1976) are used as solubilizing 
agents, may influence the conformation of the isolated protein drastically The 
variation in binding constants reported for the interaction of drugs with isolated 
receptors therefore does not warrant the existence of various receptor states or 
conformational states under physiological conditions A special problem which 
holds for the soluble as well as for the membrane-bound receptors is that with 
isolated receptors, no measurable pharmacological effect can be induced anymore, 
making their identification extremely difficult in certain cases 
Since structure-action relationships (SARs) are based on an interaction 
between the drug molecule and the receptor site, they may give information as 
to the properties of this site 
Chemical complementarity between the drug and the specific receptor site 
with which it interacts is a reasonable assumption Structure-binding relationships 
therefore can serve as a tool for the identification of isolated receptors However, 
only the receptor molecules, not the sites, can be isolated One may expect that 
structure-binding relationships for isolated receptors, if they are not denatured 
to a certain degree in the isolated form, will parallel the SARs observed with 
tissues As a rule, however, with the isolated receptors there will be no differentia-
tion between agonists, partial agonists, and competitive antagonists, because only 
affinity is measured and not intrinsic activity Opiate receptors are an exception 
in this sense because agonist binding is dependent on the presence of Na+ or 
Li+ ions while antagonist binding is not, making a differentiation possible 
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(Pert and Snijder, 1974) In efforts to isolate and identify receptors, use is made 
of agents which irreversibly bind in a selective way to the receptors, or, better, 
to the specific receptor sites However, few such agents are available (Burgen 
etat, 1974) 
4. Dualism m Receptors for Agonists and Their Competitive 
Antagonists 
Anticholinergics, antihistamimcs, α-adrenergic blockers, serotonin antag­
onists, and dopamine antagonists apparently bind through their hydrophobic 
moieties to accessory binding areas either topically or functionally They are 
related to the receptor site in a narrow sense by blocking in some way the acti­
vation of the receptor by agonists They interfere with the binding of the agonist 
to its receptor site without occupying this receptor site itself There appears to 
be a dualism in the receptor sites for agonists and corresponding antagonists 
On the basis of this concept, the lack of structural similarity between agonists 
and their corresponding competitive antagonists, the existence of close structural 
relationships between competitive antagonists blocking different types of re­
ceptors, the existence of competitive antagonists blocking receptors for different 
agonists, and the dependence of selectivity in the action of the competitive 
antagonists on the steric configuration of the hydrophobic moieties in the mole­
cule can be understood The receptor sites for agonists and competitive antag­
onists are not as common as suggested by the original "one-receptor-site concept " 
The receptor molecule or macromolecular complex, as discussed in Sec 2, 
must be assumed to occur in different states an activated R*-form and a non-
activated R-form depending on whether or not an agonist or a competitive 
antagonist is present It has been postulated (Monod et al, 1965, Karlin, 1967, 
Changeux et al, 1967, Wyman, 1967) that even in the absence of drugs there is a 
dynamic equilibrium between different functional states of the cholinergic re­
ceptor The simplest concept in this respect is the dual receptor concept, in which 
the assumption is made that there is an equilibrium between the receptors in 
the R*-form and those in the R-form in the cell membrane The R*-form con­
tributes to the effect, the R-form does not An agonist shifts the equilibrium 
toward the R*-conformation and a competitive antagonist toward the R-con-
formation The agonist has a relatively high affinity for the receptors in the R*-
conformation, and the competitive antagonist for those in the R-conformation 
This in a way fixes the receptors in their respective states (Anens and Beld, 1977, 
Pert, 1976, Raftery, 1975) Partial agonists have an affinity for both states, the 
ratio of the affinities determining the intrinsic activity of the compound As long 
as the rate constants for the equilibrium between R and R* are large enough, 
this model will predict phenomena similar to those expected for a competition 
between drugs based on the one-receptor-site concept The receptor sites for an 
agonist and a competitive antagonist—although only one receptor protein is 
involved—are therefore different (Pert, 1976, Raftery, 1975) This is in accordance 
with the dualism in receptor sites outlined before on the basis of structure-action 
relationships (Anens and Beld, 1977) 
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More direct evidence for the dualism in the cholinergic receptor, namely 
receptor sites involved primarily in the binding of the agonist and receptor sites 
involved primarily in the binding of the antagonist, is available. Reductive alkyl-
ation by JV-ethylmaleimide clearly changes the affinity of muscarinic receptors 
of neural membranes for agonistic agents without affecting the affinity for the 
antagonists (Aronstam et al., 1977). Treatment of the cholinergic receptors of the 
electroplax of Electrophorus electricus by dithiothreitol results in a loss of the 
membrane sensitivity to acetylcholine. Cholinergic agents, agonists, can protect 
against this chemical desensitization ; antagonists, such as d-tubocurarine, do 
not so protect (Bregestovski et al, 1977). 
5. The Aggregation-Segregation Concept 
For the case where the receptor molecules are embedded in the lipid mem-
brane structure, one may expect that the behavior of such protein molecules, 
e.g., their tendency to aggregate or segregate, strongly depends on the hydrophobic 
and hydrophilic properties of the protein surface, especially on that part of 
the receptor molecule in contact with the lipids in the membrane. The receptor 
proteins, although hydrophobic in their overall nature (de Robertis, 1975b), have 
an amphiphilic character. Binding of agonists, usually strongly polar agents, 
could stabilize a relatively polar conformation and thus shift the equilibrium 
toward the more hydrophilic R*-form. Binding of the hydrophobic antagonist 
would then stabilize a hydrophobic R-state. The different character of the R*-form 
and R-form will imply differences in the quaternary structure of the proteins and 
the degree and type of aggregation among receptor molecules or among receptor 
molecules and other proteins (e.g., effector proteins) present in the membrane. 
In the hydrophobic state the receptor proteins will tend to remain solitary 
in the lipid membrane environment. In the hydrophilic state, the tendency to 
aggregate among themselves or with other hydrophilic macromolecules will 
be enhanced. 
The degree of aggregation influenced by the presence of a hormone or 
neurotransmitter might determine the effect to a major extent. This concept fits 
quite well with the fluid mosaic theory of membrane structure (Singer and Nic-
olson, 1972). 
For receptor molecules present in the hydrophilic cytosol, such as the 
steroid receptors, the tendency to aggregate will be increased in the hydrophobic 
state. Steroids undoubtedly are hydrophobic in nature. The migration of the 
steroid-bound receptors via the nuclear membrane to the nucleus may well be 
related to the degree of hydrophobicity. The proteins in the luminal cell membrane 
of the toad bladder aggregate in a mosaic pattern under the influence of the 
antidiuretic hormone (Kachadorian et ai, 1975). The protein-walled pores thus 
formed may well account for the increased water permeability induced by this 
hormone. Specific receptor proteins for the different hormones activating adenyl-
cyclase are presumed to aggregate with the enzyme molecule under the influence 
of the hormones, thus activating the enzyme in an allosteric way (Cuatrecasas 
eta!., 1975; Jacobs and Cuatrecasas, 1976; Greaves, 1977). 
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The transfer of /J-adrenergic receptors from turkey erytliroL>tes in which 
the enzyme adenylcyclase is inactivated by N-ethylmaleimide to other cells 
that contain the enzyme but are devoid of ^-adrenergic receptors and the possi-
bility of activating the adenylcyclase of these cells after transfer of the /î-adrenergic 
receptors, by means of ^-adrenergic agents, provide dehnite proof of the inde-
pendence of receptor and effector molecules (the adenylcyclase) (Schramm et al, 
1977, Ross and Gilman, 1977) 
There are good indications that in the case of the receptors for acetylcholine 
at the myoneural junctions the cholinergic receptor, after activation by acetyl-
choline, interacts with an effector protein that іь directly involved in ion con­
ductance and is called an ion comluttance modulator (ICM) ICM is different from 
the cholinergic receptor protein and possibly is part of the wall of the pores 
Competitive antagonists of acetylcholine such as Л-tubocurarine bind to the 
cholinergic receptor protein, as is the case with ot-bungarotoxine, a compound 
that irreversibly inactivates the cholinergic receptor molecule On the other hand, 
compounds such as histriomcotoxin and its perhydrodenvative, certain local 
anesthetics, and possibly amantadine bind to the ICM and by doing so interfere 
with neuromuscular transmission without binding to the cholinergic receptor 
molecule (Albuquerque et al, 1978. Sobel et al, 1978) They thus act in a non­
competitive way as antagonists of acetylcholine The relationship between the 
cholinergic receptor molecule and ICM may well tie in with the aggregation 
segregation concept, which implies that only after activation by cholinergic 
agents does the receptor molecule aggregate in a specihe way with ICM, which 
only then contributes to ionic conductance (Albuquerque et al, 1978, Sobel et al, 
1978) 
Receptor sites for membrane-active drugs may also be located on proteins 
or protein complexes constituting the wall of pores (deRobertis, 1975a, Waser, 
1975) The passage of ions through such protein-walled pores in a membrane 
may well change under the influence of drugs as a result of an altered charge 
distribution in the receptor molecules constituting the pores The proteins may 
switch from an open lo a closed conformation Again an equilibrium between 
both conformations, shifted by agonists to an apparently open conformation 
and by competitive antagonists to a closed conformation, can be postulated In 
the dual-receptor-site model, although only one type of receptor protein or 
protein complex is postulated, the receptor sites for agonists and those for the 
corresponding antagonists are functionally distinct, interdependent entities 
6, Dual Receptor Model 
The reaction scheme in Sec 2 starts from the (classic) concept that the phar-
macon has to activate the receptor in order to provoke an effect An agonist is 
then characterized by its ability to change the conformation of the receptor to 
that corresponding with the activated state, ι e, RD -* R*D, while an antagonist 
will not be able to do this An alternative way of looking at this process of acti­
vation is to assume that the unoccupied receptor already exists in an equilibrium 
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with its activated form (Colquhoun, 1973, Thron, 1973), ι e, 
and that the agonist shifts this equilibrium toward R* We are dealing then with 
a two-state model The sequence of reaction in Sec 2 in fact implies three states 
for the receptor, 
R ^ ^ R* 
R_ 
and the whole sequence can be drawn as a closed figure of equilibria (Fig 1 ) 
For reasons of simplicity we shall confine ourselves to the first two steps in the 
reaction scheme of Sec 2, which in fact represents the dual receptor model 
In this concept it is supposed that the receptor in the R*-form, i e , as R* 
or R*D, contributes to the e.fect, the R-form, ι e, as R or RD, does not An agonist 
will show a high affinity for R* and eflectively shifts the equilibrium to the R*-form, 
an antagonist will show a high affinity for R and causes the equilibrium to shift 
to the R-form The total concentration of receptors is r In contrast to the classical 
view in which the agonist has to activate the receptor, it now has to shift the 
equilibrium in favor of the R*-form in order to be active 
M = 
Κι 
K2 = LM 
R Н ^ R* 
+ D + D 
RD ^ R*D 
Κι = 
[ R ] [ D ] 
[RD] 
, . _ [ R * ] [ D ] 
Κί = [R*D] 
R 
к
г
 = 
[RD] 
[R*D] 
(1) 
Although this alternative route (i e, via R*) offered by the dual receptor concept is 
irrelevant for the concentration of R*D at equilibrium, it may have much lower 
activation energies so that equilibrium is reached within experimental time The 
affinity in this model, К
я п п
, can be defined as the concentration of D at which 
half-receptor occupation occurs 
fraction occupied = 
RD + R*D 
R + R* + RD + R*D 
1 
1 +(Kl/D)[M{l +£ ) / ( ! + LM)] (2) 
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Fig. I. The three-stale kinetics for the "two-state" model. 
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 k,k2 
so that 
K„ = Kl 
M(l + L) _ K* + KfL 
1 + LM ~ 1 + K, (3) 
In the dual receptor model the fraction occupied deviates from the fraction of 
receptors activated. 
As in the case of the simple model, by definition here also the initial stimulus 
induced is proportional to the fraction of the receptors present in the activated 
state, (R* + R*D)/r. 
If as a first approximation the effect, including the specific resting tone, based 
on the equilibrium R ^ ^ R* is postulated to be proportional to the initial 
stimulus, the following equations can be derived : 
E R* + R*D 
R + R* + RD + R*D 
1 + D/Kf 
1 + L + DL/K, + D/Kf (4) 
Even in the absence of a pharmacon there will be some activated receptor re-
sulting in a basic tonus, E0 : 
E0 1 
R + R* 1 + L 
(5) 
The intrinsic activity defined as EDm3JEma:[ no longer is an ad hoc parameter 
but in this model becomes a parameter defined by equilibrium constants; i.e., 
R*D 1 1 
RD + R*D 1 + LM 1 + K2 
(6) 
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The effect of D relative to its maximal effect is then given by 
ED [fract. act.]D - [fract. ac t . ] D = 0 
so that 
^Dma» [fract. act.] D = a t > - [fract. a c t . ] D = 0 
1 
_
 1 + {KJDilMil + L)/(l + LM)] 
ED \ Κ,ΜΙΙ + L) K* + KÌL 
(7) 
(8) 
-Dm.,/50·,, I + LM 1 + K2 
Comparing Eqs. (3) and (8), we see that the 50% points in both the occupation and 
effect curves are equal, and in both cases we are dealing with normal sigmoid 
curves with a Hill slope of 1. 
It should be noted that, as in the simple model (Sect. 2), the intrinsic activity 
and apparent affinity are also interdependent parameters here; they can be repre-
sented by terms based on the various rate or binding constants. The characteristics 
of the model are, as demonstrated in Figs. 2-6 . similar to those of the classic 
model. Figure 2 shows occupation (a) and effect (b), curves calculated according to 
Eqs. (2) and (4), respectively, for a series of full agonists with different affinities. 
Figure 3 shows in an analogous way curves for a series of compounds ranging 
from full agonists via partial agonists to antagonists. 
In the case of a full agonist, i.e., K2 <<: 1, the apparent affinity approaches 
KfL (if L 5ί> 1). In the case of a full antagonist, i.e., K 2 » 1, the apparent af­
finity approaches K1 (if L » 1). 
7. Combination of Pharmaca 
If pharmaca are combined, the dual receptor model predicts normal sigmoid 
curves still with a slope of 1 ; i.e., 
^ D m a x 
1 
1 + ( Í : I 1 / D 1 ) [ M 1 ( L + П Д І + Ш . Ш і - Н О г / К и Ш і + L M 2 ) / M 2 ( L + 1)]} 
(9) 
or 
with 
E0 1 
Е0тлх [1 + (Kupp/Di )] [1 + (D2/A:2 a pp)] 
M J l + L ) _ M 2 ( l -I-L) 
*
1 ϊ ρ ρ
 " ^
1 1
 1 + LM, ' К 2 а р р " * 1 2 1 + LM 2 
(10) 
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Fig. 2 Curves calculated for occupation (a) and effect (b). Series of full agonists :L = 100; К
г
 = 10" 
К ,-values for the difTerent agonists are 10 5,10 4, IO"3, 10"2,and ΙΟ"1 M, respectively 
Figure 4 shows occupation (a) and eflect (b) calculated curves for a partial 
agonistD, in the presence ofdifferent doses ofa full agonist D 2 . Figure 5 shows ina 
similar way curves for a full agonist D, in the presence ofdifferent doses ofa 
partial agonist D 2 . 
The dual receptor model has a certain internal logic, but its simplicity, in 
spite of being one of its credits, implies that it cannot account for such phenomena 
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Fig 3 Curves calculated Гог occupation (a) and effect (b) Transition from full agonist to anugomsl 
L = 100, Κ, = ΙΟ"6 M Kj-values for the different agents are 10"3, 10 2, 10 ', 1, and 10 Note that 
a change in К
г
 affects both the 50% point and the maximum of the curve 
as receptor reserve and cooperativity To account for these phenomena the 
model has to be extended More complex variants of this model have been worked 
out in great detail by Changeux et al (1967), Karlin (1967), and Thron (1973) 
An interesting aspect of the dual receptor concept is that even in the absence 
of a pharmacon a certain fraction of the receptors exists in the activated state, 
this implies the existence of a certain resting stimulus and thus a certain specific 
1 6 5 
X-OCC.Ol 
Fig. 4. Curves calculated for occupation (a) and effect (b) D, is a partial agonist, i.e., L = 100, Κ2 = 
1, Κι = IO"6 M. D 2 is ал agonist, i.e, L = 100, K2 = 10"
3
, K, = ΙΟ"6 M Different doses of Dj : 
IO"11, ИГ1 0, З-Ю"1 0, IO"«, 3-10-», IO"', and ΙΟ"7 M. Note: At low concentrations of Dj, D, in­
creases the effect ; i.e, the compound behaves as an agonist. At high concentrations of D2, D, decreases 
the effect; i.e., the compound behaves as an antagonist. 
resting efTect. This could be, for instance, a certain smooth muscle tone related to 
the cholinergic receptor system. Application of competitive blockers acting on 
that receptor system (e.g., atropine) should then lead to an annihilation of this 
resting tone and thus to a relaxation (see Fig. 6 ). For various smooth muscle 
preparations, e.g., for the isolated gut, the existence of a resting tone may be due 
1 6 6 
¡C-OCC.Ol 
7 В 
-LOG (Ol) 
Fig. 5 Curves calculated Гог occupation (a) and effect (b). D, is a full agonist ; i.e, L = 100, K2 = 10" 3, 
Κι = 10"' M D 2 is a partial agonist, i.e. L = 100, Кг = 1, K¡ = ΙΟ"
6
 M. Different doses of D 2 : 
3- IO"8, IO"7, 5 · IO"7, IO"6, 3 · IO"6,and IO"5 M. 
to the presence of acetylcholine originating in the neural tissue of the preparation. 
In this case atropine should cause a relaxation in the "absence" of cholinergic 
pharmaca To check whether or not the resting tone can be ascribed to the pres­
ence of an endogenous agonist, e.g., acetylcholine, denervated or aged tissue 
1 6 7 
100 χ-occ.o 
Fig. 6. Curves calculated Гог occupation (a) and effect (b). Annihilation of a resting tone by an antago­
nist D:L = 2,K2 = 100. Κ,-valuesfor the dilTerent curves are 10" », 10" \ 1 0 ' , and 10"
5
 M. 
preparations should be used. (The viability of nerve tissue is lost sooner than that 
of the smooth muscle tissue.) Under such conditions the rat jejunum does not 
relax under the influence of atropine. This implies that the number or fraction 
of the cholinergic receptors present in the activated state is negligible, and in 
fact the original simple receptor model then describes the experimental phenomena 
adequately. 
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8. The Allosteric Receptor Model 
This model, in which agonist A and antagonist В bind on interdependent 
receptor sites RR' in such a way that the presence of the agonist on its receptor site 
R changes the affinity of the antagonist for its receptor site R' and vice versa in a 
strictly mutual sense, has been described in the classic receptor literature (Ariéns 
et al, 1956 , 1964). It also, in fact, is a dual receptor model. The characteristics 
of this model can be summarized by the following reaction scheme : 
RR' + A ^ = * RAR' RR' A 
RR' + В; RR'B 
RAR' + В ; RAR'B 
RR'B + A ; •• RAR'B 
KA 
KB 
K' 
л
в 
It" 
— 
= 
= 
RAR' 
RR' В 
RR'B 
RAR' В 
RAR'B 
RR'B А 
^ = Í 7 B = (1-/» 
К 
к 
RAR'B 
This model will be worked out for the situation where there is a mutual inhibitory 
relationship. As a matter of fact an enhancement of the affinities can also be 
introduced in the model. 
The occupation of the binding sites involved can be represented by 
fraction occupied by A = —— 
RAR' + RAR'B 
RR' + RAR' + RR'B + RAR'B 
A 
A + {KA(1 + B/XB)/[1 + B(l - /?)/*„]} 
(11a) 
log [B] 
Fig 7 Theoretical displacement curves for different values of the intrinsic competition constant β 
Ordinale the concentration of the agonistic receptor site occupied by A in the presence of В relative 
to the concentration of agonistic receptor site occupied by A in the absence of В Abscissa the log­
arithm of the inhibitor concentration (nM) Note. The full competitor (β = 1) displaces A completely 
from its binding sites, the partial competitor displaces A to a degree determined by β 
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A crucial term in Eq (11a) is the intrinsic competition term β, represented by 
l-KA 
Displacement of agonists by agonists or displacement of antagonists by antag­
onists is denoted by direct competition Displacement of agonists by antagonists 
and vice versa is denoted by allosteric or cross-competition For the allostenc com­
petition it can be shown in the case where β = 1 that Eq (11a) is reduced to 
that for a simple competitive interaction In the case where 0 < β < 1, the two 
agents involved behave only as partial competitors (see Fig 7 ) The binding curve 
or concentration-response curve for the agonist will be shifted by the antagonist 
but only up to a certain limit and vice versa In the case where β = О, В does not 
aflect the binding of A and vice versa In the case where β < 0, the equation rep­
resents a mutual allostenc sensitization These aspects of this model have already 
been worked out in detail (Anens et al, 1956 , 1964) An interesting characteristic 
of this model is that the binding constant of an agonist Aj as deduced from a direct 
competition (i e, displacement of an agonist Aj) differs from the binding constant 
deduced from cross-competition (ie, displacement of an antagonist B,) The 
same holds true for the binding constant of an antagonist 
The 50% inhibition points for these situations can be deduced from Eq (1 la). 
(IC S 0 ) A l direct = KAi ( 1 + - ^ - ) 
(IC 5 0 ) A l crossed = * A , ( 1 + B./K,,,) 
1 + Β,Ο - β)/Κ
Βι 
(IC30)Bl direct =KB(l+p-j 
(ICj0)B l crossed = 
І + А.и-Я/Кд, 
It should be emphasized that m the case of partial "competition," dependent 
on the concentration of the agents involved, the receptor sites for agonist and 
antagonist (located on one receptor molecule) will be simultaneously occupied 
to a minor or larger extent With excessively high concentrations of agonist as 
well as antagonist, there will be a full saturation of both recepto· sites 
In this system the following types of compounds must be distinguished. 
1 Partial agonist in the classical sense, ι е., compounds which cannot 
effectuate a maximal effect 
2 Partial competitors, ι e, agonists and antagonists with 0 < β < 1 which 
cannot completely displace each other in a cross-competition experiment 
3 Compounds with an autointeraction, ι e, agonists and antagonists which 
bind to both agonistic and antagonistic binding sites 
For the last compounds, as is easily understandable, there will be a positive or 
negative cooperation, dependent on the type of interdependence If the affinity 
170 
of the compound for both sites is equal, the slope of the concentration-response 
curve will be steeper or more shallow. If the affinity constants of the compound 
for the two sites diiïer, the curve will have a biphasic character. 
An interesting aspect of this model is that agonists and partial agonists 
have an intrinsic activity insofar as the receptor activation is concerned, while the 
partial agonists and full competitors also have an intrinsic activity insofar as their 
capacity to change (after binding to their receptors) the affinity of the agonist to its 
receptors is concerned. If this affinity is reduced to zero, the action of the then 
full "competitor" is indistinguishable from the classical model for competition 
where simultaneous presence of agonist and competitive antagonist on their 
receptors is excluded. 
In the classical model, this mutual exclusion was based on a topographical 
displacement, binding to the same site. This is not the case in the allosteric model. 
On the other hand, the concept of a partial competitor can be interpreted as a 
case of partial steric hindrance. That is, with the antagonistic agent on its receptor 
site, due to the mobility of a part of the antagonistic molecule, the agonist still 
gets a chance, although reduced, to bind. The antagonistic molecule hinders but 
does not exclude the access of the agonist to its receptor site. The result is a lowering 
of the binding constant of the agonist in the presence of the antagonist, which 
then acts as a partial competitor. Such a model was first described by SchaefTer 
and Johnson (1968) for substrate-enzyme interactions in the presence of particular 
types of irreversible antimetabolites and has been worked out as the Charnier 
model by Rocha e Silva (1970, 1978) for binding of drugs to pharmacological 
receptors. Also, in this model the interference in binding of agonist by the antag-
onist and thus the change in affinity must be mutual, which implies that the agonist 
changes the affinity of the antagonist in a similar way. 
Whereas in the allosteric model both negative and positive interference is 
feasible, the Charnier model, with its steric hindrance, cannot account for a 
mutual facilitation of the binding, the sensitization. Also, in the Charnier model a 
compound with an affinity to the agonistic as well as to the antagonistic receptor 
site (which does not seem very likely) would show a negative cooperation in its 
binding curve. 
Snyder and his group (Burt et al, 1976; U'Prichard et al., 1977; Bennet 
and Snyder, 1976) studied the binding and mutual displacement of agonists and 
corresponding antagonists extensively. Remarkably enough, he found that 
agonist molecules displace agonists more effectively than antagonists, while 
antagonist molecules displace antagonists more effectively than agonists. This 
phenomenon was observed with a number of receptor types such as dopamin-
ergic, α-adrenergic, serotonergic, and morphine receptor preparations (Tables 
I and II ). The model described before implies the occurrence of such a phenom­
enon, which does not mean that it is the only possible way to understand it. 
A similar phenomenon is to be expected if two independent receptor popu­
lations are involved. 
From Sec. 2, which covers both the Michaelis-Menten and the simple recep­
tor model, and from the dual receptor model described in Sec. 6 , 
fraction occupied = = (lib) 
l + Í K i . p p / D J C l - K D j / ^ . p p ) ] 
1 7 1 
it is obvious that these models cannot account for the phenomenon observed 
From Eq. (lib), we see that drug 2 displaces drug 1 according to its Кг.рр. It 
doesn't depend on whether or not D, is an agonist or an antagonist or whether 
or not D 2 is an agonist or an antagonist, and it is independent of Kltpp. 
Table I inhibition of[3H]Clonidine and [*Н]- №8-4101" Binding by Drugf 
Inhibiting drug, 
α-adrenergic 
Agonists 
(-Norepinephrine 
( — (Epinephrme 
Clonidine 
Oxymetazoline 
Partial agonists 
Dihydroergotamine 
α-Ergocryptine 
d-LSD 
Blocker* 
Phentolamine 
Phenoxybenzamine 
WB-4101 
K, for [Ή]-WB-4101 
binding (nM), A 
1000 
590 
430 
24 
35 
9 
220 
36 
40 
06 
X, for [3H]clonidine 
binding (nM), В 
17 
59 
57 
19 
24 
8 
220 
22 
60 
200 
Ratio 
A/B 
59 
100 
75 
13 
15 
1 1 
10 
016 
0 07 
0003 
"WB-4101 = 2-([2 ,6-dimethoxy]phenoxyethylamino)methylbenzodiOMn 
'After U'Prichard el al (1977) 
Table II inhibition о/^ЩНаІоретіаоІапа^ЩОоратіпе Binding by Drugs' 
Inhibiting drug, 
dopaminergic 
Agonists 
Dopamine 
Apomorphme 
Partial agonist 
d-LSD 
Antagonists 
Spiroperidol 
(+)Butaclamol 
Fluphenazine 
Haloperidol 
К, for [3H]haloperidol 
binding (nM), A 
670 
51 
20 
0 25 
0 54 
0 88 
14 
K, for [3H]dopamine 
binding (nM), В 
175 
86 
30 
1400 
80 
230 
920 
Ratio 
A/B 
38 
6 
07 
00002 
0007 
00O4 
0002 
'After Burl e t at (1976) 
9. Binding and Displacement on Two or More Independent 
Classes of Receptor Sites 
Drug binding to proteins is most commonly described in terms of indepen­
dent, noninteracting binding sites (Stemhardt and Reynolds, 1969) Scatchard 
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(1949) originally formulated this as 
where V = bound-drug concentration in moles per mole of protein, n, = number 
of binding sites in class ι', K, = dissociation constant of class /. 
If proteins, e.g., plasma proteins such as albumin, are exposed to pharmaca, 
the pharmaca will bind to the population of different binding sites on the pro­
teins in accordance with their binding constants for these sites. Different drugs 
may have certain binding sites in common in the population of sites. The binding 
constants of the drugs for their common binding sites are fully independent; 
e.g., sites on which drug A binds strongly may have a weak affinity for В and vice 
versa, etc. Combination of pharmaca will result in mutual displacement from 
the common binding sites in accordance with their binding constants. 
10. Two-Site Model 
For the two-site model, binding can be described as 
1 1 
V= + (13) 
1 + K./D 1 + X,/D 
Combination of two drugs which bind to these sites will generally result in an 
independent distribution of the drugs over these sites. This can be demonstrated 
with the binding of fatty acids to bovine albumin. On this protein two sites, a 
site S which preferentially binds short-chain fatty acids and a site L which pref­
erentially binds long-chain fatty acids, appear to be involved (Rodrigues de 
Miranda et al., 1976) (see Table III ). Table III shows that butyric acid displaces 
octanoic acid* (the asterisk indicates the labeled compound) less effectively than 
butyric acid* and that octanoic acid displaces butyric acid* less effectively than 
octanoic acid*. 
This two-site model offers a simple explanation for the phenomenon re-
ТаЫе HI 
Displacement of Fatly Acids Bound to Bovine Albumin (ЗОРС)" 
Compound 
Butyric acid 
Octanoic acid 
Bind 
SileS 
120 
40 
ing constants 
OiM) 
SiteL 
1430 
2 
Displacement constants 
(μΜ) for the displacement of 
Butyric* acid* 
120 
25 
Octanoic* acid 
770 
2 
' For details, see Rodrigues de Miranda el al (1976) Note that at least two binding sites, one preferentially occupied 
by butyric acid and one preferentially occupied by octanoic acid, are involved 
' · : labeled. 
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ported by Snyder (Tables I and II ). In the case of the dopaminergic receptor, 
for example, it can be assumed that two sites are involved there also, namely 
site 1, for which Xidopamme = 17.5 пМ and Kihaiopmdoi = 920 nM, and site 2, for 
which Кг dopamine = 670 nM and X2h„ep„ id0, = 1.4 nM (see Table II ). 
Figures 8 (a) and (b) represent curves showing the mutual displacement of 
dopamine and haloperidol calculated on the basis of these constants. Figure 8 (a) 
is a plot of the sum of the fractional occupation of the two binding sites by 
dopamine* against the log concentration of this compound. This was done in the 
absence of a second compound and in the presence of dopamine and haloperidol 
in concentrations which if given alone would occupy 50% of the sites with the 
lowest binding constants. Figure 8 (b) similarly gives the binding of haloperidol* 
in the absence of a second compound and in the presence of dopamine and halo­
peridol. The curves clearly show that at the lower dose ranges dopamine* is 
more effectively displaced by dopamine [Fig. 8(a)] and haloperidol* more 
effectively by haloperidol [Fig. 8 (b)], as observed by Snyder (Burt et ai, 1976). 
However, at higher dose ranges (not studied by Snyder), the reverse situation 
obtains. 
The receptor sites on which the agonist most effectively displaces agonists, 
and, in fact, the receptor for which the agonists have the highest affinity, probably 
are physiologically the most relevant ones. The affinity constants of the agonists 
on these receptors correlate reasonably well with the activity for these agents 
tested on biological systems (U'Prichard et al., 1977). 
10 8 
I F i l l I I I I I ' 
4 2 0 10 8 6 4 2 0 
-log (Dopamine*! - log [ Haloperidol*) 
Fig 8. Calculated log concentration curves for the sum of the fractional occupations of two classes 
of binding sites for (a) dopamine· and for (b) haloperidol* based on the binding constants given in the 
text The figures give a binding curve for dopamine* [(a)l] and haloperidol* [(b)l] alone and such 
curves in the presence of dopamine at 670 nM [(a)3 and (b)2] and haloperidol at 920 nM [(a)2 and 
(b)3], concentrations in which the agents saturate the binding site with the lowest binding constant 
for 50%. Note· In the lower concentration ranges, dopamine more effectively than haloperidol 
displaces dopamine* (a) and haloperidol more effectively than dopamine displaces haloperidol* (b). 
At the higher dose range the reverse situation exists. 
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Remarkably, the partial agonists take an intermediate position in their 
affinities for both the preferential agonist binding sites and for the preferential 
antagonist binding sites This may reflect that partial agonists not only biolo­
gically but also physicochemically take an intermediate position between agonists 
and the corresponding antagonists 
There is growing evidence, indeed, for the occurrence of two types of recep­
tors for various neurotransmitters such as dopamine (Cools and Van Rossum, 
1976, Cools, 1977) and noradrenaline (Doxey et al, 1977). 
11. Reflection 
In this chapter our aim has been to show the simplest models for pharmacon-
receptor-effector systems One must be well aware that the simplest concept or 
model describing certain biological phenomena has priority over more complex 
concepts The elaboration of more complex general models leads to the fields 
of theoretical biology or biomathematics A disadvantage of the more complex 
models—and there is no limit to the complexity—is that, because of the large 
number of variables, rate constants, etc, involved, they usually will give a variety 
of answers in the interpretation of certain biological phenomena and thus do not 
show discrimination The concept to be preferred for practical use is therefore 
one in which the number of operational variables is limited to the smallest 
number Simple models as a rule are special cases of more complex general 
models and have the advantage of elucidating and emphasizing, in a heuristic 
form, fundamental concepts 
One may not expect, however, that one universal concept or theory of drug 
action will account for all mechanisms of action of bioactive agents 
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SURMARY 
The phenomenon, that some tissues respond to extremely low doses 
of a drug and others do not, has been explained by postulating 
the presence of recognition mechanisms in responsive and their 
absence in non-responsive tissues. The molecular structures 
necessarily involved in these recognition mechanisms are called 
receptors. The study of receptors in tissues has revealed that 
the effect of structurally related drugs is mediated through 
one receptor system. The receptor concept has from this realiza-
tion on evolved into fysical reality, concomitantly with a grow-
ing desire to isolate receptors and study them in a more or less 
purified state. Most receptors manifest their presence often 
exclusively in intact tissue. The detection of receptors in 
broken cell preparations depends in the first place on the 
availability of a suitable ligand, labelled in such a way that 
it can easily be measured by physical or chemical means. The 
availability of tritium labelled drugs, neurotransmitters and 
hormones at high specific radioactivity has opened the possibil-
ity to detect specific receptor binding in tissue fragments and 
subcellular fractions. These developments have given a new di-
mension to the study of the mechanisms at the basis of drug 
action. The present thesis is intended to be a contribution in 
this respect. It is divided into four parts preceded by a general 
introduction. 
Part I "The histamine receptor" deals with the synthesis of 
the tritium labelled optical antipodes of chlorpheniramine. The 
attempts to detect specific binding to the histamine receptor 
using these compounds as affinity labels have revealed an ex-
tremely low receptor density in target tissue. Detailed studies 
of the binding at the histamine receptor require a more refined 
technique and a labelled ligand with a more favourable ratio of 
specific over unspecific binding. 
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Part II "The muscarinic acetylcholine receptor" describes 
the characterization of the muscarinic cholinergic receptor in 
a subcellular fraction of bovine tracheal smooth muscle with 
tritium labelled (+)- and (-)-benzetimide and atropine as tools. 
The bovine caudate nucleus is a relatively rich source of mus-
carinic receptors. Digitonin is the only compound amongst a 
variety of detergents, which can convert the muscarinic receptor 
fron a membrane bound into a soluble state without loss of bind-
ing properties. The comparative study of binding properties of 
muscarinic receptors in bovine tracheal smooth muscle, parotid 
gland and caudate nucleus indicates that muscarinic receptors 
in the peripheral and central nervous system are very much alike. 
No evidence necessitating a subdivision of muscarinic receptors 
has been found. The biphasic inhibition of H-Dexetimide binding 
by agonists of the muscarinic receptor cannot be explained by a 
simple competition of ligands for a single binding site. Alter-
native mechanisms to explain the binding data are not entirely 
satisfactory. 
Part III "The dopamine receptor" describes the binding of 
tritium labelled spiroperidol to calf caudate nucleus homogenates 
and its inhibition by non-labelled dopaminergic ligands. The 
results can be explained by assuming the presence of two binding 
sites with high affinity for spiroperidol. The separate role of 
each of these binding sites in dopaminergic transmission remains 
unclear. 
Part IV "Simple theoretical models for drug-receptor inter-
action" deals with elaborations of some simple models for drug-
receptor interaction in order to explain some of the experimental 
findings in this thesis and those of other investigators. The 
dual receptor model, the allosteric receptor model and the two 
site receptor model are discussed. 
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SAMENVATTING 
De vraag, waarom een orgaan op vaak extreem lage doseringen van 
een stof reageert met een duidelijk herkenbaar effect en andere 
organen dit niet doen, heeft men beantwoord door in voor de stof 
gevoelige orgaansystemen de aanwezigheid van herkenningsmecha-
nismen voor de betrokken stof te poneren. De daarbij noodzake-
lijkerwijs betrokken moleculaire structuren heeft men receptoren 
genoemd. De studie van deze receptoren in orgaansystemen heeft 
tot het inzicht geleid, dat effecten van structureel verwante 
stoffen door interactie met één en hetzelfde receptorsysteem tot 
stand komen. Het receptor concept heeft zich in de loop der tijd 
ontwikkeld van een operationeel begrip tot een fysische realiteit 
en naarmate deze realiteit duidelijker vormen aannam, ontstond de 
behoefte receptoren in meer of minder zuivere toestand te bestu-
deren. Daar receptoren hun aanwezigheid vaak uitsluitend in 
intact weefsel manifesteren, is men voor de detectie van recep-
toren in gefragmenteerd weefsel aangewezen op het waarnemen van 
binding van een voor dat doel geschikt en van een herkenbaar 
label voorzien farmacon. Met het ter beschikking komen van radio-
actief gemerkte farmaca is het mogelijk gebleken de specifieke 
receptor binding in gefragmenteerd weefsel te detecteren. Deze 
ontwikkelingen hebben nieuwe wegen geopend om de mechanismen, 
die aan de farmacon-receptor interactie ten grondslag liggen, 
te bestuderen. Het onderhavige proefschrift beoogt in deze zin 
een bijdrage te zijn. Het is verdeeld in vier secties, voorafge-
gaan door een algemene inleiding. 
In sectie I "The histamine receptor" wordt de synthese van 
de radioactief gemerkte optische antipoden van chlorpheniramine 
beschreven, alsmede de pogingen met behulp van deze stoffen de 
histamine receptor in doelweefsel op te sporen. De receptordicht-
heid in doelweefsel blijkt dermate laag te zijn, dat een gede-
tailleerde studie van de binding aan de histamine receptor een 
verdere verfijning van de technieken noodzakelijk maakt. 
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In sectie II "The muscarinic acetylcholine receptor" wordt 
de karakterisering van de muscarineachtige acetylcholine recep-
tor in een subcellulaire fractie van het gladde spierweefsel uit 
de runder trachea met behulp van tritium gemerkt (+)- en (-)-
benzetunide en atropine beschreven. De nucleus caudatus van het 
rund bevat eveneens aanzienlijke hoeveelheden muscarine recep-
toren. Digitonine blijkt als enige van een aantal oppervlakte 
actieve verbindingen in staat te zijn de muscarine receptor van 
de membraan gebonden vorm in een opgeloste vorm over te voeren 
zonder verlies van zijn bindingseigenschappen. De vraag of 
muscarine receptoren in het perifere en centrale zenuwstelsel 
verschillend zijn, moet voor de speekselklier, het gladde spier-
weefsel m de trachea en de nucleus caudatus van het rund althans 
voorlopig ontkennend beantwoord worden. De inhibitie van H-
Dexetimide binding door agomsten kan niet verklaard worden met 
een eenvoudig competitiemodel. De aangedragen alternatieve 
mechanismen geven geen afdoende verklaring. 
In sectie III "The dopamine receptor" wordt de binding van 
tritium gemerkt spiroperidol aan homogenaten van de nucleus cau-
datus van het kalf en de inhibitie daarvan door met-gemerkte 
dopaminerge liganden beschreven. Wanneer men aanneemt, dat spiro-
peridol in de nucleus caudatus bindt aan twee bmdingsplaatsen 
met hoge affinitiet kan het verloop van de inhibities op een-
voudige wijze verklaard worden. De afzonderlijke rol van beide 
bmdingsplaatsen in de dopaminerge transmissie blijft echter 
een open vraag. 
In sectie IV "Simple theoretical models for drug-receptor 
interaction" wordt een aantal eenvoudige alternatieve modellen 
voor farmacon-receptor interactie nader uitgewerkt en wordt na-
gegaan in hoeverre deze modellen de experimentele bevindingen 
in dit proefschrift alsmede die van andere onderzoekers kunnen 
verklaren. Het clual" receptor model, het allostere receptor model 
en het "two site" receptor model worden aan de orde gesteld. 
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